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ABSTRACT 
PA\-trans retinoic acid (RA), the most active metabolite of vitamin A, is a 
key signaling molecule indispensible for embryonic development. It is most intriguing 
that too much or too little RA will cause similar types of malformations in some organ 
systems such as the kidney. Our laboratory has previously established a mouse model 
in which excess RA, like RA deficiency, perturbed kidney development and led to 
various types of renal malformations in the embryo. The aim of this thesis was to 
investigate why excess and deficiency of RA could result in similar types of 
malformations by employing this RA-induced renal malformations mouse model. We 
hypothesized that the teratogenic effect of excess RA was mediated via suppression of 
RA synthesis, which led to RA deficiency, thereby resulting in malformations. 
First, time and dose response studies were conducted in ICR mice to 
determine the embryo's susceptibility to the teratogenic effect of RA in inducing renal 
malformations and other types of malformations. It was found that at the dose of 125 
mg/kg RA being injected intraperitoneally on embryonic day (E) 8 and 22 hours, renal 
malformations were consistently found in all near-term fetuses at El8, among which 
about 75% developed bilateral renal agenesis. These dosage and time point were 
employed for all subsequent experiments. 
The enzyme retinal dehydrogenase (Raldh), with 3 subtypes including 
Raldhl, 2 and 3, is responsible for RA synthesis in the embryo. To determine if there 
was any negative feedback regulation between externally supplied RA and RA 
synthesis, after maternal RA injection, mRNA expressions of all 3 subtypes of Raldh 
in the embryo were examined by in situ hybridization and quantitative real-time 
xviii 
RT-PCR from E9.5 to El2.0; while expressions in the developing kidney was 
examined from El 1.0 to E12.0. Results showed that there was prolonged significant 
down-regulation of all 3 subtypes of Raldh in both the whole embryo and the 
developing kidney. Concomitant with down-regulated expressions of RA synthesizing 
enzymes, RA levels in the whole embryo and in the developing kidney, as measured 
by using HPLC and a RA-responsive cell line respectively, were significantly 
reduced. 
Lastly, to test our hypothesis that excess RA perturbed kidney 
development via causing RA deficiency, following teratogenic RA insult (125 mg/kg) 
on E8 and 22 hours, pregnant mice were orally supplemented with single or multiple 
low doses of RA (0.625 - 2.5 mg/kg) at regular intervals starting between El0.0 to 
El 1.0. Fetuses were examined at El8. Indeed, it was found that RA supplementation 
could significantly reduce the frequency and severity of renal malformations in time-
and dose-dependent manner. Moreover, the rescue effect was not limited to kidney 
development; other malformations affecting the eye, ear, jaw and limb were also 
ameliorated by low doses of RA supplementation. 
To conclude, results of this thesis support our hypothesis, and this 
previously undescribed mechanism of “too much causes too little" may shed light on 
elucidating why excess and deficiency of RA can cause similar types of 







































Chapter 1: General Introduction 
1.1 INTRODUCTION TO RETINOIDS 
Retinoid is described as natural or synthetic compound with chemical or 
functional properties similar to the vitamin A family. Based on its molecular 
structure, it is defined as “a class of compounds consisting of four isoprenoid units 
joined in a head-to-tail manner" (lUPAC, 1983). Basic structure of retinoid consists 
of three main parts: a trimethylated cyclic end group, a conjugated side chain and a 
polar functional end group. Double bonds in the side chain may exist in either 
cis/tmns isomeric forms. The oxidation state of the functional end groups may vary 
to form alcohol, aldehyde or carboxylic acid. These alternations generate a large 
number of retinoid isomers. Isomers are divided into three classes based on their 
structures. Class I retinoids, such as retinol, retinal and retinoic acid, are created by 
the manipulation of the polar functional group and the polyene chain of vitamin A. 
Class II retinoids are formed by the replacement of the cyclic end group of vitamin 
A with different substituted and non-substituted rings. These include acitretin and 
etretinate (Rashmi Sharma, 2005). For Class III retinoids like bexarotene and 
tazarotnen, they have less flexibility than the other two classes. Differences of their 
molecular structures significantly alter their physicochemical properties and 
bioactivity (Vahlquist and Rollman, 1987). Among different retinoid isomers, 
diW-trans retinoic acid (RA) is believed to be the most biologically active metabolite 
of vitamin A. 
Most retinoids required for our body function have to be taken in through 
diet. Their bioactivity per unit mass varies between isomers. To be convenient, the 
World Health Organization (WHO) suggests expressing the bioactivity of different 
forms of vitamin A in the diet to be equivalent with the bioactivity of diW-trans 
retinol, rather than in unit mass. One retinol equivalent (RE) is defined as the 
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activity of 1 ^g of 2i\\-trans retinol (Bieri and McKenna, 1981). The conjugated 
structure of the retinoid is responsible for its red, orange or yellow color. Thus, many 
orange and yellow vegetables and fruits are rich sources of retinoids; for example, 
carrots, pumpkin and sweet potatoes, which contain 5-10 mg RE/100 g (USDA, 
2004). Yet, the food with the most abundant retinoids is liver, which contains 4-20 
mg RE/100 g (USDA, 2004). 
Retinoids are well-known in playing an important role in regulating adult 
vision (Pitchon et al.，2006; Chang et a l , 2008), skin development (Wolbach and 
Howe, 1925), fertility (Kirkwood et al., 2010), nervous system (Rahman et al., 
1996), immune system (Elmadfa et al., 1994) as well as embryo development. The 
study of retinoid functions in biological system has a long history. Investigations on 
the effect of vitamin A deficiency have started since the 1920s (Wolbach and Howe, 
1925). 
1.2 ROLE OF ENDOGENOUS RETINOIC ACID IN EMBRYONIC 
DEVELOPMENT 
The role of endogenous RA in embryonic development has long been 
investigated (Hale, 1933). It is shown to be one of the key morphogens during 
embryonic development (Thaller and Eichele, 1987), and is found in most 
embryonic tissues (Horton et al., 1987; McCaffery and Drager, 1994; Schweigert et 
al., 2002). It is involved in the development of many organs during embryogenesis, 
such as the formation of eyes (Matt et al., 2005), ears (Romand et al., 2006), facial 
region (Schneider et al., 2001), brain (Halilagic et al., 2007) and the limbs 
(Lewandoski and Mackem, 2009). The mechanism of RA in these processes includes 
direct control of transcription, differentiation and apoptosis. 
- 3 -
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RA regulates embryonic development by controlling the expression of 
specific genes at various gestational periods. More than 500 genes are found to be 
directly or indirectly regulated by RA (Balmer and Blomhoff, 2002). Hox genes, a 
group of genes specifying embryonic anteroposterior patterning in early embryo 
development, is controlled by RA (Durston et al., 1989). Tight regulation of these 
genes is important for the proper positioning of embryonic anlage. Besides Hox 
genes, the signaling molecule Shh (Sonic Hedgehog), and several enzymes such as 
protein kinase C are also regulated by RA, which are important for multiple 
activities during development. 
Other genes that can be activated by RA, such as Pdxl, Hoxa5, Pitx2 and 
c-ret are important for the development of pancreas, lung, eye and kidney 
respectively. Temporal and spatial disruption of endogenous RA synthesis may 
disturb their expressions and result in malformation of different organs. RA may also 
serve as a repressor. Fgf8 expression is repressed by RA in between the anterior 
cardiac domain and primitive streak in the mouse embryo during early gastrulation, 
which is necessary for proper somitogenesis (Vermot and Pourquie, 2005) and 
ventral neural patterning (Diez del Corral et al., 2003). 
RA may increase the expression of several proteins that take part in the 
differentiation program and thus induces differentiation. This can be regarded as a 
secondary RA response. Experiments show that RA is a universal differentiation 
agent; it can induce differentiation of neuron progenitor cells while reduce its 
proliferation (Kaplan et al., 1993). RA can also induce differentiation of primary 
stem cells to immature neurons via up-regulation o f p 2 1 expression (Takahashi et a l , 
1999). 
RA-induced apoptotic cell death is common in normal embryo 
development. The most typical example is interdigital apoptosis during limb 
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development (Stewart et al., 2000). RA synthesis is restrictedly found in the 
interdigital region. Severe interdigital webbing was found in the embryo of 
RA-deficient mouse due to a reduction of interdigital apoptosis (Crocoll et al., 2002). 
RA-stimulated apoptosis is also found in the development of urogenital system; 
connection between the ureter and the bladder depends on apoptosis in the common 
nephric duct, which is controlled by RA signaling (Batourina et al., 2005). 
1.3 REGULATION OF RETINOIC ACID m EMBRYONIC CELLS 
Under normal conditions, there is no maternal transfer of RA to the 
embryo (Morriss-Kay and Sokolova, 1996). In placental species, RA is synthesized 
within the embryonic cell from retinol obtained from maternal circulation. In 
oviparous species, retinol is stored in the egg yolk as the source of retinoids. No 
matter it is by yolk sac or placental transfer, the equilibrium between retinol and RA 
must be tightly regulated in order to provide an optimal temporal and spatial 
distribution of retinoids for embryogenesis. This regulation includes a balance 
between RA-synthesizing and RA-catabolizing activity, and also depends on the 
unique distribution pattern of several retinoid binding proteins and receptors. 
1.3.1 Retinoic acid synthesis and degradation 
As mentioned earlier, RA can activate or suppress the expression of 
several genes that are important for embryogenesis. Yet, different genes respond at 
different levels of RA (Boncinelli et a l , 1991), so a precise control of RA is needed. 
Experiments show that RA synthesizing enzymes play a major role in regulating RA 
level in embryonic cells. When comparing the effect of RA synthesizing enzyme 
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knockout mice and single RA receptor knockout mice on embryo development, 
embryos from RA-synthesizing enzyme knockout mice were found to have more 
severe malformations (Niederreither et al., 1999). The regulation of RA synthesis is 
evidently important; tissue-specific expression of RA-catabolizing enzyme provides 
an additional control of RA in the embryonic cell (Sakai et al., 2001). 
The first step of RA synthesis is the reversible oxidation of retinol to 
retinaldehyde that is carried out by alcohol dehydrogenase (Adh) and retinol 
dehydrogenases (Rdh). Genetic studies show that at least three Adhs (Adhl, 3, 4) 
and two Rdhs (Rdhl and RdhlO) take part in the first step of oxidation. Their 
expressions are overlapping and widespread in the embryo (Ang et a l , 1996; Zhang 
et al., 2001). However, the fate of RA being synthesized via these two groups of 
enzymes is proposed to be different. Experiments show that RA synthesized by the 
oxidation via Adh is mostly further metabolized into oxidized products and removed 
from the cell. This suggests that Adh may have a role in removing excess retinol 
(Molotkov et al., 2002). Conversely, RA synthesized via the oxidation by Rdh 
mostly contributes to RA signaling in the cell. Since the oxidation of retinol to 
retinaldehyde is a reversible reaction, equilibrium between these two forms of 
retinoid provides further control of the endogenous RA level in the cell (Gallego et 
al., 2006). 
Equilibrium between retinol and retinaldehyde may occur in every cell, 
however, only cells that have retinaldehyde dehydrogenases (Raldh) can perform the 
second step oxidation, which converts retinaldehyde to RA. Raldh consists of three 
isoforms, namely Raldhl, Raldh2 and RaldhS. They show specific expression 
patterns with little overlapping (Mic et al., 2002). Among these three iso forms, 
Raldh2 is first expressed in the embryo at the beginning of gastrulation 
(Niederreither et al., 1997), which is about embryonic day (E) 7 in mouse embryo. 
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RA synthesis in the embryo is mainly contributed by Raldh2. Among mutants with 
knockout of retinoid-associated factors, null mutation of Raldh2 results in the most 
harmful effects on embryo development and causes embryonic lethality at 
mid-gestation due to defective heart (Niederreither et al., 1999). The 
retinaldehyde-oxidizing activity among the three isoforms is different. Raldhl has 
relatively lowest activity (McCaffery et al” 1992), while Raldh2 and Raldh3 have 
similar activity (McCaffery and Drager, 1995). The difference in activity between 
iso forms is important in providing a RA gradient in a developing structure. 
To control an optimum level of RA in the cell, RA-catabolizing enzyme 
is equally important. RA degradation is carried out by three cytochrome P450 (Cyp) 
enzymes, namely Cyp26Al (Abu-Abed et al., 2001), Cyp26Bl (Yashiro et al., 2004) 
and Cyp26Cl (Uehara et al., 2007). Cyp26 further oxidizes RA into more polar 
products such as 4-hydroxy-RA and 4-oxo-RA, which will finally be eliminated 
from the cell. The three iso forms of Cyp26 express in tissue specific manner, and 
their expression patterns are complementary with the RA-synthesizing enzymes. 
Co-regulation of different iso forms of RA synthesizing and catabolizing 
enzymes can produce zones with different RA concentrations in the developing 
tissue. For example, in the developing retina, Raldhl with weaker oxidizing activity 
is expressed at the dorsal region, while RaldhS with stronger activity is expressed in 
the ventral region. Meanwhile, Cyp26a 1 is expressed in between them (McCaffery 
et al., 1999). Distributions of these enzymes provide three zones with different RA 
concentrations within the retina, with highest RA concentration at the ventral region, 
medium level at the dorsal region and a very low level at the central. This shows that 
homeostasis of RA depends on a balance between different forms of RA 
synthesizing and also catabolizing enzymes. 
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1.3.2 Retinoic acid signaling 
Indeed, tight regulation of RA level in the embryonic cell is not solely 
controlled by the synthesizing and catabolizing enzymes. Other retinoid-associated 
factors are involved, such as retinol receptors, retinoic acid receptors and also their 
binding proteins. Temporal and spatial expressions of these factors are also 
important in providing an optimum environment for embryonic growth. 
In mammals, when retinol enters the embryonic blood circulation, it is 
taken up by retinol binding protein 4 (RBP4). This protein carries retinol to the cell 
by binding to the cell surface RBP receptor known as Stra6. Retinol enters the cell 
and binds to the cellular retinol binding protein II (CRBPII) followed by two steps 
of oxidation to become RA. RA thus generated will bind to the cellular retinoic acid 
binding protein II (CRABPII). This cytoplasmic protein directs RA into the nucleus 
to bind with nuclear RA receptors (RARs). RAR forms heterodimers with retinoid X 
receptors (RXRs). This complex will then bind to the retinoic acid response element 
(RARE), which is located at the promoter region to control the transcriptional 
activity of the target gene. For cells expressing CYP26 enzymes, RA generated and 
diffused from adjacent cells will be degraded by the enzyme and be eliminated from 
the cell. 
1.4 EFFECT OF EXCESS VITAMIN A / R A ON EMBRYOGENESIS 
Teratogens are substances that cause embryo to develop abnormalities. 
Examples include certain chemicals, viruses and radiation. Different forms of 
retinoids including RA are well-known teratogens (Colbert et al., 1993). The 
teratogenic effect of excess vitamin A on embryo development was first examined 
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by Cohlan et al. (1953). 
1.4.1 Examples of human animal studies 
To date, a lot of experiments have been conducted to show the effect of 
excess RA on embryo development. These experiments involved applying 
exogenous RA into pregnant animal models, or using RA-catabolizing enzyme 
knockout mice. It was shown that excess RA could induce a spectrum of 
malformations in the embryos of different animal models, including monkeys, 
chicks, pigs, dogs, rabbits, hamsters, guinea pigs, rats and mice (Fraser and Travill, 
1978; Geelen, 1979; Newell-Morris et al., 1980; Kistler, 1981; Maden, 1994). 
Excess RA affects normal endogenous RA signaling in the cell. For example, excess 
RA causes over-expression and activation of RA receptors, or the receptors being 
expressed at ectopic locations. 
When teratogenic doses of RA were injected to golden hamsters at 
different gestational period to determine the birth defects that could be induced by 
RA, more than thirty types of malformations were found in near-term fetuses 
(Shenefelt, 1972). The most prevalent defect was exencephaly, cleft palate, spina 
bifida, eye and ear abnormalities, hypoplasia of mandible and maxilla, and the 
absence of tail. Besides inducing malformations, exogenous RA also caused an 
increase of resorption rate. Several mechanisms have been proposed for the 
teratogenic effects of RA, including apoptosis, repatteming, neural crest cell 
migration and altered differentiation. 
In Cyp26al knockout mice, endogenous RA levels were increased at 
some embryonic tissues. Abnormalities found in the embryos include spina bifida 
and caudal regression, which were similar to those induced by administration of 
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excess RA to pregnant mice (Sakai et a l , 2001). Moreover, embryos of Cyp26al 
null mutants died during mid-late gestation (Abu-Abed et a l , 2001). 
It is rare for humans to take in teratogenic doses of retinoids through 
diets or injections. Yet, there are evidences which show that humans are also 
susceptible to high levels of retinoids during pregnancy that induce congenital 
defects by the following means: 
1. Overdose of vitamin supplements during pregnancy. The dose of vitamin A 
intake recommended by WHO (1998) for pregnant women is higher than 
non-pregnant women. Recommended dietary intake of vitamin A for pregnant 
women is 1000 RE, while for non-pregnant women is 600 RE only. Thus, some 
pregnant women may take vitamin A supplements. However, overdose of 
vitamin A may cause teratogenic effects. 
2. Using drugs with high concentrations of retinoids. Over 10,000 natural and 
synthetic retinoids are used in pharmacological applications. The most typical 
examples are iso-tretinoin gel used to treat acne and etretinate used to treat 
psoriasis (Happle et al., 1984). Although the half-life of a single dose of these 
drugs is less than 12 hours (hr), after multiple dosing, their half life may become 
more than 2 years due to storage in adipose tissues (Lucek and Colbum, 1985; 
DiGiovanna et al., 1989). 
3. Using non-retinoid drugs. Several drugs themselves are not retinoids, but they 
may affect RA signaling. Example includes anti-fungal drug ketoconazole, 
which is a Cyp inhibitor (Van Wauwe et al., 1988). Thus, it may cause an 
increase in RA levels in the cell. 
4. Environmental pollutants. Some environmental pollutants can disturb RA 
signaling in the cell, such as dioxin (Weston et al., 1995) and poly chlorinated 
biphenyls (Morse and Brouwer, 1995). They are organic compounds that can be 
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found in the wastes of factories and electric motors. Also, a kind of insecticide 
methoprene may active RXR receptor in humans (Harmon et al” 1995). 
Overexposure to the above chemicals during pregnancy may cause 
teratogenic effects on the embryo. So pregnant women not only have to be aware of 
their vitamin A intake, but also have to pay attention to the drugs they use and the 
environmental conditions. 
1.4.2 Mechanisms of retinoid teratogenesis 
Retinoid teratogenesis can be mediated via different mechanisms, such as 
apoptosis, and alteration in proliferation, differentiation and cell migration. 
Normally, more than one of these mechanisms are involved in inducing 
malformations. 
1.4.2.1 Apoptosis 
As mentioned earlier, apoptosis is required for normal embryonic event, 
such as interdigital apoptosis in limb development. However, excessive apoptosis 
may also induce malformations in different organ systems. It was found that 
exogenous RA treatment at mid-gestation caused excessive cell death in the 
maxillary and mandibular prominences and led to craniofacial abnormalities. 
Ectopic expression of RARp also induced excessive apoptosis in the same area 
(Osumi-Yamashita et al., 1992). These findings suggest that RA-induced apoptosis 
in the facial region may be mediated via the action of ectopic induction of RARfi, 
thereby causing abnormal morphogenesis. A similar case was previously shown by 
our laboratory. Excessive apoptosis was found in the tail bud of the embryo after 
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pregnant mouse was treated with a teratogenic dose RA, which induced severe 
truncation of the body axis (Shum et al., 1999). In this case, Wnt-Sa, a gene 
important for tail bud development was significantly down-regulated, which led to 
apoptosis in the tail bud. Apoptosis in developing tissues may reduce the number of 
precursor cells and result in agenesis or hypoplasia of the tissues. 
1.4.2.2 Altered proliferation 
The development of craniofacial abnormalities after teratogenic RA 
treatment is not solely attributed to apoptosis; it can also be caused by reduced 
proliferation (Abbott et al., 1990). However, in cases of limb defects induced by 
excess RA, RA did not increase apoptosis, but the mitotic index of limb bud cells 
was significantly decreased (Abbott et al., 1990), suggesting that reduced 
proliferation might be the cause for RA-induced malformation in the limb. 
RA is used for the treatment of Kaposi's sarcoma (KS) (Nagpal et al., 
1997). Other retinoids are also shown to have inhibiting activity on KS cells in vitro. 
Experiments showed that retinoids inhibited proliferation of KS cells by 
down-regulating interleukin-6 (IL-6) expression and thus reduced its protein levels, 
which is an important growth factor for KS cells. RA could also cause reduction of 
proliferation in human myeloma cell line (Okamura et al., 1998), neuroblastoma cell 
line (Irving et al., 1998), and head and neck squamous carcinoma cell line (Giannini 
et al., 1997). 
1.4.2.3 Altered cell migration 
Another teratogenic mechanism of RA in causing malformation is 
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alteration of migration of precursor cells. When rat embryo was treated with 
exogenous RA at E9, facial abnormalities were found in the embryo, which may be 
due to ectopic migration of anterior hindbrain neural crest cells (Lee et a l , 1995). 
Their original destination should be the first branchial arch. However, after 
disturbance by RA, they ectopically migrated to the second branchial arch, resulting 
in a first branchial arch of smaller size. This alternation of cell migration behaviour 
may be due to changes in the composition of the extracellular matrix and the 
expression of adhesion molecules after RA treatment (Griffith and Wiley, 1990). 
Experiments showed that after exposure of the embryonic tail bud to teratogenic 
dose of RA, more lectins could bind to the extracellular matrix around the secondary 
neural tube as well as the no to chord with higher affinity. This teratogenic 
mechanism of RA could also be applied to eye defects found in mice (Ozeki and 
Shirai, 1998). 
1.4.2.4 Altered differentiation 
RA can alter the differentiation of many cell types, which is important for 
normal embryonic development. However, similar to apoptosis, uncontrolled 
differentiation caused by excess RA may lead to abnormalities in the embryo. RA 
plays an important role in the central nervous system by controlling anteroposterior 
patterning. After RA treatment, the forebrain of Xenopus embryo reduced in size in 
a dose-dependent manner (Agarwal and Sato, 1993). Higher doses of RA caused a 
more truncated brain. Experiment showed that the diminishing in size of the 
forebrain was not due to a reduction in the number of progenitor cells, but was due 
to changes in the cell fate. The progenitor cell for the forebrain changed from 
neuronal to epidermal phenotype after RA treatment. These findings showed that 
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RA-induced alteration in cell-type differentiation could cause defects in the central 
nervous system. Similarly, altered differentiation was also found in chondrocytes 
after RA treatment (Horton et al., 1987), which might take part in abnormal 
development of the limbs and craniofacial structures. Experiments showed that after 
12 hr of RA treatment, chondrocytes stopped the synthesis of collagen type II, the 
cartilage precursor; instead, the cells started to produce collagen type III, which is 
the precursor of fibronectin. 
1.4.3 Critical period of RA administration caused specific malformations 
In general, developing embryos are more susceptible to teratogens than a 
late stage fetus. Taking RA as an example, embryos at blastocyst or early germ-layer 
stage is relatively insensitive to RA. Embryos become highly sensitive to RA during 
the period of organogenesis. The susceptibility reduces again at fetal developmental 
period. 
The relationship between the time of RA administration and the specific 
malformations being induced involves the concept of “critical period". Critical 
period refers to the time of RA treatment that causes a specific malformation. The 
critical period for RA is well studied in rats and hamsters (Shenefelt, 1972; Holson 
et al., 1999). Shenefelt (1972) pointed out that “in many cases, the critical period for 
inducing specific malformation is well before the presence of that specific anlage". 
For example, RA administration at E6.25 induced mandible hypoplasia in hamsters 
(Shenefelt, 1972). However, the first visceral arch (precursor of mandible) does not 
form until E8, which implies that the teratogenic effect of RA is delayed for 1.75 
days. 
It was shown that a single teratogenic dose of RA would be eliminated 
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from the embryo within 8 hr (Satre and Kochhar, 1989). Thus, it is unlikely that RA 
is directly affecting the development of the mandible. Moreover, Marin-Padilla 
(1966) found that retinoid started to affect the embryo 6 hr after administration, 
which implies that RA-induced mandible hypoplasia is not caused by delayed 
absorption of RA. So far, the delayed action of RA cannot be explained by the above 
mentioned RA teratogenic mechanisms. The embryonic event occurring between the 
time of RA administration and the time of formation of the precursor remains 
unclear. 
1.5 EFFECT OF VITAMIN A / R A DEFICIENCY ON EMBRYOGENESIS 
Besides excess RA, RA or vitamin A deficiency during pregnancy is also 
well-known in causing congenital malformations in the embryo. Many studies have 
investigated the effect of RA or vitamin A deficiency on embryo development. The 
first study was conducted by Hale (1933) in feeding female pigs with vitamin 
A-deficient diet before pregnancy and at early gestation. The effect of RA deficiency 
can also be studied by using the knockout mice of RA-synthesizing enzymes or 
retinoid receptors. Other methods include the use of RAR competitive antagonists 
and RA-synthesizing enzyme inhibitor. 
Results of feeding pigs with vitamin A-deficient diet showed that most of 
the offspring developed ocular defects, such as missing or diminished eye balls, and 
the absence of eye lid (Hale, 1933). Other malformations included cleft palate, hare 
lip, abnormal external ear and unascended kidney. However, since vitamin 
A-deficient diet was provided to the female animals prior to mating, this might 
affect the reproductive system, such that implantation became more difficult. It was 
found in rats that even when fertilized eggs successfully implanted, majority of the 
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embryos were resorbed at E12.5. In order to examine malformations in near-term 
fetuses, pregnant rats were supplemented with RA at mid-gestation. The dose of RA 
was tightly controlled to a level just enough to rescue embryos from resorption (Zile 
and DeLuca, 1968). Results showed that many additional birth defects could be 
attributed to vitamin A deficiency during pregnancy. These included renal 
malformations, herniated diaphragm, lung agenesis, ectopic termination of ureters, 
agenesis of male accessory sex glands and undescended testis (Wilson and Warkany, 
1948; Wilson and Warkany, 1949; Wilson et al., 1953). 
Another means to develop RA deficiency in the embryo is the use of 
RA-synthesizing enzyme mutants. As mentioned earlier, the first step of RA 
synthesis is the reversible oxidation from retino 1 to retinaldehyde by Adh or Rdh. 
Knockout of different iso forms of RA synthesizing enzymes produces various 
degrees of vitamin A deficiency in the embryos (Zhang et al., 2001; Sand ell et al., 
2007; Zhang et al., 2007). This finding reveals that different iso forms of Adh or Rdh 
have different oxidizing activities to synthesize RA. Among these iso forms, only 
Rdh 10 knockout caused embryonic lethality at mid-gestation, showing that RdhlO 
contributes to the majority of retino 1 oxidation in the embryo. 
The second step of oxidation involves different iso forms of the Raldh 
enzyme, which converts retinaldehyde to RA. Mutation of these enzymes disrupted 
RA signaling in the cell, and embryos showed vitamin A deficiency syndromes. 
Among the three iso forms of Raldh, only Raldh2 knockout mice died at 
mid-gestation due to defective heart (Niederreither et al., 1999; Dupe et., 2003; Fan 
et al., 2003). Similar to the case of pregnant rat fed with vitamin A-deficient diet, 
RA supplementation to Raldh2'^' null mutants could rescue embryos from resorption 
(White et al., 2000). Studies of knockout mice of different RA-synthesizing enzymes 
showed that malformations developed in the embryos were similar to those 
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developed in rats fed with vitamin A-deficient diet, including neural tube defects, 
heart and kidney abnormalities (Niederreither et al., 1999). 
Another method to disturb RA signaling in the embryo is via disruption 
of RAR and RXR isoforms. Offspring of retinoid receptor knockout mice exhibited 
nearly all the malformations similar to those found in embryos of RA-synthesizing 
enzyme knockout mice and rat fetuses with vitamin A deficiency. 
Study of knockout mice has the limitation that embryos are deprived of 
RA since conception. However, by using RA receptor competitive antagonists or 
RA-synthesizing enzyme inhibitors (Stratford et a l , 1996; Schneider et al., 2001; 
Mey et al., 2003), the developmental stage of the embryo at which RA is deprived 
can be controlled so as to determine when RA is needed for the development of 
specific process. For example, it was shown that administration of RAR antagonist 
(AGN193109) to pregnant mice at different gestational stages produced embryos 
with congenital and postnatal defects that were similar to the above mentioned 
diet-induced vitamin A-deficient animals (Kochhar et al., 1998). 
According to WHO, vitamin A deficiency can be found in more than half 
of the area in the world, especially in South-East Asia and Africa (WHO). About 250 
million children suffered from vitamin A deficiency syndromes, and up to 500,000 
of them become blind in each year. Vitamin A deficiency in children also increases 
the risk of death from different infections. During pregnancy, the demand for 
vitamin A increases for both embryo and mother at late gestation. Mother with 
insufficient vitamin A may show a high prevalence of night blindness in this period. 
Insufficient vitamin A during pregnancy in humans may also increase the mortality 
rate in both the mother and her offspring. Clinical studies also show that maternal 
vitamin A deficiency is associated with the increase in mother-to-child transmission 
of HIV (Semba et al., 1994). 
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1.6 EXCESS AND DEFICIENCY OF R A CAUSE SIMILAR TYPES OF 
MALFORMATIONS 
Excess and deficiency of RA can both lead to a wide spectrum of 
malformations in different organ systems. Moreover, it is interesting that they can 
cause similar types of malformations in some organ systems, for example, renal 
malformations. Renal agenesis, which is the total absence of kidney, was found in 
the pups of RARay-z- mutant, while hypoplastic kidney, which is a kidney of smaller 
size, occurred in the RXRaJRARa" embryos (Mendelsohn et al., 1994; Kastner et al., 
1997). Recently, our laboratory has established a RA-induced renal malformations 
mouse model by administration of a teratogenic dose of RA to pregnant mice at 
mid-gestation (Tse et al., 2005). All near-term fetuses were found with renal 
malformations, which are similar to RA-deficient mice. These findings show that a 
tight control of retinoid levels is required for normal kidney development. This 
mouse model is thus useful for investigating the teratogenic mechanism of RA. 
1.6.1 Retinoic acid-induced renal malformations mouse model 
In this model, 125 mg/kg of RA was injected intraperitoneally into 
pregnant ICR female mouse at E9. Kidney malformations were examined in 
near-term fetuses at El8. All fetuses were consistently found with renal 
malformations. To determine when exogenous RA started to disturb kidney 
development, kidneys of control (vehicle-treated) and RA-treated embryos were 
freshly isolated at different time points for morphological comparison. The 
metanephric kidney starts to develop at E l l in the mouse. At El l .25, RA-treated 
kidney showed similar morphology as the control. The ureteric bud (UB) had 
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penetrated into the metanephric mesenchyme (MM) and formed the first T-shapcd 
branching. However, after that, RA-treated kidney ceased its development. The UB 
did not branch and the MM failed to differentiate into nephrons. At El5.25, 
RA-treated kidney had degenerated into a cluster of cells while the control kidney 
underwent extensive UB branching and nephrogenesis. Immunohistochemical study 
further showed that the RA-treated kidney had many apoptotic bodies in the MM, 
which might lead to the degeneration of the kidney. 
To investigate the molecular changes between RA-treated and control 
kidneys, the expression of several genes crucial for kidney development including 
c-ret，Gdnf, and Wtl was quantified by real-time RT-PCR. Among these genes, only 
the expression of Wtl was altered. The expression of Wtl in the RA-treated kidney 
was significantly down-regulated when compared with the control at E l l and El2. 
The finding that Wtl heterozygous embryos were more susceptible to RA-induced 
renal malformations than their wild-type littermates further proved that 
down-regulation of Wtl was directly involved in the pathogenic mechanism of 
RA-induced renal malformations. 
1.7 STRATEGY OF THESIS 
Our laboratory has previously established a mouse model in which 
excess RA, like RA deficiency, perturbed kidney development and led to various 
types of renal malformations in the embryo. Down-regulation of Wtl and increased 
apoptosis in the kidney primordium was found after maternal RA-treatment. 
However, the underlying mechanism of RA teratogenesis remains unclear. Two 
questions arise in this model. First, how can excess and deficiency of RA lead to the 
same type of renal malformations? Second, how can the teratogenic dose of RA 
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affect the kidney rudiment which does not develop until 2 days after RA treatment? 
So far, all known teratogenic mechanisms of RA (as discussed in 1.4.2) cannot 
account for these two phenomena. All these mechanisms start to affect its target 
within 12 hr after RA treatment. To address this, I have set up a hypothesis that the 
teratogenic effect of excess RA is mediated via prolonged suppression of RA 
synthesis, which leads to RA deficiency, thereby resulting in renal malformations. 
The aim of this thesis was to test the above hypothesis. Experiments were 
based on the use of our established RA-induced renal malformations mouse model. 
Since this proposed mechanism of RA teratogenesis may not be limited to 
RA-induced renal malformations, but can occur in other RA-induced malformations, 
therefore, besides the kidney, malformations in other organ systems were also 
examined in details. The first part of my project was to determine the optimum time 
and dose for RA administration for inducing renal defects in the embryos (Chapter 
3). It was found that at the dose of 125 mg/kg RA being injected intraperitoneally 
into pregnant mice at hour 22 on E8 (E8-22hr), renal malformations were 
consistently found in all near-term fetuses at El8, among which about 80% were 
bilateral renal agenesis. These dosage and time point were employed for all 
subsequent experiments. The frequency of other malformations such as cleft palate, 
eye defects, abnormal external ear, micrognathia and sirenomelia was recorded. 
Apart from analyzing malformations, the teratogenic effect of RA on various growth 
parameters including weight, crown-rump length, head length and tail length were 
also studied. 
After finding out the optimum time and dose for RA treatment, I have 
determined if there was any negative feedback regulation between externally 
supplied RA and endogenous RA synthesis in the embryo (Chapter 4). The inRNA 
expression of the three isoforms of RA synthesizing enzyme Raldhl, Raldh2 and 
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RaldhS and the three isoforms of RA catabolizing enzyme Cyp26al, Cyp26hJ and 
Cyp26cl were studied by in situ hybridization and quantitative real-time RT-PCR. A 
significant down-regulation of all three iso forms of Raldh was found in the whole 
embryo as well as in the embryonic kidney after teratogenic RA treatment. Next, to 
determine whether down-regulation of expression of RA synthesizing enzymes 
could result in RA deficiency, RA levels in the whole embryo and in the embryonic 
kidney were measured by using HPLC and a RA-responsive cell line respectively. 
Result showed that RA levels were significantly reduced in the whole embryo and in 
the embryonic kidney after maternal treatment with a teratogenic dose of RA. 
The last part of my project was to test whether deficiency of RA would 
indeed perturb kidney development (Chapter 5). To this end, following teratogenic 
RA insult (125 mg/kg) on E8-22hr, pregnant mice were orally supplemented with 
multiple low doses of RA (0.625-2.5 mg/kg) at regular intervals starting from 
different time points. Kidney development was examined morphologically at El8 . It 
was found that the frequency and severity of renal malformations were significantly 
reduced by RA supplementation. Moreover, the rescue effect was not limited to 
kidney development; other abnormalities affecting the jaw, eye, ear and limb were 
also ameliorated by low doses of RA treatment. Finally I have studied how 
supplementation with low doses of RA could rescue the development of the kidney. 
Results showed that Wtl expression was significantly up-regulated and apoptosis in 
the kidney primordium was ameliorated after RA supplementation. 
Finally, in Chapter 6, all the results were summarized and future 
perspectives on this work were discussed. 
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2.1 MOUSE MAINTENANCE AND MATING METHODS 
All experiments were carried out using ICR (Institute of Cancer Research) 
male and female mouse colonies which were originally established by breeding pairs 
obtained from Harlan Laboratory at UK. They were kept in an animal holding room 
at the Laboratory Animal Services Centre of the Chinese University of Hong Kong, 
in which humidity, temperature and noise were well controlled. Mice were provided 
with irradiated LabDiet for Rodents {PMI Nutrition) and ozone-sterilized tap water. 
All the mice were housed under a 14:10 hours (hr) light-dark cycle, in 
which the light period started from 11:00 am to 1:00 am. Female and male mice of at 
least 8 weeks old were used for mating. One female and one male were paired up for 
two hr from 9:00 am to 11:00 am. Checking of copulation plug in the female mouse 
was carried out at 11:00 am. If a plug was found in the vagina, successful mating 
was assumed to have occurred. The midpoint of the mating period, which was 10:00 
am, was regarded as embryonic day (E) 0. 
2.2 ALL-TRANS RETINOIC ACID PREPARATION AND INJECTION 
AW-trans retinoic acid (RA) was prepared in a 50 ml falcon tube wrapped 
in aluminum foil to prevent photo iso merization. One hundred mg of RA (Sigma) 
was dissolved in 1.5 ml of absolute ethanol (BDH) with shaking at 300 revolutions 
per minute (rpm) at 2 5 � C in a thermomixer (Eppendorf) for 3 hr. Peanut oil (Sigma) 
was added to make up a volume of 15 ml at a final concentration of 6.66 mg/ml and 
then vortexed vigorously for another 3 hr. The RA suspension was stored in the dark 
at 4°C and used within 2 weeks. 
Before injection, the RA suspension was warmed to room temperature 
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and vortexed for 1 minute. Pregnant mice were injected intraperitoneally with an 
appropriate volume of RA with a 20 gauge (G) needle (0.90 x 38 mm; Terumo) fitted 
onto a 1 ml syringe, whereas control mice were injected with same volume of 
vehicle (10% ethanol in peanut oil). 
2 .3 WHOLE MOUNT IN SITU HYBRIDIZATION 
2.3.1 Riboprobe synthesis 
2.3.1.1 Bacterial culture 
Frozen bacteria stock with transformed target genes was added into a 50 
ml falcon tube with 10 ml of Lysogeny broth (LB, Invitrogen) and 800 jig of 
ampicillin {Roche). It was grown in an orbital incubator shaking at 300 rpm at 37°C 
overnight. 
2.3.1.2 DNA plasmid extraction 
Extraction of the cDNA plasmids was carried out by using the Plasmid 
DNA Extraction Mini Kit (Favorgen). After overnight incubation, bacteria were 
subjected to centrifugation at 3,000 rpm for 10 minutes (min) to form pellet. The 
bacterial cell pellet was resuspended in 200 |LI1 of FAPDl buffer. Further lysis of the 
bacteria was achieved by adding 200 |al of FADP2 buffer for 2 min and 300 jiil of 
FADP3 buffer for 10 min. The lysate was subjected to centrifugation at 13,000 rpm 
for 5 min. The supernatant containing the DNA was filtered by the FAPD column 
and centrifuged at 8,000 rpm for 30 seconds (sec). The DNA was trapped by the 
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column and the supernatant was discarded. The column was washed with 400 |LI1 of 
W1 buffer and followed with 750 of wash buffer. After washing, the column was 
dried by centrifugation at foil speed (14,000 rpm) for 30 sec. The column was 
transferred to a new tube and 50 |LI1 of diethylpyrocarbonate (DEPC)-treated water 
was added to the centre of the column matrix and stood for 2 min. The column was 
centrifuged at full speed again to elute the dissolved DNA plasmid. 
The quality and the size of the extracted DNA plasmid were checked by 
electrophoresis in a 0.8% agarose gel. Its concentration was measured by a 
spectrophotometer (GeneQuant, Pharmacia Biotech) at the wavelength of 260 nm. 
The rest of the plasmid was stored at -20°C until use. 
2.3.1.3 Linearization of plasmid 
The cDNA plasmid was linearized by restriction enzyme. The type of 
enzyme used was depended on the type of plasmid and also the restriction site of the 
cloned target gene. The reaction mixture was composed of the following: 
Plasmid 5 ^ig 
Reaction buffer (1 OX) 5 |al 
Restriction enzyme (10 units/)il) 2 \i\ 
DEPC-treated water adjusted to 50 |LI1 
The reaction was carried out in a thermomixer at 37°C with gentle 
mixing. 
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2.3.1.4 Purification of linearized plasmid 
After linearization, the DNA was extracted by adding equal volume of 
pheno 1: chloro form: iso amy 1 alcohol (25:24:1, v:v:v) and mixed well. The solution 
was centrifuged at 14,000 rpm for 5 min at 4°C. The upper aqueous layer was taken 
and equal volume of chloroform:isoamyl alcohol (24:1, v:v) was added. The 
solution was mixed well and subjected to centrifligation at 14,000 rpm for 5 min at 
4°C. The upper aqueous layer containing the DNA was transferred to a new tube, 
and added with 0.1 volume of 3 M sodium acetate and 2 volume of cold 100% 
ethanol. The DNA was precipitated at -20°C overnight. After that, the reaction 
mixture was centrifuged at 14,000 rpm for 15 min at 4°C. The supernatant was 
discarded and the pellet was washed with cold 70% ethanol twice. The DNA pellet 
was then dried by Speed Vac {Savant) for 3 min. Finally the pellet was dissolved in 
20 \i\ of DEPC-treated water. The quality of the linearized DNA was checked by 
electrophoresis in a 0.8% agarose gel. Its concentration was measured by 
spectrophotometry at the wavelength of 260 nm. The DNA was stored at -20°C. 
2.3.1.5 In vitro transcription and labeling 
RNA was prepared by in vitro transcription of the linearized target DNA 
with appropriate RNA polymerase. The RNA was labeled by digoxigenin (DIG) 
RNA labeling nucleotide mix (Roche), which contained DIG-labeled UTP and 
unlabeled ATP, CTP and GTR The reaction mixture was composed of the following: 
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Linearized plasmid 1 |ag 
Transcription buffer (lOX) 2 |LI1 
DIG RNA labeling nucleotide mix (10 mM) 2 |LI1 
RNasin ribonuclease inhibitor (40 units/|Lil) 0.5 |LI1 
RNA polymerase (20 units/|il) 1.5 i^l 
DEPC-treated water adjusted to 20 \x\ 
The reaction mixture was incubated at 37°C for 2 hr in a thermomixer. 
After incubation, the quality and the size of the RNA was checked by 
electrophoresis in a 0.8% agarose gel. The cDNA remained was degraded by adding 
2 |al of DNasel (10 units/^il; Roche) and incubated at 37°C for 15 min. After that, 
100 |Lil of Tris-EDTA (TE) buffer, 10|i l of 4 M LiCl and 300 |al of ice-cold 100% 
ethanol were added and kept at -20°C for 2 hr to precipitate the RNA probe. Finally, 
the reaction mixture was subjected to centrifugation at 14,000 rpm at 4°C for 5 min. 
The supernatant was discarded and the pellet was dried by SpeedVac for 3 min. The 
DIG-labeled riboprobe synthesized was dissolved in 40 |LI1 of DEPC-treated water 
and stored at -80°C. The concentration and the size were checked by 
spectrophotometry and electrophoresis respectively. 
2.3.2 Sample collection 
Samples were handled by heat-treated RNase-free tools. First, embryos 
were dissected in cold DEPC-treated phosphate buffered saline (PBS) and 
immediately fixed in freshly prepared 4% paraformaldehyde dissolved in 
DEPC-treated PBS for overnight at On the next day, embryos were washed by 
PBT (PBS + 0.1% Tween-20) twice at 4°C. Embryos were then dehydrated by 
- 2 7 -
Chapter 2: General Materials <Sc Mclhocls 
passing through a series of methanol in increasing concentrations (25%, 50%, 75% 
and 100%) at 4°C with gentle rolling. Depended on the size of the embryo, the 
dehydration time ranged from 15 min for E9.5 embryos to 30 min for E l 2 embryos. 
Embryos were kept in 100% methanol at -20°C until use. 
2.3.3 Hybridization 
The processing time for different treatments was depended on the size of 
the embryo and was listed in Table 2.1. All the procedures were carried at room 
temperature unless specifically stated. Embryos were rehydrated by passing through 
a series of methanol in decreasing concentrations (75%, 50% and 25%). After that, 
embryos were washed with PBT twice. Then 6% H2O2 was added in order to 
inactivate endogenous phosphatases. Embryos were washed with PBT for 3 times to 
remove all H2O2. Proteinase K {Roche), at a concentration of 10 |ag/ml, was applied 
to digest the embryo, and the reaction was stopped by 2 mg/ml glycine (BDH). 
Embryos were washed with PBT twice and then fixed in 4% paraformaldehyde with 
0.2% glutaraldehyde in PBT. After washing with PBT twice, pre-warmed 
pre-hybridization mix [50% deionized formamide; 5X SSC (0.75 M NaCl; 0.075 M 
sodium citrate); 1% sodium dodecyl sulphate (SDS); 50 |ig/ml yeast tRNA; 50 
|ig/ml heparin] was added with gentle rocking at 70°C. 
After pre-hybridization, pre-hybridization mix was replaced by 
hybridization solution that contained 1 ^ig DIG-labeled RNA probe in 
pre-hybridization mix. Hybridization was carried out in an incubator at 70°C with 
gentle rocking overnight. 
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Table 2.1 Processing time of different steps for embryos at different stages. 
Stage of embryo E9.5 ElO.O E10.5 Ell.O E11.5 E12.0 
Dehydration in 15 min 20 min 25 min 30 min 30 min 30 min 
methanol 
Rehydration in 15 niin 20 min 25 min 30 min 30 min 30 min 
methanol 
PBT washing x 2 15 min 17 min 17 min 20 min 25 min 30 min 
6% H2O2 50 min 1 hr 1.25 hr 1.5 hr 1.75 hr 2 hr 
PBT washing x 3 12 min 17 min 17 min 20 min 25 min 30 min 
Proteinase K 5 min 10 min 15 min 20 min 25 min 30 min 
Glycine 5 min 5 min 5 min 10 min 10 min 10 min 
PBT washing x 2 12 min 15 min 17 min 20 min 25 min 30 min 
Glutaraldehyde + 20 min 20 min 20 min 30 min 30 min 30 min 
paraformaldehyde 
PBT washing x 2 12 min 17 min 17 min 20 min 25 min 30 min 
Pre-hybridization 1.5 hr overnight 
Hybridization overnight 
2.3.4 Post-hybridization wash and antibody treatment 
On the following day, the hybridization mix was discarded and embryos 
were washed with solution 1 (50% formamide; 5X SSC, pH 4.5; 1% SDS) twice at 
70°C for 30 min in each step. At the same time, holes were pinched in the embryo 
by a tungsten needle to prevent trapping of non-specific probes. After that, sample 
was washed with solution l:solution 2 (0.5 M NaCl; 10 mM Tris-HCl, pH 7.5; 0.1% 
Tween-20) in 1:1 ratio of volume at 70°C for 15 min. Embryos were further washed 
with solution 2 for 3 times for 15 min each. After washing, the remaining unbounded 
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RNA probes were degraded by incubation with 100 ^ig/ml of RNase A {Roche) in 
solution 2 at 37°C for 30 min. After digestion, samples were washed with solution 2 
for 15 min, followed by washing with solution 3 (50% formamide; 2X SCC, pH 4.5) 
for 3 times at 65°C for 30 min each and then with TBST solution (0.14 M NaCl; 2.7 
mM KCl; 25 mM Tris-HCl, pH 7.5; 0.5% Tween-20) for 3 times for 10 min at room 
temperature. Next, embryos at E9.5-E10.5 and E11.0-E12.0 were blocked with 10% 
heat-inactivated sheep serum (Jackson ImmunoReasearch) for 1.5 hr and overnight 
respectively. Embryos were then incubated overnight at 4°C with pre-absorbed 
(refer to sections 2.3.4.1 and 2.3.4.2 for details) alkaline phosphatase-conjugated 
anti-DIG antibody {Roche). 
2.3.4.1 Embryo powder preparation 
Embryo powder was prepared by homogenization of El3.5 mouse 
embryos in PBS. The homogenate was mixed with ice-cold acetone and kept in ice 
for 30 min. After that, the mixture was centrifuged at 10,000 rpm for 10 min at 4°C. 
The pellet was washed with ice-cold acetone, air-dried and then ground into powder. 
It was stored at -20°C. 
2.3.4.2 Pre-absorption of antibody 
Three milligrams of embryo powder was mixed with 0.5 ml TBST and 
heated at 70°C for 30 min. At the same time, sheep serum was heated at 56°C for 30 
min. After heating, both embryo powder and sheep serum were chilled on ice. Then, 
5 [i\ of sheep serum and 1 |al of alkaline phosphatase-conjugated anti-DIG antibody 
was added to the embryo powder mixture and incubated at 4°C for 5 hr. The mixture 
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was then centrifliged at 14,000 rpm for 5 min at 4°C. The supernatant was collected 
and made up to 2 ml with 1% heat-treated sheep serum in TEST. 
2.3.5 Post-antibody wash and staining 
After overnight incubation with the antibody, embryos were washed with 
TEST for three times for 5 min each to remove the unbound antibody. Embryos 
were further washed in TEST for 5 times for 1 hour each to ensure that the embryo 
was free of unbound antibodies. Embryos were then pre-conditioned with NTMT 
(100 mM NaCl; 50 mM MgCk; 100 mM Tris-HCl, pH 9.5; 0.1% Tween 20] for 10 
min. Embryos were then stained in the dark with 22.5 |LI1 of nitro blue tetratzolium 
(NBT, Roche) [75 mg/ml stock in 70% N,N-dimethyl formamide {Sigma)] together 
with 17.5 [L\ of 5-bromo-4-chloro-3-indolyl phosphate (BCIP, Roche) [50 mg/ml 
stock in N,N-dimethyl formamide] in 5 ml of NTMT. When the signal was fully 
developed, embryos were washed with PBT twice to remove all staining solution. 
Embryos were then fixed in 4% paraformaldehyde in PBS at 4°C overnight. On the 
next day, embryos were washed once with PBS for 15 min and then cleared by 
passing through a series of glycerol in increasing concentration (50%, 75% and 
100%). The expression pattern was examined under a stereo micro scope and images 
were taken by a digital camera (DFC 480, Leica). 
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2.4 REAL-TIME QUANTITATIVE REVERSE TRANSCRIPTION 
-POLYMERASE CHAIN REACTION ( R T - P C R ) 
2.4.1 Sample collection 
Samples were handled by heat-treated RNase-free tools. First, embryos 
were freshly dissected in cold DEPC-treated PBS. Excess PBS was removed and 
replaced with 10-fold volume of RNA/a^er RNA Stabilization Reagent (Qiagen). 
The sample in KNAlater solution was kept at 4°C overnight, and then stored at -20°C 
until use. 
2.4.2 RNA extraction 
Total RNA was extracted from the tissue sample by using the Tissue 
Total RNA Mini Kit {Favorgen). First, the RNAtoe厂 solution was removed from the 
sample. The sample was then lysed in 350 |LI1 of F A R B buffer with vortexing to form 
a clear solution. The lysate was filtered through a filter column (provided in the kit) 
into a collection tube. The volume of the clear lysate was measured and equivalent 
volume of cold 70% ethanol was added to the lysate and mixed well. The mixture 
was transferred to a FARB column and centrifuged at 14,000 rpm for 1 min. After 
centrifligation, the RNA was trapped on the column and the flow-through was 
discarded. The column was washed with 500 |il of wash buffer 1, followed by twice 
with 700 1^ 1 of wash buffer 2. The flow-through was discarded, and the column was 
dried by centrifugation at 14,000 rpm for 3 min. The column was put into an elution 
tube. DEPC-treated water at a volume of 40 |LI1 was added to the center of the 
column and allowed to stand for 2 min. The tube was centrifuged at 14,000rpm for 2 
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min to elute the extracted RNA. RNA concentration was measured by a 
spectrophotometer at the wavelength of 260 nm. The RNA solution was stored at 
-80°C for further use. 
2.4.3 Reverse transcription into cDNA 
The extracted RNA was used as a template for transcribing into cDNA by 
the use of High Capacity cDNA Reverse Transcription Kit {Applied Biosysterns). 
The reaction mixture was composed of the following: 
Extracted RNA 5 [ig 
Reverse transcription buffer (lOX) 1 |il 
dNTP(lOOmM) 0.4 |al 
Reverse transcription random primers (lOX) 1 jil 
丁 IV/f 
MultiScribe Reverse Transcriptase (50 units/|j,l) 0.5 |il 
RNase inhibitor (20 units/|il) 0.5 |il 
DEPC-treated water adjusted to 10 |al 
Reverse transcription was performed in a CI000 Thermal Cycler 
(BioRad) at 25°C for 10 min, 37°C for 120 min and 85°C for 5 sec. The cDNA 
synthesized was stored at -20°C for further use. 
2.4.4 Quantitative real-time PCR 
The cDNA synthesized was subjected to PCR by using the ABI 7900 
Fast Real-Time PCR system {Applied Biosystems). Before the reaction, cDNA was 
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diluted 10-fold with DEPC-treated water and the reaction mixture was composed of 
the following: 
Diluted cDNA 1 |il 
Forward primer (400 |LIM) 0.125 i^l 
Reverse primer (400 |LIM) 0.125 |il 
iTaq SYBR® Green 
PGR Master Mix (2X) (BioRad) 2.5 |al 
DEPC-treated water adjusted to 5 pi 
Standards of cDNA with known concentrations of the target gene (refer 
to section 2.4.5) were added alongside with the sample in order to quantify the 
amount of DNA in the sample. Each sample and standard was applied in triplicate to 
ensure accurate measurement. The reaction mixture was amplified with PCR 
conditions set up as follow: initiation at 95°C for 10 min, followed by 40 cycles 
comprising of denaturation at 95°C for 15 sec, annealing at 55°C for 30 sec and 
extension at 72 for another 30 sec. The result was analyzed by ABI Prism® SDS 
2.3 software (Applied Biosystems). 
2.4.5 Preparation of cDNA standards 
The cDNA of the target gene was synthesized from cDNA plasmids as 
described in sections 2.3.1.2 to 2.3.1.4. After the cDNA was synthesized, its 
concentration was determined by a spectrophotometer at the wavelength of 260 nm. 
It was subjected to 10-fold serial dilution to form standards ranging from 0.02 pg to 
20 pg. These cDNA known concentrations were used as the standard for RT-PCR. 
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2.5 HIGH PRESSURE LIQUID CHROMATOGRAPHY ( H P L C ) 
2.5.1 Chromatographic system 
HPLC is a commonly used method for measurement of retinoids. It is 
highly specific, sensitive and accurate. It can also detect different forms of retinoids 
in the sample. HPLC was performed by Alliance® HPLC System with a 2996 
photodiode array detector (Miters). The Alliance column heater was used to control 
the temperature within the column. Instrument control and data processing were 
done by Empower 2 software (Miters). The column used was Sunfire CI8 Sentry 
Guard column (Waters) 4.6 x 150 mm with 5 [im beads. 
2.5.2 Standards preparation 
RA stock solution was prepared by dissolving RA in absolute ethanol. It 
was placed in a micro fuge tube, gassed with nitrogen, sealed with parafilm and 
wrapped in aluminum foil to prevent degradation by oxygen and light. It was stored 
at -80°C. The concentration of the RA solution was determined by Beer's Law. 
Molar extinction coefficient of a\\-trans RA is 39750 while the equivalent 
wavelength is 325 nm (Gundersen and Bio mho ff, 2001). 
Standards calibration was carried out by diluting RA stock solution with 
ethanol to produce RA concentrations at 1, 2, 5 and 10 ng/ml. The calibration curve 
was constructed with the y-axis being the peak area and x-axis being RA 
concentrations. The retention time for RA was determined by injecting RA alone. 
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2.5.3 Embryo sample preparation 
The RA in the embryo sample was first extracted before quantification by 
HPLC. The extraction protocol was modified from Suh et al. (2006), All the 
procedures were carried in the dark to prevent photo-degradation of RA. The 
embryo sample was transferred to a 15 ml falcon tube. Two millilitres of cold PBS 
with 33.3 nM acitretin (Fluka) was added to the tube. Acitretin was an external 
standard important for calculation of the recovery ratio (refer to section 2.5.5). The 
tube was chilled on ice and the embryo sample was lyzed by sonication (Vibra-Cell 
v e x 130, Sonics & Materials) with a pulse of 10 sec on and 30 sec off for a total of 
6 cycles. Ten micro litres of the lysate was used for protein measurement by Bradford 
assay (section 2.5.6). Acetonitrile/butano 1 (1:1, v/v) at a volume of 1.4 ml and 0.01% 
antioxidant butylated hydroxy! toluene (BHT, Sigma) were added to the lysate and 
vortexed for 60 sec. After that, saturated K2HPO4 solution (1.3 kg/L, USB) was 
added and mixed for 30 sec, followed by centrifUgation at 4,000 g at 4°C for 10 min. 
The supernatant was collected and dried by nitrogen gas. The dried extract was first 
dissolved in 500 of methanol, followed by addition of 500 |LI1 of PBS. Both steps 
were carried out under ultrasonification to facilitate the dissolution. Finally, the 
sample was filtered by 0.22 ^im nylon filter and transferred to the auto sampler for 
HPLC analysis. 
2.5.4 HPLC conditions 
The condition of HPLC was conducted according to Schmidt et al. (2003) 
with some modifications. The pH of 40 mM ammonium acetate buffer (USB) was 
adjusted to 5.75 by acetic acid. Ammonium acetate buffer and methanol (1:1, v/v) 
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was used as Bulfer A, while pure methanol was used as Buffer B. The proportion of 
these buffers at different time was listed in Table 2.2. 
Table 2.2 HPLC conditions to elute retinoic acid. 
“ T i m e (min) Flow (ml min]) % Buffer A % Buffer B 
0 0.1 ^ 
1 0.8 ^ 15 
20 0.8 0 100 
22 ^ 0 
23 0.8 ^ 15 
34 0.8 85 15 
The column was kept at 30°C and the wavelength for sample detection 
was 340 nm. RA was quantified by using the standard curve as described in section 
2.5.2 
2.5.5 Sample recovery 
RA in the sample might not be totally extracted. Moreover, RA extracted 
might be lost during processing. In order to calculate the exact amount of RA in the 
sample, sample recovery had to be calculated. Before sample preparation, 33.3 nM 
of acitretin (external standard) was added into the sample. After extraction and 
quantification of RA, the recovery ratio was calculated by comparing the peak area 
of acitretin in the sample and the peak area of direct injection of acitretin only. Thus, 
the exact amount of RA in the sample could be calculated with the calibration curve 
and the recovery ratio. 
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2.5.6 Bradford assay 
The protein concentration of the sample was measured by Bradford assay 
(Bradford, 1976). The standard curve was determined by known concentrations of 
bovine serum albumin (BSA, Sigma), ranging from 0 to 25 |ag/ml. The sample, at a 
volume of 800 was well mixed with 200 |LI1 of Bradford solution (Bio-rad) for 10 
min at room temperature and a blue colored solution was formed. The protein 
concentration was positively proportional to the blue colour intensity. The intensity 
was measured by a spectrophotometer at the wavelength of 595nm. 
2 .6 RA-RESPONSIVE CELL LINE 
RA-responsive cell line was first developed by Wagner in 1992 
(McCaffery et a l , 1992). This reporter cell line was derived from the F9 cell line 
that was stably transfected with the RAR/] gene, which has a RARE in the promoter 
region and a lacZ gene as the reporter. In the presence of RA, RA will first bind to 
the RA receptor in the cell. This complex will then bind to the RARE and drives the 
expression of lacZ gene that codes for the p-galactosidase enzyme. When the 
substrate 5-bromo-4-chloro-3-idolyl-P-galactopyranoside (X-gal) is added, 
P-galactosidase will turn it into a blue colored product. Thus, increasing RA 
concentrations will increase the expression of P-galactosidase, resulting in the 
formation of more blue colored products. The intensity of blue colored products can 
be measured by a spectrophotometer. This cell line is very sensitive to RA and can 
detect a wide range of RA concentrations from to 10'^ M. 
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2.6.1 Cell culture 
Cells in freezing medium were kept in a sealed plastic ampule and stored 
in liquid nitrogen. All procedures of handling the cell were done in a sterilized 
bio-safety cabinet. Cells were immediately thawed in a 37°C water bath after 
removing from the nitrogen tank. The ampule was then sterilized by 70% ethanol 
and cut open with a hot knife. The cells in the freezing medium were pipetted into 
10 ml of Hanks' medium {Gibco) immediately in order to dilute the toxic effect of 
the thawed dimethyl sulfoxide (DMSO) in the freezing medium. Cells were spun 
down by centrifugation at 3,000 rpm for 3 min. The cell pellet was resuspended in 5 
ml of culture medium at 37°C. The composition of the culture medium is listed 
below: 
Dulbecco's Modified Eagle's Medium (DMEM, Gibco) 
Fetal bovine serum (FBS, Gibco) 10% of total volume 
NaHCOs 1.5 g 
G418 {Sigma) 2 mg/ml 
Penicillin G {Sigma) 100 units/ml 
Streptomycin {Sigma) 0.1 mg/ml 
Autoclaved water adjusted to 1 L 
Cells in 5 ml culture medium were grown in a 25 c m � culture flask 
(Nunc), which was pre-coated with 0.1 % gelatin solution and kept in a 5% CO2 
incubator at 37°C. The medium was changed daily. When cells almost reached full 
confluence, they were detached from the flask by incubating with 3 ml of 0.25% 
trypsin (Gibco) at 37°C for 2 min. Reaction was stopped by adding 10 ml of culture 
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medium, and cells were then spun down by centrifugation at 3,000 rpm for 3 min. 
The cell pellet was resuspended in 2 ml of culture medium for further culture or for 
seeding the 96-well plate as described in section 2.6.2. To store the cell, 1 ml of 
freezing medium was used to resuspend the cells instead of the culture medium. 
Cells suspended in freezing medium were pipette into a plastic ampoule and the 
ampoule was carefully sealed by heating the neck of it. Sealed ampoule was first 
cooled above the liquid nitrogen for 2 hr, and then immersed in liquid nitrogen for 
long term storage. 
2.6.2 Seeding and loading sample to 96-well plate 
A 96-well plate {Nunc) was used to carry out the RA-responsive cell line 
assay. All the wells were first incubated with 100 [d of 0.1 % gelatin for half an hour. 
The gelatin solution was then discarded and each well was washed once with 100 fil 
of Hanks' medium (Gibco). 
The number of cells suspended in the culture medium was counted by 
using a hematocytometer. Cells at a density of 4x10'^ in 100 \x\ of culture medium 
were seeded onto each well and then incubated at 37°C until reaching about 80% 
confluence. The RA-containing sample in 100 |il of culture medium and RA 
standard solutions at a volume of 100 |LI1 were added to separate wells. The RA 
standard solutions were prepared by serial dilution of 100 mM RA stock solution to 
• 7 12 • 
form RA solutions at final concentrations from 10' M to 10' M following the 
procedure in Table 2.3. 
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Table 2.3 Procedures for making RA standard solutions at different 
concentrations. 
Volume of 
Final concentration Volume of Volume of , 
culture 
o f R A RA solution DMSO . 
medium 
lOmM 10 III of 100 m M R A 9 M -----
1 mM 10 of 10 m M R A -----
500 |iM 50 III of 1 m M R A ^ 50 
10 _ (10-5 M ) * 20 III of 500 M R A -…- 980 
10-6 - 10-12 M 10-fold serial dilution with culture medium 
The RA standard solutions were added in triplicate for accurate 
measurement. Cells was incubated in a 5% CO2 incubator at 37°C for 16 hr, which 
was previously shown to be the time for maximal expression of P-galactosidase in 
the cell (Lee, 2008). 
2.6.3 X-gal staining 
Quantification of the enzyme p-galactosidase was done by adding its 
substrate X-gal (Gibco) to form blue colored products. At the end of the culture 
period, cells were subjected to X-gal staining. First, the culture medium was 
discarded and cells were fixed with 100 |al of 1% PBS for 10 min at room 
temperature. After fixation, cells were washed with 100 \i\ of PBS for three times. 
This was followed by adding 100 |al of staining solution (1 mg/ml X-gal in dimethyl 
formamide; 3.3 mM KFe(CN)6.31^20; 3.3 mM K3Fe(CN)6-3H20; 6 mM MgCh in 
PBS) to each well and stained for 2 hr in a 37°C incubator protected from light. 
After staining, the cell was washed with 100 |al of PBS for three times. The intensity 
of the blue colored products formed was then measured by a spectrophotometer 
(Benchmark, BioRad) at the wavelength of 650 nm. 
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3.1 INTRODUCTION 
Either too much or too little RA is found to cause malformations in 
embryos. The underlying mechanism for its teratogenicity remains unclear. 
Susceptibility to RA depends on several factors, including the developmental stage 
of embryo at the time of RA exposure, the dosage of RA, the genotype of the 
offspring, the method of administration and other environmental factors. 
3.1.1 Time response to RA 
As discussed in section 1.4.3, Shenefelt (1972) demonstrated that 
different malformations in hamsters could be induced by RA treatment at specific 
time period. Experiments involved administration of RAto pregnant hamsters at 6 hr 
interval from hour 18 on day 5 of gestation (E5-18hr) to E12-18hr. The critical 
period for RA administration to induce specific malformations was also shown in 
mouse and rat fetuses. A single dose of RA was injected intraperitoneally to C57 
pregnant mice on E7, E8, E9, ElO or E l l (Ozeki, 1998). Results showed that 
anophthalmos appeared in the E7 group alone, microphthalmos was found in E7 and 
E8 groups, whereas goniodysgenesis was shown in the E7, E8, and E9 groups. These 
findings suggested that even when targeting the same organ, i.e. the eye, different 
time of RA administration could cause different types of eye abnormalities in the 
mouse fetuses. Besides causing specific malformations, behavioral effects were also 
affected by RA in a stage-dependent manner. For example, exposure of RA to 
pregnant rat on E l l - E l 3 , but not earlier or later, increased daytime activity of the 
offspring in residential running wheels (Holson et al., 1999). Moreover, 
embryo lethality was also dependant on the time of RA administration. One hundred 
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percent resorption was only found when 120 mg/kg body weight of RA was fed to 
pregnant rats on ElO (Kistler, 1981). All these findings suggest that the susceptibility 
to RA teratogenicity depends on the developmental stage of the embryo at the time 
of exposure. 
In general, embryo development can be divided in three stages, which are 
early germ layer stage, organogenesis stage and fetal stage. During blastocyst and 
early germ layer stages, which is about week 2 in human pregnancy, embryos are 
relatively less sensitive to teratogenic agents including RA. During this stage, most 
embryos are found with an ‘‘all or none，，response to RA (Kistler, 1981). Embryos 
that cannot withstand the teratogenic effect of RA will die and be eliminated, while 
the rest will develop normally. 
Conversely, embryos during organogenesis (about week 3 to week 8 in 
human gestation) are highly sensitive to RA teratogenesis. Most embryonic anlagen 
start to proliferate at this period, which is controlled by RA. Overdose of exogenous 
RA will perturb its signaling in the anlage and elicit spectrum of malformations in 
fetuses, including CNS and urogenital defects, abnormalities of eyes and ears, and 
also malformed limbs. Moreover, RA administration at this period was found to 
disturb the expression of Hox genes (Simeone et al., 1995), which are important for 
normal anteroposterior patterning in early embryo development. Excessive apoptosis 
was also found at the craniofacial region and tail bud region after RA treatment 
during organogenesis (Noriko Osumi-Yamashita, 1992; Shum et a l , 1999). 
During fetal stage, which is from the end of week 8 until parturition in 
humans, susceptibility to RA-induced anatomical malformations is gradually 
decreased. Yet, this is the period which is sensitive to behavioral teratogenesis 
(Auroux, 1997). When pregnant rats were overdosed with RA at this period, the 
quantity of neuroblasts in fetuses as well as 10-days postnatal rats were found to 
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dccrcasc ami sonic of the newborns exhibited spasticity, tremors imd hyperactivity 
(Langiiian and Welch, 1 %7). Behavioral tcratogcncsis was also lb unci in human 
cases; pregnant women who were exposed to 13-cis RA gave birth to children 
without observable malformations but with rcduccd intelligence (Adams J, 1991). 
Tcratogenesis of ethanol was found to have similar time response as RA. 
Like RA’ administration of ethanol to pregnant mouse at E7 caused microphthalmia 
(Godin et al., 2010), at E8 induced exencephaly (Kotch and Sulik, 1992), at E8.5 
yielded heart malformations (Daft et al., 1986) and at E9 yielded malformed limbs 
(Kotch et al., 1992). It is proposed that ethanol takes part in the alternation of RA 
level in the embryo (Duester, 1991; Godin et al., 2010). 
3.1.2 Dose response to RA 
Many experiments demonstrate that RA exhibits dose-dependent 
teratogenic effect on embryos. When a single dose of 2.5, 10, 30，60 or 100 mg/kg 
RA was orally administered to pregnant mice (Campbell et al., 2004), limb defects 
and cleft palate were found to be induced in a dose-dependent manner. It is 
suggested that RA has a threshold dose for its teratogenicity to induce a particular 
defect in the embryo. However, the threshold value for human teratogenicity has 
been debated for centuries. One prospective study was conducted from 1984 to 1987 
(Rothman et al., 1995) in which 22,748 pregnant women were examined on their 
diets, medications, illnesses, chemical exposure as well as medical history. From 
these women, 339 babies were found with congenital defects, and results showed 
that the prevalence was related to vitamin A intake during the first trimester of 
pregnancy. It was suggested that the threshold intake of vitamin A per day was 3,000 
RE. About I in 57 fetuses was found with dcfccts attributed by vitamin A intake over 
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this threshold. 
RA has a short half life. It was shown that when 100 mg/kg of RA was 
orally administered to pregnant micc at E l l , RA was fully metabolized within 8 hr 
(Satrc and Kochhar, 1989). Normally, maternal RA docs not pass to the embryo 
through the placenta. However, when exogenous RA was applied to pregnant mice, 
RA levels in the embryo had elevated 5- to 10-fold as soon as 1 hour after RA 
treatment (Kochhar, 1976) and reached a maximum level at 3 hr (Satre and Kochhar, 
1989). 
3.1.3 Other factors affecting susceptibilities to RA 
Sensitivity to RA teratogenicity in different species and strains is well 
studied, \3-cis RA induced limb malformations in humans, primates and also rabbits 
(Hummler et a l , 1990; Rizzo et al., 1991; Tzimas et al., 1994). However, rats and 
mice were totally unsusceptible (Tzimas et al., 1994; Nau, 1995). There are also 
strain differences to RA teratogenicity. Differential susceptibility to teratogenic 
doses of vitamin A was demonstrated in three strains of albino rats (Nolen, 1969). 
Also, among different mouse stains, C57 mice are more susceptible to RA-induced 
eye defects than ICR mice (Lau, 2009). 
Other than genetic differences, different routes of administration of RA 
can also cause variations in susceptibility. RA can be supplied to animals by 
incorporation into the diet, oral gavage, and subcutaneous, intramuscular or 
intraperitoneal injection. The choice of administration method depends on the type 
of animal models used, the dosage of RA, and how long RA is required to be 
sustained. Experiments showed that many retinoids were teratogenic when applied 
to pregnant animals orally, but not teratogenic when administered dermally 
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(Kochliar and Cliristian, 1()()7). Moreover, I he blood level of� re t inoid alter oral 
retinoid treatment was louncl to be higher than the blood level oi" retinoid Ihllovving 
dermal injection (Johnson, 1997). 
Environmental changes including temperature, noise, humidity and light 
may also affect the susceptibility to RA in animals. Mice arc highly sensitive to the 
changc of light-dark cycle. The circadian clock is synchronized by light. In 
mammals, it regulates energy homeostasis and prepares individuals for predictable 
events such as sleep and food availability. Experiment confirmed that disturbance of 
the circadian clock might affect glucosc tolerance in mice (Fonken et al., 2010). Our 
laboratory has shown that maternal blood glucose level can affect RA level in the 
embryo (Chan, 2011), further supporting that the susceptibility of the embryo to RA 
will depend on environmental factors. 
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3.2 i:\Pl:KIMi:N rAI. l)i:SICN 
As mentioned earlier, the critical period for RA to inducc specific 
malformation in some organs is well before the presence of that specific anlagc. 
Moreover, both excess and deficiency of RA can induce same types of 
malformations in some organ systems. However, to date, all the known teratogenic 
mechanisms of RA cannot explain these phenomena. The aim of this thesis was to 
test my hypothesis of “too much causes too little’’，i.e. excess RA exerting 
teratogenic effect via causing RA deficiency, in accounting for these phenomena. 
This hypothesis was tested by using our established RA-induced renal 
malformations mouse model as described in section 1.6.1. This model was chosen 
because the two mentioned phenomena occurred in this model, and also because it is 
already known that excess RA induces renal malformations via down-regulation of 
夏竹/ and increases in apoptosis. Thus, I can test whether these changes may be 
explained by my proposed mechanism. First, I have determined the time and dose 
response to RA teratogenicity in inducing renal malformations. I have carried out 
this study again instead of adopting the same dose and time point that were 
originally developed by our laboratory. It was because the RA-induced renal 
agenesis mouse model in our laboratory was established more than 10 years ago and 
many factors including the building for holding the animals and the rodent chow fed 
to the animals had changed. Moreover, the ICR mouse stock had changed as well 
since there was a virus outbreak at the Laboratory Animal Services Centre and all 
ICR mice of the old colony were eradicated and breeding pairs were imported for 
rc-cstablishment of a new colony. All these environmental and genetic factors 
aftcctcd the embryo's susceptibility to the teratogenic effect of RA. More 
importantly, sincc my hypothesis might not be limited to RA-induccd renal 
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mal mat ions, but could he applied to other types ofdcfccts induccd by tcratogcniu 
doses of RA, there lore, the Ircquciicy of other mallbrmations was also examined in 
the time and dose response studies. 
RA in varying dosages was injected to pregnant inicc at different time 
points. Pregnant micc were sacrificed at E l8 and fetuses were removed for 
examination of renal malformations as well as other defects. 
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3.3 IVl VI KKIALS AND IMl/mODS 
1 Time response to RA 
Preparation of RA stock suspension was described in section 2.2. The RA 
suspension stored at 4 T was warmed to room temperature and vortexed for a minute 
before use. The RA stock suspension in a concentration of 6.66 mg/ml was injected 
intraperitoneally into pregnant mice at a dose of 125 mg/kg body weight on one of 
the 4 time points: E8-20hr, E8-22hr, E9 or E9-2hr. Mice injected with equivalent 
volume of suspension vehicle (15 j-il/g body weight) at E8-22hr served as the control. 
Pregnant mice were sacrificed at E l8 and fetuses were removed for morphological 
examinations. 
3.3.2 Dose response to RA 
Different dosages of RA (25, 50, 100, 125 and 150 mg/kg) was injected 
to pregnant mice at E8-22hr. The RA stock suspension was diluted with peanut oil so 
that equivalent volume (15 |il/g body weight) was injected for different dosages 
(except a larger volume of the RA stock suspension was injected for the dosage of 
150 mg/kg because it was difficult to make RA suspension at a concentration higher 
than 6.66 mg/ml). Mice injected with equivalent volume of suspension vehicle 
served as the control. Similar to the time-response study, pregnant mice were 
sacrificed at El 8 and fetuses were removed for morphological examinations. 
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Examination of fetuses 
RA-treated mice were sacrificcd at El8 by ccrvical dislocation and 
near-term fetuses were removed from the uterus. The number of implantation sites, 
resorption sites and live fetuses were recorded. Live fetuses were dried by tissue 
paper, and their weight, crown-rump length, head length and tail length were freshly 
measured. Fetuses were then killed by hypothermia via keeping at 4 � C for 3 hr 
before examination. External malformations of the eye, ear, jaw, palate and limb 
were inspected under a stereomicroscope. The abdomen was open and the 
development of the kidney was visually examined. 
3.3.4 Statistical analysis 
The effect of RA in inducing renal malformations was compared by 
Jonckheere-Terpstra test. Normal kidney and different types of renal malformations 
were classified into 6 grades, from the least severe to the most severe. The grading 
system was shown in Table 3.1. 
Table 3.1 Grading system of renal malformations 
Renal malformations Grading 
Two normal kidneys 1 
Unilateral non-agenesis renal malformations 
(contralateral kidney being normal) 2 
Bilateral non-agenesis renal malformations 3 
Unilateral renal agenesis (remaining kidney being normal) 4 
Unilateral renal agenesis 
(remaining kidney with non-agcncsis renal malformations) 5 
Bilateral renal agenesis 6 
- 5 1 -
(luiptcr J: Time Dose Responses lo KA 
By using the same grading system, correlation between renal 
iiKil format ions and the time or the dose of RA treatment was determined by 
Spearman's rank correlation. This test will carry out a non-parametric measure of� 
statistical dependence between two variables and generate a Spearman's rank 
correlation coefficient (/:、）with a value ranging from -1 to +1. A value closes to -1 
means there is a strong negative correlation between the two variables, while a value 
doses to +1 means there is a strong positive correlation between the two variables. 
The extent of statistical dependence is shown in the /7-value. 
Different growth parameters (weight, crown-rump length, head length 
and tail length) and frequencies of different non-renal malformations between 
RA-treated and control groups were compared by Independent Samples t-test and 
Chi-square test respectively. All statistical analyses were performed using SPSS 
software {SPSS), with statistical significance level set at 尸 < 0.05. 
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3.4 Ri : s i ) i ; r s 
3.4.1 Time response 
Our laboratory has previously shown that 125 mg/kg of RA injected at 
mid-gestation caused caudal regression syndrome alongside with renal 
malformations in the fetuses. This mouse model was employed for testing the 
hypothesis of "too much causes too little" as the underlying mechanism of 
RA-induced renal malformations and possibly other types of malformations To 
begin with, a detailed time response study was carried out to determine the critical 
period of injection of 125 mg/kg of RA in inducing renal malformations. RA was 
injected at several time points including E8-20hr, E8-22hr, E9 and E9-2hr, whereas 
control was injected with vehicle on E8-22hr. Kidney development was then 
investigated in El 8 fetuses (one day before birth). 
3.4.1.1 Time response to RA-induced resorption 
RA injected at mid-gestation increased the frequency of resorption of the 
fetuses. Results were tabulated in Table 3.2 and presented in Graph 3.1. For the 
control injected with vehicle on E8-22hr, the frequency of resorption was only 3%. 
When 125 mg/kg of RA was injected on E8-20hr, half of the fetuses (50%) were 
resorbed. Interestingly, when the same dose of RA was injected 2 hr later, which was 
E8-22hr, resorption was reduced to 14.04%. The frequency further reduced to 
11.71% and 10.61% when RA was injected on E9 and E9-2hr respectively. These 
results suggested that the earlier the time of RA injection, the higher the pcrccntagc 
of embryos being resorbed. 
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3.4.里.2 Time response to RA-indiiccd renal malformations 
RA induced different types of renal malformations in the fetuses. These 
included renal agenesis and non-agenesis renal malformations such as hypoplastic 
kidney, polycystic kidney and dysplastic kidney. They could occur either unilaterally 
or bilaterally. Different types of renal malformations in El 8 fetuses were illustrated 
in Figure 3.1. As shown in the control (Figure 3.1 A), two bean-shaped kidneys were 
clearly seen and a pair of adrenal glands were located above the two kidneys. Figure 
3. IB illustrated an example of bilateral renal agenesis, which is the most severe type 
of renal malformation. Both kidneys were absent in the fetus, however, a pair of 
adrenal glands was still clearly seen. Figure 3.1C showed an example of unilateral 
renal agenesis alongside with a normal kidney. The kidney on the left side of the 
figure was absent while the kidney on the right was normal. Figure 3.ID showed 
another example of unilateral renal agenesis, but the remaining kidney was 
hypoplastic (right side of the figure). The hypoplastic kidney was significantly 
smaller in size than the normal one. Figure 3.IE showed a dysplastic kidney (left 
side of the figure) together with a normal kidney. Dysplastic kidney was dysregular 
in shape and the original bean shape was distorted. Figure 3.IF showed an example 
of bilateral polycystic kidney, which could be recognized by the presence of 
fluid-filled cysts. In all the different types of renal malformations, a pair of adrenal 
glands was always present. 
Injection of 125 mg/kg RA at different time points induced different 
frequency and types of renal malformations in the fetuses. Results were tabulated in 
Table 3.2 and presented in Graph 3.2. Results of statistical analysis on the etYect of 
RA injected at different time points in inducing renal ma 1 format ions were shown in 
Tabic 3.3. 
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In the vcliiclc-trcatcd control group, all the fetuses possessed normal 
kidneys. When RA was injcctcd on n8-2()hr, 100% of the fetuses were found with 
renal malformations, among which 75% exhibited the most severe type of renal 
malformations, i.e. bilateral renal agenesis, and 11% developed unilateral renal 
agenesis. The remaining malformations found were polycystic kidney, dysplastic 
kidney and hypoplastic kidney. The frequency of occurrence of these non-agenesis 
malformations was similar. When RA was injected on E8-22hr, which was 2 hr later, 
renal malformations occurred in a similar pattern. All of the fetuses were found with 
renal malformations, with 75% being bilateral renal agenesis and 8% being 
unilateral renal agenesis. Statistical analysis result indicated that the effect of RA 
injection at these two time points in inducing renal malformations did not show any 
significant difference. However, when RA injection was shifted 2 hr later (E9), the 
frequency of renal malformations was reduced to 83%. Moreover, the frequency of 
bilateral renal agenesis dramatically dropped from 75% to 27%. Most of the 
malformations found were bilateral non-agenesis renal malformations. The effect of 
RA injection on E9 in inducing renal malformations was significantly different from 
the effect of injection on E8-20hr (p < 0.001) and E8-22hr (p < 0.001). When RA 
was injected on E9-22hr, the frequency of renal malformations was further reduced 
to 69%, but there were no significant differences in terms of the severity of 
malformations in comparison to injection on E9. 
By testing the results with Spearman's rank correlation, it was shown that 
there was a significant negative correlation (r, = -0.419; p < 0.001) between the time 
of RA injection and renal malformations, i.e. the earlier the RA was injected, the 
higher the frequency and the more the severity of renal malformations were found in 
the fetuses. Taken together, results showed that RA-induced renal malformations 
was time-dependent. 
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riiMt�3.:2 Kffect of 125 iii^/k^ RA or vchicic as control injected at different 
time points on resorption and in inducing renal malformations. 
Treatment groups Control RA (125 mg/kg) 
Injection time E8-22hr E8-20hr E8-22hr E9 E9-2hr 
No. of litters 5 5 9 10 5 
No. of implantations 66 56 114 111 66 
No. of live fetuses 64 28 96 98 59 
No. (%) of implantations 2 28 18 13 7 
underwent resorption (3) (50.00) (15.79) (11.71) (10.61) 
No. (%) of live fetuses with 64 0 0 17 18 
two normal kidneys (100) (0) (0) (17.35) (30.51) 
No. (0/0) of live fetuses with 0 28 96 81 41 
renal malformations (0) (100) (100) (82.65) (69.49) 
R.H 1 1 . 0 21 72 26 15 -Bi la tera l renal agenesis 
(0) (75.00) (75.00) (26.53) (25.42) 
-Unilateral renal agenesis 
(remaining kidney with 0 3 8 1 1 5 
non-agenesis renal (0) (10.71) (8.33) (11.22) (8.47) 
malformations) 
-Unilateral renal agenesis 
0 0 0 1 0 
(remaining kidney being 
normal) � � � 0.02) (0) 
-Bi la te ra l non-agenesis 0 2 10 33 10 
renal malformations (0) (7.14) (10.42) (33.67) (16.95) 
-Unilateral non-agenesis 
renal malformations 0 2 6 10 11 
(contralateral kidney (0) (7.14) (6.25) (10.20) (18.64) 
being normal) 
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Table Statistical analysis on the effect of 125 nij^/k^ RA injected at 
different time points in inducing renal malformations. 
TIME RESPONSE 
Renal malformations 
‘ • ‘ I I .11 I I ,1. . .1 - . , . . . . . . I I . . . _. • 
Time of RA injection E8-20hr E8-22hr E9 E9-2hr 
厂-value vs. control < 0.001* < 0.001* < 0.001 * < 0.001 * 
/;-valuc vs. E8-20hr - 0.975 <0.001* <0.001* 
/?-value vs. E8-22hr - - < 0.001* < 0.001* 
"-value vs. E9 - - _ 0.091 
Spearman's rank correlation 
rr • . � -0.491 coerricient (/•、.） 
尸-valiie of Spearman's rank 
. <0 .001 ' 
correlation 
* Statistically significant (Jonckheere-Terpstra test) 
# Statistically significant (Spearman’s rank correlation) 
3.4.1.3 Time response to RA-induced changes in growth parameters 
Besides inducing renal malformations, RA also affected various growth 
parameters of the fetuses. Four growth parameters were measured. They were 
weight, crown rump length (CRL), head length (HL) and tail length (TL). All of 
these parameters were measured on fresh E l8 fetuses once they were removed from 
the uterus. The way to measure CRL, HL and TL was illustrated in Figure 3.2. 
Results were summarized in Table 3.4 and presented in Graph 3.3. Results of 
statistical analysis on the effect of RA injected at different time points on various 
growth parameters were shown in Table 3.5. 
The mean weight of E l8 fetuses was 1.29 g. The weight of fetuses 
treated with RA at all 4 time points was significantly (p < 0.001) reduced when 
compared with the control (Graph 3.3A). When RA was injcctcd on BcS-20hr, the 
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mean weight of fetuses was rcclucccl by over 31% to ().S9 g. RA injcction on l'X-22lir 
gavc similar result. The mean weight of fetuses with RA injcction on F.9-21ir was 
1.05 g, which was the highest among the four RA-trcatcd groups. These results 
showed that the earlier the time of RA injection, the larger the reduction on the 
fetus's weight. 
Crown-rump length is a typical measurement for estimating the 
gestational age or general growth of the embryo. It is the length from the top of the 
head (crown) to the bottom of the buttock (rump) (Figure 3.2A). RA-treated fetuses 
were all significantly {p < 0.001) reduced in their CRL when compared to the 
control (Graph 3.3B). Again, the effect on CRL by injection on E8-20hr and E8-22hr 
did not show any significant difference. A trend similar to the result of the weight 
was found, i.e. the earlier the time of RA injection, the greater the reduction on the 
fetus's CRL. 
The head length is measured from the tip of the nose to the hindbrain 
(Figure 3.2B). Fetuses that were subjected to RA treatment at all time points had a 
significant (p < 0.001) reduction in the HL in comparison with the control (Graph 
3.3C). RA treatment on E8-22hr resulted in fetuses with the smallest HL. However, 
this value was not significantly different from the HL of fetuses injected with RA on 
E8-20hr. Again RA injected on E9-2hr caused the least reduction in HL among these 
4 time points. 
The tail length is defined as the length from the base to the tip of the tail 
(Figure 3.2C). The mean tail length of control fetuses was 12.17 mm. After RA 
treatment at the 4 time points, all fetuses were consistently found with absence of 
tail (Graph 3.3D). So, the effect of RA injection at the 4 time points on tail length of 
fetuses at El 8 was the same. 
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Tahle 3.4 Kffcct of 125 nij»/kg RA or vchicic as control injected at different 
time points on various growth parameters of E l8 fetuses. 
Treatment groups Control RA (125 mg/kg) 
Injection time E8-22hr E8-20hr E8-22hr E9 E9-2hr 
No. of litters 5 5 9 10 5 
No. of live fetuses 64 28 96 98 59 
Mean weight (g) 1.29 0.89 0.91 0.96 1.05 
士 SEM ±0.01 ±0.02 ±0.01 ±0.01 ±0.02 
Mean CRL (mm) 23.85 19.98 19.46 20.60 21.98 
i S E M 士 0.12 士 0.Z3 ±0.16 土 0.12 士 0.25 
Mean HL (mm) 11.70 10.06 9.84 10.23 10.69 
士 SEM ±0.06 土 0.10 土 0.07 ±0.05 士 0.11 
Mean TL (mm) 12.17 
0 0 0 0 
土 SEM 士 0.06 
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lahle 3.5 Statistical analysis on the effect of 125 nij^/k^ RA injected at 
ditfereiit time points on various j»rowth parameters of El8 fetuses. 
TIME RESPONSE 
_ _ _ _ _ _ _ _ Weight 
Time of RA injection E8-20hr E8-22hr E9 E9-2hr 
I II -丨 I • 
/，-value vs. control <0.001* <0.001* <0.001* < 0.001* 
/;-value vs. E8-20hr - 0.574 0.004* <0.001* 
/?-value vs. E8-22hr - - 0.003* <0.001* 
/;-value vs. E9 - - _ <0.001* 
CRL 
Time of RA injection E8-20hr E8-22hr E9 E9-2hr 
“ ‘ •' • “ •' ‘ •••• ‘ • - •‘ • “‘ - I • I I ... I I, M I 
/?-value vs. control < 0.001* < 0.001* < 0.001* < 0.001* 
/7-value vs. E8-20hr - 0.101 0.015* <0.001* 
"-value vs. E8-221ir - - <0.001* <0.001* 
尸-value vs. E9 - - _ <0.001* 
HL 
Time ofRA injection E8-20hr E8-22hr E9 E9-2hr 
= = = = = = = = = = = = = = = = = = = = = = = = = = 
p-value vs. control <0.001* <0.001* <0.001* <0.001* 
p-value vs. E8-20hr - 0.119 0.121 <0.001* 
p-value vs. E8-22hr - - <0.001* <0.001* 
尸-value vs. E9 - - _ < 0.001* 
TL 
Time ofRA injection E8-20hr E8-22hr E9 E9-2hr 
p-value vs. control <0.001* <0.001* <0.001* <0.001* 
厂-value vs. E8-20hr - 1.000 1.000 1.000 
p-value vs. E8-22hr - - 1.000 1.000 
/?-value vs. E9 - - i .000 
* Statistically significant (Independent Samples t-test) 
3.4.1.4 Time-response to RA-induced non-renal malformations 
The proposed mechanism of excess RA exerting teratogenic effect via 
causing RA deficiency may not be limited to RA-induced renal malformations, but 
can also be applicable in other RA-induced dcfccts. For example, clctl palate caiiscd 
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by non-fusion of the secondary palatal shelves; eye dcfccts, which incluclc tliu 
absence of eyelid or bulging eyes; abnormal external cars, which includc unfused 
ear patches and absence of external ear; micrognathia, which is hypoplasia of jaws, 
and sirenomclia, which is fused hindlimbs. Hcncc, the frequency of these different 
types of RA-induced malformations in fetuses injected with RA at different time 
points were determined. Results were summarized in Table 3.6 and presented in 
Graph 3.4. Results of statistical analysis were shown in Table 3.7. 
Control fetuses did not spontaneously develop any of these 
malformations. However, 100% of fetuses consistently developed cleft palate in 
response to RA injection at all 4 time points (Graph 3.4A). For eye defects, 46% of 
fetuses with RA injection on E8-201ir developed these defects, which was the 
highest frequency among the 4 tested time points (Graph 3.4B). When RA injection 
was shifted 2 hr later (E8-22hr), the frequency of eye defects was reduced to 28%. 
When RA injection was shifted later for another 2 hr (E9), only 7% of fetuses 
developed eye defects. However, it is interesting that the frequency rose to 14% 
when RA was injected at E9-2hr. A similar trend was found for the frequency of 
abnormal external ears (Graph 3.4C). RA injection on E8-20hr produced the highest 
frequency (36%) of ear defects, whereas the frequency was dramatically reduced to 
1% when injection was shifted later to E9.0. This trend similarly occurred in 
RA-induced sirenomelia (Graph 3.4E). RA injection on E8-20hr induced the highest 
frequency of fetuses with sirenomelia (61 %), while RA injection on E9 caused the 
lowest frequency (13%). As for micrognathia, RA injection on E8-22hr induced the 
highest incidence of this defect (82%), but the frequency dramatically dropped by 
more than half (33%) when RA was injected 2 hr later on E9 (Graph 3.4D). Together, 
results of the time response to RA-induced non-renal malformations clearly 
demonstrated that cach type of RA induccd-ma 1 torniation has a specific critical 
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pcrimi sensitive to R八 teratogenesis. Some types of malformations have a narrow 
tiiiic w indow for RA teratogenesis such as kidney and eye malformations, whereas 
some types of malformations, such as def t palate and shortening of the tail, have a 
wider period sensitive to RA. 
Table 3.6 Effect of 125 mg/kg RA or vehicle as control injected at different 
time points in inducing non-renal malformations. 
Treatment groups Control RA (125 mg/kg) 
Injection time E8-22hr E8-20hr E8-22hr E9 E9-2hr 
No. of litters 5 5 9 10 5 
No of live fetuses 64 28 96 98 59 
No. (%) of live fetuses 0 28 96 98 59 
with cleft palate (0) (100) (100) (100) (100) 
No. (%) of live fetuses with 0 13 26 7 8 
eye defects (0) (46.43) (27.08) (7.14) (13.56) 
No. (%) of live fetuses with 0 10 34 1 5 
abnormal external ears (0) (35.71) (35.42) (1.02) (8.47) 
No. (%) of live fetuses with 0 18 79 32 21 
micrognathia (0) (64.29) (82.29) (32.65) (35.59) 
No. (%) of live fetuses with 0 17 45 13 10 
sirenomelia (0) (60.71) (46.88) (13.27) (16.95) 
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lahle 3.7 Statistical analysis on the cffect of 125 ni^/kji： RA injected at 
(iifferciit time points in inducing non-rcnal malformations. 
TIME RESPONSE 
Cleft palate 
Time of RA injection E8-20hr E8-22hr E9 E9-2hr 
.丨 ~ ~ ^ -I 1 I ' ••"• III •！ tJ v n w • i，，L_L-., I' .M. M … . • •…-..一.. , • ” _ • . I —— . , 
/^-valuc vs. control <0.001* < 0.001* <0.001* <0.001* 
/^-valuc vs. H8-20hr - N/A N/A N/A 
/)-value vs. H8-22hr - - N/A N/A 
/，-value vs. E9 - - _ ]sj/A 
Eye defects 
— " • ••• • .... • L-l.- .”••••.•••• IL • 一 MM. - I — , . •— 
Time of RA injection E8-20hr E8-22hr E9 E9-2hr 
/?-value vs. control <0.001* <0.001* 0.031* 0.003* 
P-value vs. E8-20hr - 0.052 <0.001* <0.001* 
/;-value vs. E8-22hr - - <0.001* 0.048* 
/;-value vs. E9 - - _ 0.185 
Abnormal external ears 
Time ofRA injection E8-20hr E8-22hr E9 E9-2hr 
— I I I ‘ •丨  I I -
/?-value vs. control <0.001* < 0.001* 0.425 0.019* 
/rvalue vs. E8-20hr - 0.977 <0.001* 0.002* 
尸-value vs. E8-22hr - - < 0.001* <0.001* 
p-value vs. E9 - - _ 0.018* 
Micrognathia 
Time of RA injection E8-20hr E8-22hr E9 E9-2hr 
^ ^ ^ ^ ^ , = ‘ - • • • . • “ '•• t •• s ^ ^ ^ a a a ^ ^ ^ a a g i a ^ ^ ^ s a s ^ a ^ 
厂-value VS. control < 0.001* <0.001* <0.001* <0.001* 
p-value vs. E8-2Qhr - 0.042* 0.002* 0.012* 
/?-value vs. E8-22hr - - <0.001* <0.001* 
p-value vs. E9 - - - 0.610 
Sirenomelia 
•—" ''" ‘ ^ ^ ^ g e s . 'I • L '• •'—- — ••'•  “ ‘ H — “ • I . ' } '•• ssssisass-!：--— 丄圓i — • .•一 -————- • i • • 
Time ofRA injection E8-20hr E8-22hr E9 E9-2hr 
“ ‘ ‘ .— • -'-' • ‘ ‘ ‘ •' “ ‘ — - - •  ‘‘=== 卜-”_•_•• … , • ‘ ‘ • • •• B E S S E S —L— = = = = ? • • • ‘ - X — - I _•••— 
尸-value VS. control <0.001* <0.001* 0.003* <0.001* 
厂-value vs. E8-20hr - 0.198 <0.001* <0.001* 
value vs. E8-22hr - - <0.001* <0.001* 
尸-valuc vs. E9 - 0.527 
* Statistically significant (Chi-squarc test) 
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3.4.2 Dose response 
Since the aim of this study was to use the RA-induccd renal 
malformations to test our proposed mechanism of RA tcratogenesis, it is important 
that a high frequency and severity of RA-induced renal malformations were induced 
in the fetuses after RA treatment. Results of the time response study showed that 125 
mg/kg o f R A injected on E8-20hr and E8-22hr induced 100% renal malformations in 
the fetuses, among which 75% were bilateral renal agenesis. However, the frequency 
of resorption induced by RA injection on E8-20hr (50%) was more than 3-fold 
higher than that when RA was injected on E8-22hr (14%). Thus, it was concluded 
that E8-22hr was the optimum time for RA injection to induce renal malformations. 
Next, I have conducted a dose response study. Various dosages of RA (25, 50, 100, 
125 and 150 mg/kg) were injected to the pregnant mice on E8-22hr. Abnormalities 
in the fetuses were examined at El8. 
3.4.2.1 Dose response to RA-induced resorption 
The result of frequency of resorption under different dosages of RA 
injected on E8-22hr was summarized in Table 3.8 and presented in Graph 3.5. For 
the vehicle-treated control, there was only 3% of resorption. When 25 mg/kg and 50 
mg/kg of RA were injected, the resorption was 5% and 2% respectively. The 
frequencies were similar to the control, showing that these two dosages of RA did 
not affect the frequency of resoption. However, when 100 and 125 mg/kg of RA 
were injected, the frequency of resorption increased to 18% and 14% respectively. 
At the dose of 150 mg/kg of RA, the frequency of resorption raised shapely to 79%. 
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Dose response to RA-iiidiiccd rciuil miUforimitions 
The frequency and severity of RA-induccd renal malformations were 
highly dependant on the time of RA treatment. Here, it showed that their occurrence 
was also highly depended on the dose of RA. Data were tabulated in Table 3.8 and 
presented in Graph 3.6. Results of statistical analysis on the effect of different 
dosages of RA in inducing renal malformations were shown in Table 3.9. 
Without RA treatment, fetuses were consistently having two normal 
kidneys. When different dosages of RA were injected, all dosages showed a 
significant {p < 0.001) effect in inducing renal malformations in comparison to the 
control. When 25 mg/kg of RA was injected, 16% of fetuses developed renal 
malformations, and all malformations found were of the non-agenesis type, 
including hypoplastic kidney, dysplastic kidney and polycystic kidney. When 50 
mg/kg of RA was injected, the frequency of renal malformations increased to 41%. 
The majority was non-agenesis renal malformations, only 2% of fetuses developed 
bilateral renal agenesis and 6% developed unilateral renal agenesis. When the dose 
was further increased to 100 mg/kg, 91% of fetuses were found with renal 
malformations. Moreover, the frequency of bilateral renal agenesis significantly rose 
to 49%, and unilateral renal agenesis also increased to 13%. At the dose of 125 
mg/kg, 100% of fetuses were found with renal malformations, among which 75% 
was bilateral renal agenesis. Non-agenesis renal malformations were reduced to 25%. 
Statistical analysis by Jonckheere-Terpstra test showed that each RA dose had a 
significant difference in inducing renal malformations when compared to other 
doses of RA and also to the control {p < 0.01). The only exception was the 
comparison between the effcct of 125 mg/kg and 150 mg/kg of RA (p = 0.076). At 
the dose of 1 50 mg/kg of RA, 100% of fetuses developed bilateral renal agenesis. 
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1 lowcvcr, there was no significant cliircrencc between 125 and 150 mg/kg o! KA 
possibly bccausc of the small sample size of 150 mg/kg RA due to the high 
frequency of resorption (79%). 
Analysis by Spcannan,s rank correlation showed that there was a 
significant (p < 0.001) correlation between the dose of RA and the frequency and 
severity of renal malformations. The Spearman's rank correlation coefficient was 
+0.806, showing that as the dose of RA increased, a higher frequency and more 
severe renal malformations were found in the fetuses. 
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Table 3.S KlTect of different dosaj^cs of RA or vchicic as control injected on 
K8-22hr on resorption and in inducing renal malformations. 
Dosages of RA (mg/kg) | Control 25 50 100 125 150 
No. of litters 5 5 4 5 9 4 
No. of implantations 66 61 50 55 114 47 
No. of live fetuses 64 58 49 45 96 10 
No. (%) of implantations 2 3 1 10 18 37 
underwent resorption (3) (4.92) (2.00) (18.18) (15.79) (78.72) 
No. (%) of live fetuses with 64 49 29 4 0 0 
two normal kidneys (100) (84.48) (59.18) (8.89) (0) (0) 
No. (%) of live fetuses with 0 9 20 41 96 10 
renal malformations (0) (15.52) (40.82) (91.11) (100) (100) 
. 0 0 1 22 72 10 
-B i l a t e ra l renal agenesis 
(0) (0) (2.04) (48.89) (75.00) (100) 
-Uni la te ra l renal agenesis 
(remaining kidney with 0 0 2 6 8 0 
non-agenesis renal (0) (0) (4.08) (13.33) (8.33) (0) 
malformations) 
-Uni la te ra l renal agenesis 
. 0 0 1 0 0 0 
(remaining kidney being 
1� (0) (0) (2.04) (0) (0) (0) 
normal) 
-B i l a t e ra l non-agenesis 0 3 9 10 10 0 
renal malformations (0) (5.17) (18.37) (22.22) (10.42) (0) 
-Uni la te ra l non-agenesis 
renal malformations 0 6 7 3 6 0 
(contralateral kidney (0) (10.34) (14.29) (6.67) (6.25) (0) 
being normal) 
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lahle 3/) Statistical analysis on the effcct of different dosaj^es of KA injectcd 
on E8-22hr in iiidiiciii^ renal malformations. 
TIME RESPONSE 
Renal malformations 
Dosages ofRA (mg/kg) 25 50 100 125 150 
/^-valuc vs. control 0.001* <0.001* <0.001* <0.001* <0.001* 
尸-value vs. 25 mg/kg RA - 0.002* < 0.001* < 0.001* < 0.001* 
厂-value vs. 50 mg/kg RA - - <0.001* <0.001* <0.001* 
"-value vs. 100 mg/kg RA - - - 0.001* 0.005* 
/;-value vs. 125 mg/kg RA - 0.076 
Spearman's rank correlation 
+0.806 
coetticient (/:、.） 
"-value of Spearman's rank 
<0.001" 
correlation 
* Statistically significant (Jonckheere-Terpstra test) 
^ Statistically significant (Spearman,s rank correlation) 
3.4.2.3 Dose-response to RA-induced changes in growth parameters 
Different doses o f R A injected on E8-22hr caused different effects on the 
four growth parameters (weight, CRL, HL and TL). Data were summarized in Table 
3.10 and presented in Graph 3.7. Results of statistical analysis on the effect of 
different doses o f R A were shown in Table 3.11. 
For control fetuses, the mean weight was 1.29 g. Fetuses injected with 25 
mg/kg or 50 mg/kg o f R A had similar weight as the control (Graph 3.7A). However, 
when 100, 125 and 150 mg/kg doses o f R A were injected, the weight of the fetuses 
gradually decreased. The mean weight of fetuses treated with 100 mg/kg o f R A was 
significantly (p < 0.001) reduced by 23% to 0.99 g, while the mean weight of fetuses 
treated with 150 mg/kg of RA was further significantly (p < 0.001) dropped by 37% 
to 0.81 g. 
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l:or ( � R L again, the doses o f � 2 5 mg/kg and 50 mg/kg o f � R A did not 
cause any significant ditTcrcncc Ironi the control (Graph 3.713). Similar lo the trend 
of the weight, when 100, 125 and 150 mg/kg doses of RA were injcctcd, the CRL of 
the fetuses gradually decreased. Significant differences were found among these 3 
doses (p < 0.001) as well as to the control {p < 0.001). 
The mean HL of control fetuses was 11.8 mm. At the dose of 25 mg/kg, 
RA did not cause any significant changes in the HL of the fetuses (Graph 3.7C). 
However, significant {p = 0.019) decrease in HL was observed when 50 mg/kg of 
RA was injected. The mean HL continued to decrease when the dose of RA 
increased, such that at the dose of 150 mg/kg of RA, the HL was reduced by 25% to 
8.8 mm. 
As for the tail length, a significant (p < 0.001) reduction was already 
observed at the dose of 25 mg/kg of RA (Graph 3.7D). Further increase in the 
dosages of RA to 50 mg/kg or above led to total loss of the tail. 
Table 3.10 Effect of different dosages of RA injected on E8-22hr on various 
growth parameters of E18 fetuses. 
Dose of RA (mg/kg) Control 25 50 100 125 150 
No. of litters 5 5 4 5 9 4 
No. of live fetuses 64 58 49 45 96 10 
Mean weight (g) 1.29 1.27 1.27 0.99 0.91 0.81 
士 SEM 士 0.01 ±0.01 ±0.01 ±0.02 土 0.01 士 0.04 
Mean CRL (mm) 23.85 24.02 23.61 20.64 19.46 18.2 
士 SEM ±0.12 ±0.13 ±0.15 ±0.19 ±0.16 士 0.65 
Mean HL (mm) 11.70 11.75 11.50 10.29 9.84 8.80 
士 SEM ±0.06 ±0.04 ±0.06 ±0.09 ±0.07 ±0.28 
Mean TL (mm) 12.17 
0 0 0 0 
± SEM ±0.06 ±0.38 
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liihlc 3.11 Statistical analysis on the cffcct of different (iosaj^cs of RA injectcd 
on K8-22lir on various growth parameters of E18 fetuses. 
DOSE RESPONSE 
Weight 
Dosages of RA (mg/kg) 25 50 100 125 150 
/"value vs. control 0.314 0.144 <0.001* < 0.001* < 0.001* 
/;-value vs. 25 mg/kg RA - 0.629 <0.001* <0.001* <0.001* 
value vs. 50 mg/kg RA - < 0.001* <0.001* <0.001* 
尸-value vs. 100 mg/kg RA <0.001* <0.001* 
/;-value vs. 125 mg/kg RA - < 0.020* 
CRL 
Dosages of RA (mg/kg) 25 50 100 125 150 
/7-value vs. control 0.320 0.202 <0.001* <0.001* <0.001* 
/?-value vs. 25 mg/kg RA - 0.037* <0.001* <0.001* <0.001* 
/>value vs. 50 mg/kg RA - - <0.001* <0.001* <0.001* 
p-valuevs. 100 mg/kg RA <0.001* < 0.001* 
p-value vs. 125 mg/kg RA - 0.016* 
HL 
- • - • • __.-- • • ‘ -丨二 . •• • ‘ __L ..- • '...f- •-• -. •-• • - • 一 
Dosages of RA (mg/kg) 25 50 100 125 150 
p-value vs. control 0.493 0.019* <0.001* <0.001* <0.001* 
/rvalue vs. 25 mg/kg RA - <0.001* <0.001* <0.001* <0.001* 
/?-value vs. 50 mg/kg RA - - <0.001* <0.001* < 0.001* 
/rvalue vs. 100 mg/kg RA < 0.001* < 0.001* 
p-value vs. 125 mg/kg RA - < 0.001* 
TL 
Dosages of RA (mg/kg) 25 50 100 125 150 
/?-value vs. control <0.001* <0.001* <0.001* <0.001* <0.001* 
厂-value vs. 25 mg/kg RA - <0.001* <0.001* <0.001* <0.001* 
/7-value vs. 50 mg/kg RA - - 1.000 1.000 1.000 
尸-value vs. 100 mg/kg RA 1.000 1.000 
/rvalue vs. 125 mg/kg RA - 1.000 
* Statistically significant (Independent Samples t-test) 
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3.4.；2.4 Dose-1 espouse to RA-indiiccd non-renal malformations 
As mentioned previously, RA will have a threshold level to inducc 
specific malformation. Here, I have investigated the dose response of RA in 
inducing different types of malformations, including cleft palate, eye dcfccts, 
abnormal external ears, micrognathia and also sirenomelia. Data were summarized 
in Table 3.12 and presented in Graph 3.8. Results of statistical analysis were shown 
in Table 3.13. 
Control fetuses did not spontaneously develop any of these 
malformations. When 25 mg/kg of RA was injected, 53% of the fetuses were found 
with cleft palate (Graph 3.8A). At the dosage of 50 mg/kg, the frequency of cleft 
palate increased to 82%. When the dosage of RA reached 100 mg/kg or above, all 
fetuses were consistently found with this defect. In general, similar trend was 
observed for RA-induced eye defects (Graph 3.8B), abnormal external ears (Graph 
3.8C), micrognathia (Graph 3.8D) and sirenomelia (Graph 3.8E), with the frequency 
of these defects increased as the dose of RA increased. However, there were some 
variations among different types of malformations that were worth noticing. For 
some malformations, such as eye defects and sirenomelia, fetuses did not respond to 
RA at the dosage of 25 mg/kg and only slightly at the dosage of 50 mg/kg. In 
comparison to cleft palate in which 82% of fetuses responded to 50 mg/kg of RA in 
developing this defect, only 10% and 2% of fetuses developed eye malformations 
and sirenomelia respectively. Moreover, some malformations did not show a steady 
increase in the frequency as the dosage of RA increased. For example, while eye 
defects occurred at similar frequency (around 30%) in fetuses treated with 100 and 
1 25 mg/kg RA, the frequency dramatically raised to 100% at the dosage of 150 
mg/kg. Similar trend was observed in the response of Ictuses to RA-induccd 
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ahnonnal external cars. While around 35% of fetuses developed abnoniial external 
ears at the dosage of 100 and 125 nig/kg ol RA, the Ircqucncy raised to 100% at the 
dosage of 125 mg/kg. Together, these findings indicate the importance of dose cffccl 
and threshold level in affecting the response of different tissues of the fetuses to RA 
tcratogenesis. 
Table 3.12 Effect of different dosages of RA or vehicle as control injected on 
E8-22hr in inducing non-renal malformations. 
Dosages of RA (mg/kg) Control 25 50 100 125 150 
No. of litters 5 5 4 5 9 4 
No. of live fetuses 64 58 49 45 96 10 
No. (%) of live fetuses 0 31 40 45 96 10 
with cleft palate (0) (53.45) (81.63) (100) (100) (100) 
No. (%) of live fetuses with 0 0 5 16 26 10 
eye defects (0) (0) (10.20) (35.56) (27.08) (100) 
No. (%) of live fetuses with 0 4 12 16 34 10 
abnormal external ears (0) (6.9) (24.49) (35.56) (35.42) (100) 
No. (%) of live fetuses with 0 6 9 31 79 10 
micrognathia (0) (10.34) (18.37) (68.89) (82.29) (100) 
No. (%) of live fetuses with 0 0 1 12 45 8 
sirenomelia (0) (0) (2.04) (26.67) (46.88) (80) 
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r:il>k�3.13 Statistical analysis on (he effect of dilfereiit dosages of RA injcctcd 
oil K8-22hr in inducing non-renal malformations. 
DOSE RESPONSE 
Cleft Palate 
laacrgmi wu in p "tiEr.-ga i'l ..bj ...' ‘ -r -t ”••• -• ‘ i t • • i • _. „ , „ ^ • ,, , • . • i. . , , , . . .. . , . .. . • — .. , . .. _ 
Dosages of RA (mg/kg) 25 50 100 125 150 
厂-value vs. control <0.001* <0.001* <0.001* <0.001* <0.001* 
/)-valuc vs. 25 mg/kg RA - 0.002* <0.001* <0.001* 0.005* 
"-value vs. 50 mg/kg RA - - 0.003* <0.001* 0.141 
厂-value vs. 100 mg/kg RA - - - N/A N/A 
/?-value vs. 125 mg/kg RA - N/A 
Eye defects 
Dosages of RA (mg/kg) 25 50 100 125 150 
/rvalue vs. control N/A 0.010* <0.001* <0.001* <0.001* 
/>value vs. 25 mg/kg RA - 0.013* <0.001* <0.001* <0.001* 
/rvalue vs. 50 mg/kg RA - - 0.003* 0.019* <0.001* 
尸-value vs. 100 mg/kg RA - - - 0.305 < 0.001* 
p-value vs. 125 mg/kg RA - <0.001* 
Abnormal external ears 
‘ ‘ • - - • ••• ,1.' -• • • J- . . ‘ - • - • — , , • • - • ' — — - • ‘―—^―— • , . . , . , . 
Dosages of RA (mg/kg) 25 50 100 ^ 
, , I I ' l l 
p-vaiue vs. control 0.035* <0.001* <0.001* <0.001* <0.001* 
厂-value vs. 25 mg/kg RA - 0.011* <0.001* <0.001* <0.001* 
p-value vs. 50 mg/kg RA - - 0.241 0.181 <0.001* 
/rvalue vs. 100 mg/kg RA - - - 0.987 <0.001* 
p-value vs. 125 mg/kg RA - <0.001* 
Micrognathia 
Dosages of RA (mg/kg) 25 50 100 125 150 
/7-value vs. control 0.009* <0.001* < O.QQl* <0.001* <0.001* 
p-value vs. 25 mg/kg RA - 0.234 <0.001* <0.001* <0.001* 
p-value vs. 50 mg/kg RA - - <0.001* <0.001* <0.001* 
p-value vs. 100 mg/kg RA - - _ 0.073 0.041* 
p-value vs. 125 mg/kg RA - - - - 0.146 
Sirenomeiia 
— — i i » i , ',11- . - •••_•• .1.11^ •• •• ‘ “ “ |—II- — •• .1. u'i'iii'.' • ‘ . I ' •• - • 一 , , . , i" ••  -„., • ••!• •, •••' ‘ 
Dosages of RA (mg/kg) 25 50 100 125 150 
p-value vs. control N/A 0.258 <0.001* <0.001* <0.001* 
p-value vs. 25 mg/kg RA - 0.274 <0.001* <0.001* <0.001* 
/7-value vs. 50 mg/kg RA - - <0.001* <0.001* <0.001* 
/7-valuc vs. 100 mg/kg RA - - 0.023* 0.002* 
/7-valuc vs. 125 mg/kg RA - - - - 0.046* 
* Statistically significant (Chi-square test). 
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3.5 L)is( uss iON 
The aim of this chapter was to find out the optimum time and dose o f R A 
treatment to pregnant mice to inducc the highest frequency and severity of renal 
malformations in their fetuses. Results showed that the teratogenic effect of RA in 
inducing renal malformations was time- and dose-dependent. The dose of 125 mg/kg 
of RA injected on E8-20hr and E8-22hr both induced 100% renal malformations 
among which 75% were bilateral renal agenesis. However, when the injection time 
was shifted 2 hr later, i.e. E9, the frequency of renal malformations was decreased to 
83%, and the frequency of bilateral renal agenesis was dramatically reduced to 27%. 
Moreover, results of statistical analysis showed that the dose of RA was significantly 
directly correlated with the frequency and the severity of renal malformations being 
induced in the fetuses (r, = +0.806; p < 0.001). Taken together, 125 mg/kg of RA 
injected on E8-22hr was the optimum dose and time of RA injection. It consistently 
induced renal malformations in 100% of fetuses, among which 75% was bilateral 
renal agenesis. Moreover, unlike the time point of E8-20hr, the resorption frequency 
(15%) was more comparable with the control. This combination of time and dose of 
RA injection was therefore adopted in subsequent experiments for testing our 
proposed RA teratogenic mechanism. 
In the previous result of our laboratory, 125 mg/kg of RA injected on E9 
could induce 100% bilateral renal agenesis in the fetuses (Tse et al., 2005). However, 
this high frequency of bilateral renal agenesis cannot be induced now. It may be due 
to changes in the mouse stock and other environmental factors. These changes may 
causc some genetic and physiological differences in the pregnant mouse, and thus 
affect the embryo's susceptibility to RA. 
Kidney development consists of three stages: pronephros, nicsoncphros 
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:md nictancphms. All of them develop fro in the same embryo nic anlagc, the 
intermediate nicsodcrm. Pronephros develops at the cervical region of the 
intermediate mcsodenn (Bouchard et al., 2002) and appears first among the three 
systems. It starts to appear at about E8 of mouse development. However, it regresses 
within a very short period, about 1 day in mice. After its regression, mesonephroi 
start to develop at the dorso-lumbar region of the intermediate mesoderm. Their 
development is completed at about E12 in mice. Most of the mesonephroi degrade 
before El2. However, some of them persist and take part in the formation of the 
male genital system, such as ductuli efferentes (Vize et al., 1997; Drummond et al , 
1998; Drummond, 2000). 
Metanephros is the permanent kidney. It starts to develop at El 1 in mice. 
It is developed from two different structures, which are the ureteric bud and the 
metanephric mesenchyme. The ureteric bud is an outgrowth of the Wolffian duct. It 
penetrates into the metanephric mesenchyme at El 1 and initiates metanephric 
development. Development of the metanephros depends on reciprocal inductive 
interaction between the metanephric mesenchyme and the ureteric bud (Kuure et al., 
2000). Branching of the ureteric bud into the collecting duct system depends on 
signals generated from the metanephric mesenchyme, whereas differentiation of the 
metanephric mesenchyme into nephrons depends on signals from the ureteric bud. 
For example, the metanephric mesenchyme expresses a growth factor called glial 
cell line-derived neurotrophic factor (Gdnf) to stimulate the outgrowth of the 
Wolffian duct to form the ureteric bud. At the same time, the Wolffian duct and 
ureteric bud express c-ret, which is the receptor of Gdnf. 
It was reported that when pregnant mice were orally administered with 
100 mg/kg of RA on E l l , the RA concentration in the embryo already increased 
10-folcl half an hour after treatment and reached the peak level by 3 hr (Satrc and 
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Kochlur,卜)SO). The RA level then returned to normal allcr 8 hr. In our model, the 
teratogenic dose of RA injcctcd on IZ8-22hr may be fully metabolized within similar 
perkxi of time. However, as mentioned above, metanephros in micc does not start to 
develop until E l l . This implies that the exogenous dose of RA should not be acting 
dircctly on the kidney. 
Renal malformations usually do not occur as an isolated defect, but occur 
as a spectrum of malformations, such as DiGeorge syndrome. Other than renal 
malformations, this syndrome includes congenital heart diseases, palatal 
abnormalities, craniofacial syndromes, imperforate anus and skeletal abnormalities 
(Conley et al., 1979). These RA-induced defects may share a common teratogenic 
mechanism. Thus, other than renal malformations, the fetus in the present study was 
also examined for some of these RA-induced defects, including cleft palate, eye and 
ear abnormalities, jaw and hindlimb malformations. Results showed that most of 
these defects induced by RA also demonstrated a time- and dose-dependent response 
to RA. In general, the earlier the time of RA injection, and the higher the dose of RA, 
the higher the frequency of these malformations. However, some defects showed a 
narrow time window at which RA could induce a high rate of malformation, such as 
micrognathia. When 125 mg/kg of RA was injected on E8-22hr, 82% of fetuses were 
found with micrognathia. However, the frequency dramatically reduced to 32% 
when the injection time was shifted to 2 hr later. Conversely, some malformations 
could be induced by RA over a longer period of time, such as cleft palate. A dose of 
125 mg/kg of RA injected between E8-22hr to E9-21ir could induce 100% of cleft 
palate in the fetuses. Furthermore, it appeared that bilateral renal agenesis was 
highly correlated with some defects, such as upper and lower jaw hypoplasia. 
Fetuses found with bilateral renal agenesis were always found with jaw hypoplasia . 
In this study, RA, besides inducing different types of malformations, was 
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also found to atlcct various growth parameters, such as weight, CRL, IIL and also 
TL. As mentioned previously, RA regulates dcvclopmcntally important genes, such 
as Uo.\ and Shh. It is possible that disruption of these genes by RA treatment may 
cause changes in the mentioned growth parameters. 
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Chapter 4 
Effect of Teratogenic Dose ofRA 
on RA Synthesis and Endogenous 
RA Levels in the Embryo 
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4.1 INIRODDC H O N 
RA level is tightly regulated during embryo development. This regulation 
is attributed to a balance between RA synthesis and RA catabolism. However, under 
the challenge of exogenous RA, not only is the endogenous RA level in the embryo 
being affected, RA synthesis and degradation are also disturbed. Moreover, retinoid 
transport through the placenta is also changed at elevated levels of RA (Collins et al., 
1994). 
4.1.1 RA synthesis in embryo 
As discussed previously, one of the most important genes involved in RA 
regulation is retinaldehyde dehydrogenase {Raldh), which encodes the RA 
synthesizing enzyme. Raldh consists of three isofonns, namely Raldhl, Raldh2 and 
RaldhS. They express at specific domains and stages during embryo development. 
Among the three enzymes, Raldh2 is found to contribute to the majority of RA 
synthesis. Only Raldh2 null mutant embryos die prenatally (Niederreither et al” 
1999). 
RA activity is first detected in the mouse embryo at E7.5, but not at E6.5, 
by using the RA-reporter cell line (Ang et a l , 1996). Raldh2 is the first enzyme to 
be expressed among these three iso forms, and it can account for the RA activity at 
this stage (Haselbeck et al., 1999). It is expressed in the mesoderm around the node， 
but not in the node itself. It is also expressed in the primitive streak and the 
mesoderm up to the presumptive hindbrain during head fold stage (Niederreither et 
al., 1997). At mid-gastrulation, it is expressed in the undifferentiated somites, 
mcscnchymc around the neural tube, developing limbs and gut as well as specific 
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regions in the brain (Nicclcrrcithcr ct al., 1 997; 1 lasclbcck ct al., I At a later 
stage, RahlliJ is found to he intensively expressed in several organs, including I he 
heart (Moss ct al., 1998), lung (Malpcl ct al., 2()()()) and kidney (Batounna ct al., 
2001). Raldh2 expression around the node during early gastrulation is found to 
support axial patterning in early embryo, while Raldhl expression at the spinal cord, 
lung, heart and kidney at later stages is involved in the development of these organs. 
The expression of the other two enzymes is found to initiate at later 
stages. Raldh I expression is first observed at the mesencephalon, retina, third 
branchial pouch and also the middle of the otic vesicle of E9.5 mouse embryos 
(Haselbeck et al , 1999). At a later stage, it is expressed at the mesonephros, which 
supports the development of the urogenital system. Raldh 3 is first detected in the 
mouse embryo at E8.5-E8.75. Its expressions in the mouse embryo are well 
characterized (Balkan et al , 1992; Grun et al., 2000; Mic et al., 2000). In E9 mouse 
embryos, its expression is found at the surface ectoderm of the eye. Later, it is 
localized at the ventral retina, dorsal margin of the otic vesicles and olfactory 
neuroepithelium. 
At the early stage of kidney development, Raldh2 is strictly expressed in 
the metanephric mesenchyme, while Raldh 1 and RaldhS are localized in the ureteric 
bud (Batourina et al., 2001; Niederreither et al., 2002). At a later stage, Raldh2 is 
strongly expressed in the developing glomeruli and also the collecting tubules. 
In a previous study in which the three iso forms of Raldh enzymes were 
separated on native gel by isoelectric focusing and then their activities being 
determined by a RA-responsive cell line, it was found that these three enzymes 
could contribute to all the RA generated in the early mouse embryo (McCaffcry and 
Drager, 1 997). 
-xo-
('/uiplcr 4: RA Synllicsis /•ju/o^cnons AM 
4.1.2 Delectioii of eiido^eiioiis RA in embryo 
Endogenous RA levels in the embryo can be determined by several 
methods. One widely employed method is by using a RA reporter. This reporter is 
stably trans feet ed with the RAR/3 gene which has a RARE in the promoter region 
and a lacZ gene as the reporter. In the presence of RA, RA will first bind to the RA 
receptor and this complex will then bind to the RARE and drives the expression of 
lac Z gene that codes for the P-galactosidase enzyme. When the substrate X-gal is 
added, (3-galactosidase will turn it into a blue colored product. Thus, increasing RA 
concentrations will increase the expression of (3-galactosidase, resulting in the 
formation of more blue colored products. By using this reporter, several RARE-lacZ 
transgenic mouse lines were generated (Reynolds et al., 1991; Rossant et al , 1991; 
Balkan et al., 1992). Staining of the transgenic embryos for lacZ activity reveals 
regions with RA activity, which will turn blue color. It is a means to localize in situ 
RA distribution in the mouse embryo. Using this method, it is shown that RA is 
detectable at the late primitive streak-head fold stage, but is only located at the 
posterior region (Maden, 2000). 
The same reporter has been trans feet ed into embryonic carcinoma cells to 
generate the RA-responsive cell line (Wagner et al., 1992; McCaffery and Drager, 
1997). This cell line has been widely used in detecting low levels o f R A in different 
embryo samples. When a piece of embryo sample is placed on top of the cells and 
cultured for a few hours, RA will be released from the sample and induce 
p-galactosidase which can generate a blue product in the cells on addition of 
appropriate substrate. The intensity of the blue color can be measured by a 
spectrophotometer. By comparing the intensity of the blue colored products with 
standards made ofscrially-diluted RA solutions, the RA concentration in (he sample 
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can be determined. This ccll line is very sensitive to RA and can clctccl a wide range 
o f R A concentrations ranging liom 10 ? to 10'" M (Lcc, 2008). 
High pressure liquid chromatography (HPLC) is also a common method 
to determine RA concentrations. It involves specific, accurate, and prccisc analytical 
procedure. By using this method, RA concentrations in different organs (Pappas ct 
al., 1993) and embryonic tissues (Maden, 2000) can be quantified. The advantage of 
HPLC is that in a single sample, it can quantify different types of retinoids, such as 
retinyl palmitate, all-//'C"LV retinol, 1 3-CLV retinoic acid and all-trans retinoic acid. 
However, its sensitivity is relatively low when compared with the RA-responsive 
cell line, so large quantity of samples is needed for the detection. Thus, it is not 
feasible to measure RA level of early stage embryo by HPLC. 
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4.2 KXPIIRIMIINIAL 1)1 SK.N 
As shown in Chapter 3, after teratogenic insult with RA on E8-22hr, all 
fetuses were found with renal malformations. In our hypothesis, the teratogenic 
etYect of exccss RA is mediated via suppression of RA synthesis, thus leading to RA 
deficicncy, thereby resulting in renal malformations. In this chapter, I have 
investigated the effect of excess RA on RA synthesis and endogenous RA levels in 
the embryo. 
First, I have determined if there was any negative feedback regulation 
between externally-supplied RA and RA synthesis. The mRNA expression of the 
three iso forms of Raldh in the whole embryo was examined by in situ hybridization 
and quantitative real-time RT-PCR from E9.5, i.e. 14 hr after RA injection, to El2.0 
at 0.5 day interval. Since metanephros does not appear until E l l , thus Raldh mRNA 
expression levels in the metanephros were quantified from El 1.0 to El2 .0 at 0.5 day 
interval by real-time RT-PCR. The RA catabolizing enzyme, Cyp26Al, Cyp26Bl 
and Cyp26Cl, are involved in the regulation of RA level in the embryo. Thus, their 
expressions were also quantified by in situ hybridization and quantitative real-time 
RT-PCR. 
To determine whether excess RA could result in RA deficiency, 
endogenous RA levels in the whole embryo (E9.5 to El2.0) and the embryonic 
kidney (El 1.0 to E12.0) were measured by using HPLC and a RA-responsive cell 
line respectively. 
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4 .3 INIAI KRIALS AND IMI/HIODS 
4.3.1 Localization of niRNA transcipts in whole embryo by in situ 
hybridization 
Pregnant mice were injected intraperitoneally with 125 mg/kg RA or 
equivalent volume of suspension vehicle as control on E8-22hr. RA-treated and 
control embryos were collected from E9.5 to E12.0 at 0.5 day interval. Embryos 
were fixed in 4% paraformaldehye and then processed for whole mount in situ 
hybridization according to the procedure as described in section 2.3 for localization 
oiRaldhl, Raldh2, RaldhS, Cyp26al and Cyp26hl mRNA transcripts. Three to four 
litters of embryos were examined in each group. 
The antisense RNA probes were generated from cDNA plasmids with 
details as below: 
Restriction enzyme RNA polymerase 
cDNA Insert size ^ ^ 
• Vector for antisense for antisense 
plasmid (bp) 
riboprobe riboprobe 
Raldhl pBluescript KS 400 Not I T3 
Raldh2 pBluescript KS 2,300 Xha I T7 
RaldhS pCR®II-TOPO 800 Not I Sp6 
Cyp26al pBluescript SK 600 EcoRl T3 
Cyp26hl pGEM5 900 EcoRl T7 
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4.3.2 Vihratome sectioning 
4.3.2.1 Preparation of GIoop 
Tissue sample for vibratiomc sectioning was embedded in Gloop. To 
prepare 100 ml of Gloop, it contains the following ingredients: 
Gelatin 0.5 g 
Sucrose 20 g 
0.2 M PB (pH7.4) 50 ml 
Chicken egg albumin 30 g 
Distilled water adjusted to a final volume of 100 ml 
The ingredients were mixed at room temperature with stirring for 
overnight and then filtered with 4 layers of gauzes to remove bubbles. It was then 
stored at 4 � C until use. 
4.3.2.2 Sample preparation and sectioning 
Embryos that had been subjected to in situ hybridization and cleared in 
glycerol were washed in 0.1 M PB (0.2 M PB: 4.56 g NaH2P04 and 23 g Na2HP04 
per litre) for 3 times to completely remove the glycerol. They were fixed in 0.4% 
paraformaldehyde in O.IM PB overnight at and then thoroughly washed with 
0.1 M PB for 3 times to remove the fixative. Just before use, the embedding medium 
was prepared by mixing 2 ml of Gloop with 120 j^ l of 25% glutaraldehyde on ice. 
The embryo sample was quickly put into the embedding medium and orientated 
under the stcrcomicroscopc to the desired plane before the embedding medium 
solidified. The embedded sample was then scctioncd by vibratome (VTIOOOS, Leica) 
into a thickncss of 20 j_iin. Cut sections were wllcctcd in 75% glycerol and then 
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mounted onto a glass slide lor examination under light microscopy. 
4.3.3 Quantification of niRNA expression levels in whole embryo and in 
metanephros by real-time RT-PCR 
RA-treated and control embryos, freed from all extraembryonic tissues, 
were collected from E9.5 to El2.0 at 0.5 day interval and stored in KHAlater RNA 
Stabilization Reagent at - 2 0 T until use. For the stage of E9.5 and El 0.0’ embryos in 
the same litter of similar size were pooled as one sample. For the stage of El 0.5 and 
El 1.0, 5 to 6 embryos of similar size in the same litter were pooled as one sample. 
For the stage of El 1.5 and El 2.0, 3 embryos of similar size in the same litter were 
pooled as one sample. Metanephroi were dissected out from El 1.0’ El 1.5 and El2 .0 
embryos in PBS and stored in RNA/ater RNA Stabilization Reagent at -20°C until 
use. Fifteen to twenty metanephroi from embryos in the same litter were pooled as 
one sample. The sample was subjected to quantification of Raldhl, Raldh2, RaldhS, 
Cyp26al, Cyp26bl and Cyp26cl mRNA expression level by real-time quantitative 
RT-PCR. Detailed protocols for performing RT-PCR were described in section 2.4. 
P-actin was used as an internal control to normalize the quantity of the sample as our 
laboratory has previously found that its expression would not be altered by RA 
treatment. Sequences of primers used for the reactions were listed below: 
Raldhl Forward primer: 5，-CAT TGC TGT TGA GTT TGC AC-3’ 
Reverse primer: 5，-TTG ATT TAT TCC TGG GGT CA-3' 
Raldh2 Forward primer: 5，-TTG CAG ATG CTG ACT TGG AC-3, 
Reverse primer: 5’-TCT GAG GAC CCT GCT CAG TT-3’ 
-S6-
(liciptcr 4: RA Syfithcsis (V' /•Jidoi^cnous RA 
K^IHLHJ I'orwarcl primer: 5’-GAT AAA GTT GGG ( T G AGC AA-V 
Reverse primer: 5 ’ - ( r A AAA TTC AGT GTC CIJA ACJ-T 
Cyp26al Forward primer: 5’-CAG TGC TAC CTG CTC GTG AT-3’ 
Reverse primer: 5,-AGA GAA GAG ATT GCG GGT CA-3’ 
Cyp26hl Forward primer: 5,-CCT GGT GAG GAT GAA TAA GG-3’ 
Reverse primer: 5’-TTT CCA CCT TAC CTC TCT GC-3' 
Cyp26cl Forward primer: 5,-GGG ACC AGT TGT ATG AGC AC-3’ 
Reverse primer: 5’-AGC CAA CTC CTT CAG CTC TT-3’ 
p-actin Forward primer: 5，-TGT TAC CAA CTG GGA CGA CA-3' 
Reverse primer: 5’-GGG GTG TTG AAG GTC TCA AA-3’ 
4.3.4 Detection of RA levels in whole embryo by HPLC 
RA-treated and control embryos from the stage of E9.5 to E12.0 at 0.5 
day interval were dissected out in the dark under dim yellow light to prevent 
photoisomerization of RA. Embryos were dissected free from all extraembryonic 
tissues in ice-cold PBS and then thoroughly washed with 3 changes of PBS to 
remove any RA or suspension vehicle that might have attached to the surface during 
removal from the abdominal cavity of the pregnant mouse. The embryo was 
individually kept in a microfUge tube. Excess PBS was removed and the tube was 
gassed with nitrogen, sealed with parafilm and wrapped in aluminum foil. It was 
quickly snap frozen and stored at -80 ()C until use. RA level in the embryo sample 
was measured by HPLC following the protocol as described in section 2.5. 
4.3.5 Detection of RA levels in metanephros by RA-responsive ccll line 
RA-treated and control embryos at E l l , El 1.5 and El2 were disscctal 
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out in i CO-CO Id PBS in the tiark uiulcr dim yellow light and llioroughly washed with 
rBS lo icniovc any RA or suspension vchicic that might have attached lo the surlacc 
of the ciiibryt) during removal from the abdominal cavity of the pregnant mouse. 
Metanephroi were isolated from the embryo in L-15 medium. Alter isolating the 
metanephroi, they were thoroughly washed again with 3 changes of PBS. Two 
metanephroi were pooled as one sample and then transferred into a 1.5 ml eppendorf 
tube. Excess medium was removed. The tube was filled with nitrogen gas, sealed 
with para film, and wrapped in aluminum foil. It was snap frozen in liquid nitrogen 
and then stored at - 8 0 � C for less than a week before measurement of RA content. 
To measure RA, the metanephric tissue was lysed by pipetting up and 
down in 100 of culture medium (the culture medium was the same as the one used 
for culturing the RA-responsive cell line and the composition was described in 
section 2.6.1). The lysed sample in the culture medium was added directly to the 
RA-responsive cells grown on the 96-well plate and incubated for 16 hr with details 
as described in section 2.6. Following X-gal staining, the intensity of color 
developed was measured by a spectrophotometer. The RA content in the sample was 
determined by the standard curve prepared from RA standard solutions. 
4.3.6 Statistical analysis 
Comparison of mRNA expression levels of RA synthesizing enzymes 
and RA catabolizing enzymes, and RA levels between RA-treated and control 
groups was carried out by Independent Samples t-test. All statistical analyses were 
performed using SPSS software (SPSS), with statistical significance level set at p < 
0.05. 
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4.4 Ri:siii;rs 
4.4.1 Comparison of mRNA expression levels of different isoforms of RA 
synthesizing enzymes Raldfi and RA catabolizing enzymes Cyp26 
bet�veen embryos of RA-treated and vchiclc-trcated control mice at 
various time points after treatment 
Results with statistical analysis on the relative expression level of RA 
synthesizing enzymes Raldh Raldh2 and RalcJhS and RA catabolizing enzymes 
Cyp26al, Cyp26hl and Cyp26cl between embryos of RA-treated and 
vehicle-treated control mice at different time points after treatment were shown in 
Table 4.1. Results were presented in Graph 4.1, Graph 4.2，Graph 4.3, Graph 4.4, 
Graph 4.5 and Graph 4.6 for Raldh 1, Rcddh2, RaldhS, Cyp26al, Cyp26hl and 
Cyp26cl respectively. 
Raldh 
At E9.5, i.e. 14 hr after teratogenic RA injection, Raldh 1 expressions in 
embryos of RA-treated mice were significantly (p = 0.034) down-regulated by more 
than half when compared with the control (Graph 4.1). This down-regulation lasted 
till E l l .5 , at which Raldh 1 expressions in embryos of RA-treated mice were reduced 
by about one third. By El 2.0, the expression of Raldh 1 of RA-treated embryos had 
returned to a level similar to the control. 
Similar to Raldh I, after teratogenic RA insult, significant (p < 0.048) 
down-regulation of Raldh2 expression in embryos of RA-treated micc was 
dctcctablc as soon as E9.5 (Graph 4.2). Down-regulation lasted till El 1.0. By El 1.5, 
the expression had restored a level similar to the control. 
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Similar to Ruldh / and RaldhJ, allcr teratogenic injection ol'KA, Ua/dliJ 
expression levels in RA-treated embryos were significantly rcduccd when compared 
with the control (Graph 4.3). Down-regulation was dctectablc as early as E9.5 and 
lasted till El 1.5. 
When comparing the relative expression levels of the 3 iso forms, Raldh 1 
and RalcIhS were similar and were very low, which agreed with the limited 
expression domains of Raldh I (Figures 4.1-4.2) and RaldhS (Figures 4.8-4.9 ) in the 
embryo. The Raldh2 expression level was the highest among the three RA 
synthesizing enzymes, which matched with its extensive expression domains as 
shown by in situ hybridization in Figures 4.3-4.7. Thus, the down-regulation of 
Raldhl after RA injection should exert the most prominent effect on RA synthesis in 
the embryo. 
Cyp26 
At E9.5, i.e. 14 hr after injection of a teratogenic dose of RA, Cyp26a 1 
expressions in the embryos of RA-treated mice were dramatically up-regulated by 
over 6 fold when compared to the control (Graph 4.4). However, by El0.0, there 
was no longer any significant difference between RA-treated and control embryos, 
implying that Cyp26a 1 expressions in RA-treated embryos dropped sharply and 
returned to a normal level within 12 hr. Similar expression levels of Cyp26al were 
still found between RA-treated and control embryos at El0.5. Yet, at El 1.0, 
Cyp26a 1 expression was found to be significantly {p < 0.032) reduced in RA-treated 
embryos when compared to the control. Significant (p < 0.007) down-regulation was 
also observed at El 1.5. By El2.0, the expression level of Cyp26aI in RA-treatcd 
embryos returned to a level similar to the control. 
For Cyp26hl, similar to Cyp26al, at E9.5, its expression level was 
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signitleantly {j)�().()()7) up-regulated by more than 5 fold in KA-lrcatcd embryos 
when compared to the control (Graph 4.5). However, within 12 hr, Cyp26hl 
expression in RA-treated embryos rcduccd sharply from E9.5 to ElO, so much so 
that the expression level ofCyp26hJ in RA-trcatcd embryos bccainc significantly (p 
< 0.049) lower than the control. This significant (p < 0.026) down-regulation was 
even more prominent at ElO.5, such that the expression level of RA-treated embryos 
was only half of that of control embryos. From Ell.O onwards, the expression level 
o^Cyp26hl in RA-treated embryos was restored to a level similar to the control. 
For Cyp26cl’ at E9.5, i.e. 14 hr after RA treatment, unlike Cyp26al and 
Cyp26hl which were highly up-regulated, the expression of Cyp26cl was 
significantly (p 二 0.001) down-regulated by 8 fold in RA-treated embryos in 
comparison to the control (Graph 4.6). Again, Cyp26cl expressions returned to 
normal levels within 12 hr. Surprisingly, the expression level of Cyp26cl in 
RA-treated embryos reduced again at E10.5 and showed a significant (p < 0.035) 
difference from the control. From Ell.O onwards, the expression level of Cyp26cl 
was similar between RA-treated and control embryos. 
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4.4.2 C oniparisoii of niRNA expression levels of different isoforms of RA 
synthesizing enzymes Raldh and RA cataboli/in^ enzymes Cyp2() 
between mctancphroi of embryos of RA-treated and vchicIe-treatcd 
control mice at various time points after treatment 
Results in Table 4.1 only compared the expression levels of different 
isoforms of Raldh and Cyp26 in the ‘‘whole embryo" of RA-treated and control 
groups; differences, if any, between the two groups in specific tissues could be 
masked by the expression levels in the whole embryo. To have a better 
understanding of RA synthesis/catabolism in the metanephric kidney at early stage 
of development, I have investigated the expression levels of different isoforms of 
Raldh and Cyp26 in metanepliroi of embryos of RA-treated and control mice at 
El 1.0, El 1.5 and El2.0. These time points were chosen because metanephric kidney 
starts to develop at around El 1.0 at which the ureteric bud has just penetrated into 
the metanephric mesenchyme. Results with statistical analysis were shown in Table 
4.2 and presented in Graph 4.7, Graph 4.8, Graph 4.9, Graph 4.10, Graph 4.11 and 
Graph 4.12 for Raldhl, Ralc!h2, RaldhS, Cyp26aI, Cyp26bI and Cyp26cl 
respectively. 
Raldh 
All three isoforms of RA synthesizing enzymes Raldh were expressed in 
the early stage metanephros. Yet, their expression levels were very different. Raldh2 
expression (Graph 4.8) was the highest among the three isoforms. Its expression in 
the metanephros at El 1.0 was 7()-tbId higher than that of RaldhS (Graph 4.9). 
Although the expression level of Raldh I (Graph 4.7) was 2.7-to Id higher than 
Raldhit was still far lower than that oi Rahlhl. Allcr RA treatment, the expression 
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level of all three isolbrnis Raldh was signitlcanlly down-rcgulalcd Irom 1:1 1.0 to 
H 1 2.0 when compared to tlic control. It is also worth noticing that for Raldh2, the 
major RA synthesizing enzyme in the metanephros, its expression level at El 1.0 and 
El 1.5 were similar, but appeared to be up-regulated by El2.0. 
Cyp26 
At El 1.0, the expression level of Cyp26al was significantly (p < 0.034) 
down-regulated by one-third in the metanephros of RA-treated embryos when 
compared to that of the control (Graph 4.10). However, no significant difference 
between the two groups was found beyond this time point. It is worth noticing that 
while the expression level of Cyp26al in the control metanephros was similar at 
El 1.0 and El 1.5, its level dropped sharply by 80% at El2.0. 
For Cyp26bl’ its expression in the metanephros of RA-treated embryos 
at El 1.0 was significantly (p < 0.032) up-regulated by 2 fold when compared to the 
control (Graph 4.11), which was opposite to that found in Cyp26al. But no 
significant differences between the two groups could be detected beyond this time 
point. Unlike Cyp26al, Cyp26bl expression in the metanephros was kept at a 
similar level from El 1.0 to E12.0. 
For Cyp26cl, its expression level in the metanephros was the lowest 
among the three isofonns. There was no significant difference in Cyp26cl 
expression between metanephroi of RA-treated and control embryos for the stage of 
El 1.0 to El2.0 (Graph 4.12). 
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liible 4.2 Relative expression levels of different isoforms ol KA synthesi/in^ 
eIIzvines Raldh and RA cataboli/inji； cn/ynics Cyp26 between 
nietanephroi of embryos of RA-trcatcd (RA) and vehicle-treated 
control (CON) niicc at different time points after treatment. 
Developmental stages Ell.O E11.5 E12.0 
Treatment groups CON RA CON RA CON RA 
No. of samples 3 4 3 3 3 4 
IT L • •、丨 • I /I I _  " i T r ,, , • I • I • … I ,.1 ,. - I ... • 1 
Expression levels of O.O丨72 0.0065 0.0124 0.0066 0.0148 0.0078 
士 0.0041 i： 0.0002 ±0.0015 士 0.0007 士 0.0010 土 0.0009 
/7-value of CON vs. RA 0.027* 0.024* 0.002* 
“ • • -'" ‘ • — — - ' - ' - ' - ' ‘ 1 BSC ‘ • ' I I i「-ir,vi,jji JUL、" • •tt-t • • ir •uasssaBSB i in i i iii iii i i ii ‘ •  • ，•-•••_ ！ • • • "去 
Expression levels of 0.4388 0.3678 0.4322 0.3593 0.5567 0.3876 
Rulcih2/l3-LWti}i±SEM 土 0.0217 ±0.0189 ±0.0109 ±0.0187 士 0.0396 土 0.0402 
/)-value ofCON vs. RA 0.029* 0.029* 0.019* 
Expression levels of 0.0063 0.0032 0.0066 0.0052 0.0045 0.0022 
Rul(ih3//Uictifi ±SEM ± 0.0000 土 0.0005 土 0.0001 土 0.0003 士 0.0008 士 0.0003 
/rvalue of CON vs. RA 0.012* 0.008* 0.033* 
Expression levels of 0.0033 0.0022 0.0036 0.0050 0.0008 0.0005 
Cyp26ciLJ[ucfin iSEM 土 0.0003 土 0.0002 土 0.0001 ± 0.0009 土 0.0001 士 0.0001 
/>value of CON vs. RA 0.034* 0.189 0.214 
Expression levels of 0.0055 0.0102 0.0059 0.0073 0.0069 0.0097 
Cyp26bl/f“wtin:tSEM 土 0.0010 ± 0.0005 ± 0.0004 土 0.0006 土 0.0017 土 0.0021 
p-value of CON vs. RA 0.032* 0.135 0.210 
Expression levels of 1.48E-M 1.5()E-4 1.51E-(>4 2.02E-04 1.74E-04 1.40E-(W 
± S E M 士().16E-()4 土0.14E-04 土().33E-04 土O.llE-04 士0.29E-04 土ai9E-04 
p-value of CON vs. RA 0.762 0.221 0.493 
* Statistically significant (Independent Samples t-test) 
4.4.3 Comparison of the in situ hybridization pattern of different isoforms 
of Raldh between embryos of RA-treated and vehicle-treated control 
mice at different time points after treatment 
Besides comparing the expression level of RA synthesizing enzymes by 
quantitative RT-PCR, I have also localized the sites of expression changcs by using 
- -
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in situ hybridi/ation. Since Raldh2 is most widely expressed and is the major RA 
synthesizing enzyme in the embryo, I have carefully investigated Raldh2 expression 
changes in different stages of mouse embryo at half day interval from E9.5 to El 2.0. 
The expression pattern of Raldh I and Raldh 3 was examined at E9.5, El 0.0, El 1.0 
and E12.0. To examine the expression in the developing kidney, El 1.0 and El2.0 
embryos that had been subjected to in situ hybridization were cut by a vibratome 
into 20 fim sections. However, only Raldh2 expression could be detected after 
sectioning. The expression levels of other genes in the developing kidney were too 
low to be detected. Thus, only results of Raldh2 sections in the kidney were 
presented. 
4.4.3.1 In situ hybridization pattern of Raldh 1 
At E9.5 Raldh 1 had limited expression domains (Figure 4.1 A), which 
agreed with the finding obtained by quantitative RT-PCR that the overall expression 
level of Raldh 1 in the embryo was very low (Graph 4.1). As shown in the control 
embryo, it was only prominently expressed in the dorsal optic vesicle (Figire 4.1C), 
in the third pharyngeal pouch (Figure 4.1G) and was also weakly in the otic vesicle 
(Figure 4. IE). The expression domains of Raldh 1 in the RA-treated embryo (Figure 
4. IB) were similar to the control, except Raldh I expressions in the optic vesicle 
(Figure 4.ID) and the third pharyngeal pouch (Figure 4.1H) were noticeably reduced. 
There was hardly any signal in the otic vesicle (Figure 4.IF). At El0.0, the 
expression domains of Raldh 1 were similar to E9.5 (Figure 4.2A). Other than the 
dorsal optic vesicle and the third pharyngeal pouch, weak expression of Raldh I was 
also observed in the RA-trcatcd embryo (Figure 4.2B). At El 1.0, distinctive Raldh I 
signal was only dctcctablc in the developing eye (Figure 4.2C). Within the 
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developing eye, there was strong expression of Raldh I in the dorsal retina and 
weaker expression in the lens (Figure 4.2E). There was a lower signal intensity of" 
Ruldhl at these sites in the RA-treated embryo (Figures 4.2D and 4.2F). The 
down-regulation o^Raldhl expression from E9.5 to El 1.0 in RA-treated embryos as 
detected by in situ hybridization agreed with the result obtained by quantitative 
RT-PCR. At El2.0, RaclhI expression was found mainly in the developing eye 
(Figure 4.2G). There was no observable difference between control and RA-treated 
embryos at this stage (Figure 4.2H). 
4.4.3.2 In situ hybridization pattern of Raldh2 
At E9.5, Raldh2 was strongly expressed at multiple sites in the embryo 
(Figure 4.3A), which agreed with the finding obtained by quantitative RT-PCR that 
Raldh2 was expressed at high levels and was the major RA synthesizing enzyme in 
the embryo (Graph 4.2). In the head, it was expressed in the region between the 
optic vesicle and the first branchial arch (Figure 4.3C). In the trunk, it was highly 
expressed in the developing lung bud, in the paraxial mesoderm, in the midgut 
diverticulum and also along the dorsolateral edges of the intra-embryonic coelomic 
cavity including tissues that formed the urogenital ridge (Figure 4.3E). Towards the 
caudal end, Raldh2 was strongly expressed in the cloacal region containing the 
nephrogenic cord tissue, and was also found in the presomitic mesoderm (Figure 
4.3E). In the RA-treated embryo, there was a general reduction in the expression 
level of Raldh2 (Figures 4.3B and 4.3F). Most easily distinguishable was the 
expression domain in the region between the optic vesicle and the first branchial 
arch bccausc of its isolated position (Figure 4.3D). At El0.0 (Figure 4.4A), Raldh2 
expression pattern was similar to that at E9.5. In the trunk, prominent expression 
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was observed along the dorso-latcral edges of the coclom and in the cloacal region, 
which included tissues for I'orming the mcsoncphric system (Figure 4.41^). 
Expression was also initiated in the otic vcsiclc (Figure 4.4C). However, unlike 
Raldh I, Raldh2 expression in the otic vesicle was restricted to the lateral portion. In 
the RA-treatcd embryo, there was hardly any expression of Raldh2 in the otic 
vesicle (Figure 4.4D). The body had truncated at a level just caudal to the cloacal 
region (Figures 4.4B and 4.4F). Moreover, while Raldh2 expression was observed in 
the clearly delineated newly-developed somites in the control embryo (Figure 4.4E), 
expression of Raldh2 in the same location of the RA-treated embryo was not 
demarcated into somites (Figure 4.4F). At El0.5, expression of Raldh2 was 
down-regulated in the differentiated somites (Figure 4.5A) while expression in other 
domains persisted. In the cranial region, other than expressing specifically in the 
lateral portion of the otic vesicle, expression was also initiated in the 
maxillo-mandibular cleft (Figure 4.5C). In the RA-treated embryo, there was hardly 
any expression in the otic vesicle and in the maxillo-mandibular cleft (Figures 4.5B 
and 4.5D). At El 1.0 (Figure 4.6A), the expression pattern of Raldh 2 was similar to 
that at El0.5. Raldh2 was almost switched off in the differentiated somites. Strong 
expression was observed in the spinal cord in the cervical region and also expression 
in the heart became prominent. In the head, specific expression in the otic vesicle 
persisted (Figure 4.6A). Other than the maxillo-mandibular cleft, Raldh2 was also 
expressed strongly in the tissue between the developing eye and the maxillary 
component of the first branchial arch (Figure 4.6C). Differences in Raldh2 
expression between control and RA-treated embryos were most easily distinguished 
in the head region. In the RA-treated embryo, Raldh2 remained unexpressed in the 
otic vesicle (Figure 4.6B). Much lower and disorganized expression was observed in 
the maxillary and mandibular components of the first branchial arch and in the tissue 
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between the developing eye and the maxilla (I'igurc 4.61)). While it was more 
ditricult to distinguish differences between control (Figure 4.6H) and RA-trcatcd 
embryos (Figure 4.6F) in the caudal region, sectioning of the embryo at the level o f� 
the doacal region revealed that in the early metanephros in which the ureteric bud 
had just penetrated into the mctanephric mesenchyme, there was high levels of 
Raldh2 expression in the metanephric mesenchyme, but no expression in the ureteric 
bud of the control embryo (Figure 4.6G). However, in the RA-treated metanephros, 
expression of Raldh2 in the metanephric mesenchyme was prominently reduced 
(Figure 4.6H). Together, the reduced expression of Raldh2 at different domains of 
the RA-treated embryos from E9.5 to El l .O agreed with the finding obtained by 
quantitative RT-PCR that there was significant down-regulation of Raldh2 in 
RA-treated embryos (Graph 4.2). At El 1.5 and El2.0, although quantitative 
RT-PCR data indicated that there was no longer any significant difference in Raldh2 
expression levels between control and RA-treated embryos (Graph 4.2), in situ 
hybridization studies clearly showed that there were observable differences, 
especially in the expression domains in the facial region (Figures 4.7A and 4.7B). 
Moreover, the specific pattern of expression of Raldh2 in the interdigital region of 
the forelimb and hind limb buds found in the control embryo (Figure 4.7C) was very 
much distorted in the RA-treated embryo at El2.0 (Figure 4.7D). To examine in 
more details the expression of Raldh2 in the developing metanephros, embryos were 
sectioned at the level of the hindlimb bud. Similar to the result of El 1.0 embryos, 
while Raldh2 expressed at high levels in the metanephric mesenchyme of the control 
embryo (Figure 4.7E), its expression in the metanephric mesenchyme of the 
RA-treated embryo was severely reduced (Figure 4.7F). These results agreed with 
the finding obtained by quantitative RT-PCR that there was significant 
down-regulation of Raldh2 in the metanephros of the RA-treatcd embryo (Graph 
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4.7), despite the llict thai no significant dilTcrcncc was dctcctcd in the whole embryo 
(Cn-aph 4.2). 
4.4.3.3 In situ hybridization pattern of RaldhS 
At E9.5, Ra/c/hS was mainly expressed in the surface ectoderm overlying 
the optic vesicle and the olfactory region (Figure 4.8C). Intensive expression was 
also observed in a pair of nephrogenic cords at the caudal region (Figure 4.8A). 
There was weak signal in the otic vesicle as well. The limited expression domains of 
RaldhS agreed with the finding obtained by quantitative RT-PCR that the overall 
expression level of RaldhS (Graph 4.3) was very much lower than that of Raldhl 
(Graph 4.2). In the RA-treated embryo, there was observable reduction in RaldhS 
expressions in the cranial expression domains (Figures 4.8B and 4.8D). At El0.0 
(Figure 4.8E), the expression pattern was similar to E9.5, except the expression 
domain was more limited to the optic vesicle rather than in the peripheral surface 
ectoderm (Figure 4.8E). The expression of RaldhS in the optic vesicle of the 
RA-treated embryo was reduced (Figure 4.8F). However, the most prominent 
change was its expression in the nephrogenic cord (Figures 4.8G and 4.8H). At 
El 1.0’ RaldhS expression in the caudal region had diminished (Figure 4.9A). In the 
developing eye, RaldhS was expressed in the ventral half of the retina. Expression at 
the otic vesicle became localized in the margin of it. Strong expression persisted in 
the olfactory region. In the RA-treated embryo, slight reduction in the expression 
level of Raldh3 was observed in the olfactory region (Figure 4.9B). At El2.0, 
expression of RaldhS in the olfactory region had disappeared (Figure 4.9C). 
Expression was limited to the ventral retina. There was no observable ditTcrcncc in 
Raldh3 expression between control (Figure 4.9C) and RA-trcatcd embryos (Figure 
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4.4.4 Comparison of the in situ hybridization pattern of Cyp26al and 
Cyp26hl between embryos of RA-treated and vehicle-treated control 
niicc at different time points after treatment 
Since preliminary study of our laboratory found that Cyp26cl was only 
expressed in the cranial region in the absence and in the presence of RA, and also 
did not express in the developing kidney, thus, comparison of in situ hybridization 
pattern in the embryo of RA-treated and control mice was only performed for 
Cyp26al and Cyp26hl. Embryos were examined from E9.5 to El2.0 at 12 hr 
interval. 
4.4.4.1 In situ hybridization pattern of Cyp26al 
At E9.5, Cyp26al was normally expressed in the cranial mesenchyme, in 
the maxillary component of the first branchial arch and in the maxillo-mandibular 
cleft (Figure 4.IOC), but was not expressed in the optic and otic vesicles (Figure 
4.1 OA). Posteriorly, it was expressed in the tail bud at the caudal extremity (Figures 
4.1 OA and 4.10E). In the RA-treated embryo, there was prominent up-regulation of 
RA in all expression domains (Figure 4.1 OB). There were also ectopic expression 
sites, such as the developing heart (Figure 4.10D). Expression in the posterior region 
had expanded to the presomitic mesoderm and also in the ventral body wall of the 
trunk (Figure 4.1 OF). These results agreed with the finding of quantitative RT-PCR 
that there was 6-fold up-regulation of Cyp26al at 14 hr after RA treatment, i.e. at 
F:9.5 (Graph 4.4). At El0.0 (Figure 4.11 A) and El0.5 (Figure 4.11 E), Cyp26ul 
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continued to express in similar domains as 1:9.5. In the KA-trcatcd ⑶山�y(), 
expression of Cyp26al in cclopic sites such as the heart and the ventral body wall 
had switched olT (Figures 4.11B and 4.1 IF). Expression had returned to similar 
levels and similar domains as the control embryo, cxcept in the tail bud region 
where Cyp26al was prominently reduced (Figure 4.11D) in comparison to the 
control (Figure 4.11C). Moreover, expression in the first branchial arch was 
distorted (Figure 4.1 IF). At El 1.0, expression of Cyp26al at the caudal extremity 
had almost diminished as the tail bud started to regress (Figure 4.12A). The main 
site of expression was in the midline of the retina (Figure 4.12A), which persisted in 
embryos at El 1.5 (Figure 4.12C) and El2.0 (Figure 4.12E). It was also expressed in 
the otic vesicle and surrounding tissues (Figure 4.12A). However, in the RA-treated 
embryo, there was prominent reduction of Cyp26al in the hindbrain region (Figure 
4.12B), which was also observable at E l l . 5 (Figure 4.12D) and El2 .0 (Figure 
4.12F). 
4.4.4.2 In situ hybridization pattern of Cyp26bl 
At E9.5, Cyp26bl was mainly expressed in rhombomere (r) 2-5 (Figure 
4.13A). Expressions in r2, r3 and r4 were restricted to the basal region, whereas 
expressions spanned the entire rhombomere in r5 and r6 (Figure 4.13C). This 
expression pattern in the rhombomeres persisted at El0.0 (Figure 4.13G). In the 
RA-treated embryo, up-regulated expression of Cyp26bl was observed in the whole 
embryo at E9.5 (Figures 4.13B and 4.13D), which agreed with the finding of a 
significant up-regulation of Cyp26hl expression levels by 6 fold as detected by 
quantitative RT-PCR (Graph 4.5). However, by El0.0’ all the ectopic sites of 
Cyp26hl expression had switched otT (Figure 4.13F). While there was not much 
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ditVcrcncc in Cyp26hl expression in the Ibrelinib and hind limb buds of control 
(t'igurc 4.13H) and A-treated embryos (Fig. 4.13F), expressions Cyp26hI in the 
rhomboniercs were severely reduccd and distorted in the RA-trcatcd embryo (Figure 
4.13H), which might explain the significant reduction in Cyp26hl expression levels 
in RA-treated embryos at this stage as detected by quantitative RT-PCR (Graph 4.5). 
In contrast, expression of Cyp26hl in the inetencephalon was prominently increased 
in the RA-treated embryo (Figure 4.13H) in comparison to the control (Figure 
4.13G). This increased expression of Cyp26hI expression in the metencephalon and 
reduced expression in the rhombo meres (r2-6) and subsequently in the 
myelencephalon persisted in RA-treated embryos at E10.5 (Figure 4.14A) and El 1.0 
(Figure 4.14C) in comparison to the control (Figures 4.14A and 4.14C). At El 1.5’ 
there was still observable reduction of Cyp26hl expression in the myelencephalon, 
but not so much in the metencephalon, of RA-treated embryos (Figure 4.14F) in 
comparison to the control (Figure 4.14E). By 12.0, there was not much difference in 
Cyp26bl expression between RA-treated (Figure 4.14H) and control embryos 
(Figure 4.14G). 
4.4.5 Comparison of RA levels between embryos of RA-treated and 
vehicle-treated control mice at different time points after treatment 
After investigating the mRNA expression level of the RA synthesizing 
and catabolizing enzymes, next, I have compared the amount of RA in the whole 
embryo with or without RA injection by using HPLC. Results were shown in Table 
4.3 and presented in Graph 4.13. 
At E9.5, i.e. 14 hr after teratogenic RA insult, the amount of RA in the 
RA-trcatcd embryo was 6 fold more than that of the control. Results in scction 4.4.1 
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show cd that all 3 isolornis ol' RA synthesizing cn/ymcs were clown-rcgulalcd while 
RA catabolizing enzymes C \'p26a I and Cyp26hl were up-regulated in R A-treated 
embryos at this time-point. This suggested that the elevated level of RA was 
attributed to the exogcnously applied RA still remaining in the embryo, but not 
endogenous RA being synthesized at this stage. However, the RA level in 
RA-treated embryos dropped rapidly within 12 hr from E9.5 to ElO.O. At the same 
period, the RA level detected in control embryos increased sharply by 6 fold. 
Because of these changes, the amount of RA detected in RA-treated embryos was 
significantly {p = 0.050) lower than the control by 37% at ElO.O. This significant (p 
=0.023) difference between the two groups was still found at El0.5. However, from 
El 1.0 onwards, there was no longer any significant difference in the RA level 
between RA-treated and control embryos. 
Table 4.3 Amount of RA in embryos of RA-treated (RA) and vehicle-treated 
control (CON) mice at different time points after treatment. 
Developmental Treatment Sample Amount of RA p-value of 
stages groups size (ng/mg protein) 土 SEM CON vs. RA 
CON 4 0 07Q ± 0 0^7 . 
E9.5 u.u/y 士 u.uj/ 0.040* 
RA 3 0.501 ±0.102 
CON 3 0 448 ± 0 041 ElO.O u.顿土 U.U4I 0.050* 
RA 3 0.274 士 0.049 
E10.5 � N 3 0.377 士 0.018 1 ^ 
RA I 3 I 0.287 ±0.018 
CON 4 0 317 士 0 052 El 1.0 u . j i / t u . u j z 0.682 
RA 4 0.341 ±0.032 
CON 3 0 295 士 0 035 
El 1.5 0.298 
RA 3 0.252 ±0.012 
C O N 5 0.230 ±0.026 
[12.0 0.697 
RA 5 0.242 ±0.014 
* Statistically significant (Independent Samples t-tcst) 
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4.4.6 Comparison of RA levels hctwecii metaiicphroi of enihryos of 
RA-trcatcd and vchiclc-trcatcd control mice at different time points 
after treatment 
Besides measuring the amount o f R A in the whole embryo by HPLC, the 
amount of RA in the metanephros of Ell.O, E l l . 5 and E12.0 embryos was also 
determined by using the RA-responsive cell line. Results were shown in Table 4.4 
and presented in Graph 4.14. 
Results showed that the endogenous RA level in the metanephros of 
control embryo gradually increased from Ell .O to E12.0. After RA treatment, the 
amount of RA in the metanephros was significantly (p < 0.001) reduced by over 
50% when compared to the control. This reduction was found at all stages from 
E l l .O to E12.0. 
Table 4.4 Amount of RA in metanephroi of embryos of RA-treated (RA) and 
vehicle-treated control (CON) mice at different time points after 
treatment. 
Developmental Treatment Sample Amount ofRA /7-value of 
stages groups size per kidney (pg) 士 SEM CON vs. RA 
CON 13 0.020 ±0.012 
Ell.O <0.001* 
KA ” 0.093 士 0.009 
CON 16 0.324 ±0.024 
Ell .5 <0.001* 
KA IC 0.129 ±0.006 
CON 17 0.387 ±0.018 
E12.0 <0.001* 
RA 11 0171 土 0.030 
* Statistically significant (Independent Samples t-test) 
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4 . 5 DISCUSSION 
Normally, RA level in the embryo is tightly regulated by a balancing 
action between synthesizing and catabolizing enzymes. Results of the present study 
showed that when embryos were exposed to aberrant concentrations o f R A . The RA 
synthesizing enzymes were down-regulated whereas the RA catabolizing enzymes 
were up-regulated. These combined actions resulted in reduced levels of RA in 
RA-treated embryos from ElO.O to El 1.0. These changes may act as a protective 
mechanism to prevent embryo from exposure to excess RA. 
After teratogenic insult of RA on E8-22hr, the RA synthesizing enzymes 
were found to be down regulated at E9.5, which was 14 hr after RA treatment. 
However, endogenous RA level detected in the embryo at E9.5 was significantly 
elevated to more than 6 fold. This suggested that the evaluated amount o f R A in the 
embryo was due to maternal transfer of the exogenously applied RA being 
transported to the embryo rather than the RA being synthesized by the embryo itself. 
Under normal conditions, maternal RA does not pass to the embryo through the 
placenta (Morriss-Kay and Sokolova, 1996). However, the biochemical pathway of 
RA is changed when it is at an elevated level (Morriss-Kay and Sokolova, 1996). 
After maternal teratogenic RA treatment, embryonic RA level was found to be 
parallel with the elevated maternal plasma RA level. This suggests that RA is 
maternally transported to the embryo through the placenta after teratogenic RA 
treatment (Collins et al., 1994). 
Results of this study showed that peak level of endogenous RA was 
found at E9.5 after RA injection on E8-22hr. In another set of experiment in which 
100 mg/kg of RA was given orally to pregnant mice at E l l (Satre and Koclihar, 
1989), RA accumulated rapidly in the embryo as soon as 0.5 hr alicr administration. 
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rcak concentration was rcachccl at 3 hr. The RA level cictcclcd in the embryo al this 
stage rcachccl 104 ng/mg protein. In my study, the amount of RA dctcctcd in the 
RA-trented embryo was only 0.5 ng/ing protein. Although it was 6 fold higher than 
the control embryo at the same stage, the RA level was still 200 fold lower than the 
result obtained by Satrc and Kochhar (1989). This revealed that the peak level of RA 
in embryos injected with RA on E8-22hr should be found before E9.5, probably at 
E9-lhr, which was 3 hr after teratogenic RA treatment. 
Besides endogenous RA level in the embryo being altered after RA 
injection, HPLC results showed that retinol levels in RA-treated embryos from E9.5 
to El2.0 were reduced when compared to the control (data not shown). This finding 
agreed with the result obtained by Sat re and Kochhar (1989). Retinol is one of the 
substrates of RA. It is present in the plasma and tissues of different species (De 
Leenheer et al., 1982; Shelley et al., 1982). Results of Collins et al. (1994) showed 
that retinol level in pregnant mouse plasma was significantly reduced after RA 
treatment. Since maternal retinol can be transferred to the embryo through the 
placenta, it is not surprising that retinol level in the embryo reduced in parallel with 
retinol level in the maternal plasma. Under normal physiology, retinol is circulating 
in the plasma by binding with its specific retinol binding protein RBP4 and 
delivered to different tissues. However, there is evidence showing that RA can also 
compete with retinol for the RBP, although RA has a lower affinity (Goodman, 
1984). Thus, when there is an influx of RA into the blood, RA may replace the 
majority of retinol to bind to RBP. As a result, unbounded retinol will be excreted 
and the retinol level in the plasma will be reduced. Through this way, teratogenic RA 
treatment may cause a decrease in retinol level in the pregnant mouse as well as in 
the embryo. This decreased level of retinol in the RA-treated embryo may be one oT 
the pathways for the subsequent reduction of RA level in the embryo sincc retinol is 
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In our hypothesis, RA-induccd prolonged down-regulation of Raldh is 
the major cause of reduction of RA level in the embryo. This was supported by the 
result of quantitative RT-PCR as well as in situ hybridization. However, the 
underlying mechanism for this down-regulation remains unclear. There are several 
examples of RA suppressing gene activity. Oct-3/4 is an important gene during early 
embryogenesis. RA-induced differentiation of embryonal carcinoma (EC) cell is 
accompanied by down-regulation of Oct-3/4. Previous study has shown that a 
sequence located at the enhancer region of Oct-3/4 was responsible for RA-induced 
suppression of this gene (Okazavva et al., 1991). Another sequence with extensive 
homology with RARE was found at the promoter region of Oct-3/4 (Pikarsky et al., 
1994). It was shown that different RA receptors could bind to this RA-responsive 
sequence in RA-treated or untreated EC cells. This is an example of RARE being 
involved in suppression of gene activity by RA. Yet, to my knowledge, no literature 
has suggested the presence of RARE at the promoter region or enhancer region in 
the RA synthesizing genes. Another example of RA suppressing gene activity was 
shown by Kamei et al. (1996). They suggested that retinoid receptors might have an 
inhibitory activity by competing for the limiting transcriptional intermediate factors. 
In the present study, down-regulation of RA was detectable at E9.5, i.e. 
14 hr after RA treatment on E8-22hr. However, previous study of our laboratory 
found that as soon as 2 hr after treatment with 50 mg/kg RA to pregnant mice on 
E8-8hr, there was already significant down-regulation of Raldh2 expression in the 
embryo (Leung, 2005). Moreover, the present study showed that there was 
prolonged down-regulation of all three isoforms of Raldh in the embryo at least till 
Ell.O. Suppression of Raldh was further prolonged in specific tissues, e.g. tlic 
metanephros. Results of in situ hyhridw/dUon revealed that there was sitc-spccific 
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down-rcgiilation ot' Raldh by RA. Similar Uncling was obtained by Niederreither ut 
al.(卜)()7) that when pregnant mice were orally ted with 100 mg/kg of RA on 1:8.5, 
there was sitc-specific down-regulation of Raldh2 in the embryo 12 hr allcr RA 
treatment. However, whether RA induces down-regulation of Raldh through dircct 
or indirect mcc ban isms remains to be determined. 
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Chapter 5 
Effect of Supplementation with 
Low Doses of RA on RA 
Teratogenesis 
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5.1 IN rR()i) i j ( I ION 
5.1.1 RA supplementation 
Vitamin A or RA deficiency during pregnancy causes high incidence of 
congenital malformations in the embryo. These include ocular defects, abnormal 
external ear, heart defects and also malformations in the urogenital system (Wilson 
and Warkany, 1948; Wilson and Warkany, 1949; Wilson et al., 1953). As discussed 
previously, Vitamin A or RA deficiency can be induced in animal models by 
providing with vitamin A- or RA-deficient diet, or using knockout of RA 
synthesizing enzymes or RA receptors. Since more than 500 genes which take part 
in organogenesis are found to be regulated by RA, temporal and spatial disruption of 
endogenous RA may disturb their transcription and result in different types of 
malformations. For example, in Raldhi'' mouse mutant, embryos showed heart 
abnormalities and reduction in cardiac Fgf signaling. After RA supplementation 
between E7.5 and E8.5, part of the cardiac malformation was rescued and Fgf 
expression was partially restored (Lin et al., 2010). 
j 
In Raldh2— - mouse embryos, no RA activity was found at E8.5 by using 
the RARE-lacZ transgenic mouse, except a weak signal was detected at the 
developing eye (Niederreither et a l , 1999). This finding shows that Raldh2 
contributes to the majority of RA synthesis in the embryo during early stage of 
organogenesis. These embryos died at El0.5, exhibiting shortening of the entire 
posterior region, absence of limb buds and also failed in looping of the heart. When 
maternal RA was supplemented from E6.75 to E10.25 at 12 hr interval, mutant 
embryos were rescued from resoprtion. Furthermore, heart looping was restored and 
hind limbs appeared normally. These results illustrate that early resorption, licart aiul 
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liiiibs dcfeels in Raldhl'' mouse embryos were particularly due to maternal kA 
deprivation. 
RA level in the embryo was temporally regulated. RA supplementation at 
particular time may rescuc specific malformations. For example, retino 1 
supplementation to vitamin A-deficient rats at E9.5 prevented abnormalities of the 
central nervous system and the heart in the embryos. However, if the 
supplementation shifted to ElO, most embryos died due to heart failure (White et al., 
1998; White et a l , 2000). 
The rescue effect of RA supplementation was also shown in in vitro 
experiment (Batourina et al., 2001). Two RAR genes, RARa and RARp2, were 
normally found in the developing kidney. When El2 kidneys of RARa" and 
RARp2'^' mouse embryos were cultured in serum-free medium, stromal cell 
patterning was altered and the branching of the ureteric bud was disrupted. However, 
when RA was supplemented in this culture system, increased number of nephrons 
and intensive branching were found in the mutant kidneys. This finding supported 
that renal malformations caused by RA deficiency could be effectively rescued by 
RA supplementation. 
5.1.2 Wilms' tumor suppressor gene Wtl 
Wilms’ tumor suppressor Wtl is a crucial transcription factor in the 
development of the urogenital system. In the developing metanephros, Wtl 
expression is restricted in the metanephric mesenchyme, but not in the ureteric bud 
(Scholz and Kirschner, 2005). In the Wtl null mutant embryo, the metanephros 
failed to develop (Kreidberg et al., 1993). By using Wtl null mutants that expressed 
diOcrcnt gene dosages of artificial Wtl, reduced expression level of Wt I was tbund 
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to b e a M T c l a t c d w i t h glomerular d i s e a s e in a c losc-c lcpci ic lcnt m a n n e r ( ( i u o ct al . , 
2()()2). 1 h e r o l e o f " , / / in d i f f e r e n t s t a g e s o f k i d n e y d e v e l o p m e n t w a s s t u d i e d b y 
treating kidney cxplanls with small interfering RNA (siRNA; Davies cl al., 2004)). 
When Wtl expression in the intermediate m e s o d e r m (anlagc of metanephros) 
explant was disrupted at E9, the ureteric bud and the metanephric mesenchyme 
tailed to grow. When its expression was ablated at E l l , the ureteric bud remained 
intact’ but the development of nephrons was significantly deteriorated. These results 
suggest that Wtl is essential for various stages of kidney development. 
Recently, fV// transcription in the kidney was studied by transgenesis in 
zebrafish (Bollig et a l , 2009). An enhancer region necessary for fVt/ expression in 
the intermediate mesoderm was found. This enhancer could respond to RA receptors 
in both in vivo and in vitro models and suggested that RARE might be present in the 
upstream region of Wtl. Interestingly, this enhancer is highly conserved between 
zebrafish and mammal, thus, it is possible that Wtl expression in mice may also be 
controlled by RA. 
5.1.3 Apoptosis 
Apoptosis is programmed and physiological cell death that is important 
for removing unwanted cells. Cell death by apoptosis can be described as ‘suicide• 
since it is an ‘active’ form of cell death. This active form of cell death may require 
the synthesis of macro molecules. Moreover, during apoptosis, endogenous 
endonucleases are activated, which causes the cleavage of chromatin at 
intcrnucleosomal region. This type of cleavage produces the distinctive “ladder” 
pattern when nuclcosomc-sizcd DNA fragments are displayed on the gel (Wyllic, 
1980). Cell (lying by apoptosis is rapidly removed by nearby cells and phagocvtcs. 
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The time that took to remove apoptotic dead cclls was reported lo be al most 2 hr in 
the developing rat kidney and eye (Perry et al., 1983; Coles et al., 1993). 
Apoptosis takes part in the development of a number of organs. The most 
typical example is interdigital apoptosis during limb formation (Stewart et al., 2000). 
Apoptosis is also involved in normal kidney development. As mentioned earlier, the 
kidney is composed of two distinctive cell types, the metanephric mesenchyme and 
also the ureteric bud. Apoptosis is important for keeping a balance in the number of 
these two types of cells in the kidney. At the peak level, about 3% of apoptotic 
nuclei is found in the developing kidney (Coles et al., 1993). This high rate of 
apoptosis is normally found at the border of the metanephros, while inner cells are 
actively proliferating and have a lower rate of apoptosis (Woolf and Welham, 2002). 
In these cells, Pax-2 and Bel-2 are highly expressed, which give ‘rescue’ signals to 
prevent apoptosis (Winyard et a l , 1996b). Null mutant mice of Pax-2 never form 
metanephros (Dressier and Woolf, 1999), while the null mutant of Bcl-2 develops 
malformed kidney (Veis et al., 1993). These findings imply that dysregulation of 
apoptosis in the kidney may cause kidney malformations. 
Indeed, previous studies showed that several types of renal 
malformations were correlated with apoptosis. These include the most severe renal 
malformation, renal agenesis, in which the kidney is totally absent. The major type 
of renal malformation found to be related to apoptosis is dysplastic kidney. In this 
type of malformed kidney, there is down-regulated expression of Pax-2 and Bcl-2 
and an increase in abnormal apoptotic cells (Winyard et a l , 1996a; Winyard et al., 
1996b). These may cause a decrease in precursor cells and result in renal 
malformations. 
- 1 1 4 -
('luiplcr 5: RA Su[>i)l('t}i('nt(ili(>n 
5.2 K\IM:KIMi:N rAL l)i:SICN 
Results of Chapter 3 demonstrated that when a teratogenic dose of RA 
(125 mg/kg) was injcctcd into pregnant micc on E8-22hr, fetuses suffered from 
severe renal malformations alongside with other congenital defects, such as 
abnormalities in eye and ear. From the result of Chapter 4, it was shown that the 
expression of RA synthesizing enzymes as well as endogenous RA levels in the 
kidney and the whole embryo were significantly reduced after teratogenic RA 
treatment. However, whether this reduction of RA synthesis and RA level indeed 
play a role in kidney malformations and other defects remain unclear. Thus, the aim 
of this chapter was to test whether supplementation with low doses of RA to 
pregnant mice could ameliorate malformations in embryos induced by teratogenic 
RA insult. 
To achieve this, following teratogenic RA insult (125 mg/kg) on E8-22 hr, 
pregnant mice were orally supplemented with multiple low doses of RA at regular 
intervals. Since results of Chapter 4 showed that reduction of RA levels in whole 
embryo started at El0.0, RA supplementation was initiated from this time point. 
First, different time points were tested to determine the critical period for RA 
supplementation to restore kidney development. Next, different dosages of RA 
(0.625, 1.25 and 2.5 mg/kg) were tested. Kidney development and other 
malformations were examined morphologically in near-term fetuses at E l8 to 
determine whether supplementation with low doses of RA could rescue these 
defects. 
Finally, as shown in the previous data from our laboratory (Tse ct al., 
2005), RA-induccd renal malformations were caused by a significant 
down-regulation of WlI as well as increased apoptosis in the metanephros at F l l . 
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After finding out the optinlunl tinlc and dose t{)r RA supplelllentation to rescue fc: na l 
111aitl)rtnations, I further investigated whether RA sUpplclllcntation co uld restore thc: 
express ion of JIV! I and suppress apoptosis in the Inetanephros. 
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5.3.1 Oral j^ avaj^ c of low doses of RA 
Preparation of the low dose of RA suspension was similar to that 
described in section 2.2. However, a stock suspension was first prepared by 
dissolving 50 mg of RA instead of 100 mg in 1.5 ml absolute ethanol and then made 
up to a final volume of 15 ml by peanut oil to a final concentration of RA at 3.33 
mg/ml. RA was further diluted to different concentrations with peanut oil before 
each supplementation regimen. RA was then orally fed to the pregnant mouse by a 
30 mm long barrel tip 20G gavage feeding needle {Fine Science Tools). Mice fed 
with equivalent volume of the suspension vehicle served as the control. 
The different dosing regimes were described in the result section. 
5.3.2 Determination of Wtl expression level by real-time quantitative 
RT-PCR 
Pregnant mice were intraperitoneally injected with a teratogenic dose of 
125 mg/kg RA on E8-22hr. Starting from ElO.O, pregnant mice were orally fed with 
1.25 mg/kg RA or equivalent volume of suspension vehicle as control for a total of 3 
doses given at 12 hr interval. At El2.0, the metanephros of embryos of 
RA-supplemented and vehicle-supplemented control mice that had been treated with 
a teratogenic dose of RA and the metanephros of embryos of mice that had not been 
exposed to any teratogenic RA insult was collected. The metanephros was dissected 
in ice-cold DEPC-treated PBS, and then stored in RNA""c". RNA Stabilization 
Reagent at -2()�C until use. Fifteen to twenty metanephroi of embryos troni the same 
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litter wcic pooled as one sample. The sample was subject ccl to quantilicatioii of IV f / 
iiiRNA expression level by real-time quantitative RT-PCR. Detailed protocols for 
pciibruling RT-PCR were described in section 2.4. ji-actin was used as an internal 
control to normalize the quantity of the sample. Sequences of primers used for the 
reactions were listed below: 
Wtl Forward primer: 5，-CAG ATG TAA TTC TAC AGG CGATTG-3' 
Reverse primer: S'-TCC CTA CAT ACT TGC AG A TTC AAA-3’ 
P-actin Forward primer: 5’-TGT TAC CAA CTG GGA CGA CA-3' 
Reverse primer: 5,-GGG GTG TTG AAG GTC TCA AA-3' 
5.3.3 Preparation of paraffin sections and TUNEL staining 
5.3.3.1 Sample collection 
At El 2.0, embryos of different groups as described in section 5.3.2 were 
dissected in ice-cold PBS. Embryos were immediately fixed in freshly-prepared 4% 
paraformaldehyde in PBS for overnight at 4°C. On the next day, embryos were 
washed with water for three times. They were then cut into half at the level just 
posterior to the forelimbs. The lower part of the embryo was kept for further 
procedures. 
5.3.3.2 Dehydration, embedding and sectioning 
The lower part of the embryo was dehydrated in a series of ethanol 
solution in increasing concentrations (70, 80, 95 and 100%) tor 15 min at room 
temperature in cach step. After dehydration，the embryo sample passed through 
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xlycnc twicc tor 5 min in each step. The sample was then Iransfcrrcd to incllcd 
paratfin wax (fibrovvax, / " ) / / ) at 6()�C with 3 changcs for 20 min cach Ibr the wax lo 
tlilly infiltrate into the sample. The sample was orientated in a glass embedding 
mould such that the kidney would be sectioned at transverse plane. After solidified, 
the wax block was removed and kept for further use. 
The wax box was trimmed to a suitable size and fixed onto an embedding 
cassette. Serial sections at a thickness of 7 was cut by a microtome (Leica) and 
placed on the Super Frost Plus microscopic slide {Menzel-Glaser). Sections were 
examined under a light microscope and slides containing sections of appropriate 
region of the embryo were used for TUN EL staining. 
5.3.3.3 TUNEL staining 
Apoptotic cells were detected by the Terminal deoxynucleotidyl 
transferase dUTP nick end labeling (TUNEL) method using the ApopTag Plus 
Peroxidase in situ apoptosis detection kit {Oncor). Staining was carried out 
according to the manufacturer's protocol with some modifications. All procedures 
were conducted at room temperature unless indicated otherwise. 
Wax on the slide was first melted on a hot plate for 1 min. It was then 
removed by passing through 3 changes of xylene for 5 min in each step. Sections 
were washed by absolute ethanol twice for 5 min each. They were rehydrated by 
passing through 95%, 80% and 70% ethanol, and then water, followed by PBS for 5 
min in each step. Endogenous peroxidase activity was quenched by washing with 
3% H2O2 in PBS for 5 min, followed by washing 3 times with PBS tor 2 min cach. 
Seventy-five micro lit res of "Equilibration Buffer，’ was added onto the slide and was 
covcrcd with the plastic covcr slip provided in the kit and allowed to stand lor 1 min. 
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A tier that, the covcr slip was removal and cxccss bullbr was drained oil". Working 
strength '\\\T cn/ymc at a volume of 55 |al/5 cnr was added onto Ihc slide. The slide 
was ctncrcd by the plastic covcr slip and incubated in a humidified chambcr at 37 C 
for 1 hour. Reaction was stopped by washing in the Wash Buffer in a coplin jar fbr 
10 min. The slide was washed with water tor 3 times, followed by PBS for 3 times 
tor 1 minute in cach step. Anti-DIG-Peroxidase at a volume of 55 \i\/5 cm^ was 
applied onto the slide and then covered by another plastic cover slip. The slide was 
incubated in a humidified chamber for 30 min. After incubation, the slide was 
washed 5 times with IX Tris-buffered saline (TBS) for 2 min in each step. Color 
was then developed by applying the following staining solution: 
50 ml solution Final concentration 
DAB (stock: 50 mg/ml) 100 100 }ig/ml 
TBS (50 mM Tris + 150 mM NaCl) 50 ml 50 mM 
35% H2O2 14|il 0.01 % 
After about 15 min (depended on the color intensity), the slide was 
washed by tap water. The slide was counterstained with 0.5% Methyl green in 0.1 M 
sodium acetate (pH4.0) for 10 min. The slide was washed by tap water and 
dehydrated in ethanol solution in ascending concentrations (70, 80, 90, 100%) for 5 
min in each step. Finally, it was cleared by 3 changes of xylene for 5 min each. A 
glass cover slip was then applied onto the slide by Perniount (Fisher). 
To count the number of apoptotic nuclei in the metanephros but prevent 
double counting, one in every 3 sections was examined by using a neurolucida 
(MBF Bioscience) and image was taken by the Spot digital camera {Spot I magi fig 
Solution). 
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5.3.4 Statistical analysis 
The ctTcct o f R A supplementation on kidney development was compared 
by Jonckhecrc-Tcrpstra test. Normal kidney and kidneys with different types of 
malformations were classified into six grades according to the same system as listed 
in Table 3.1. By using this grading system, correlation between the time or the dose 
of RA supplementation and renal malformations was determined by Spearman's 
rank correlation. 
Different growth parameters (weight, crown-rump length, head length 
and tail length), number of apoptotic nuclei and expression level of WtJ in the 
metanephros between RA-supplemented and control groups were compared by 
Independent Sample t-test. 
To compare the frequency of non-renal malformations in the fetuses 
between RA-supplemented and control groups, Chi-square test was used. All 
statistical analyses were performed using SPSS software, with statistical significance 
level set asp < 0.05. 
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5.4 Ri:siii;is 
5.4.1 l ime response to RA supplementation in rcscuinjj; kidney 
development 
Results of Chapter 4 showed that RA deficiency in the whole embryo 
was evident by El0.0 after exposure to a teratogenic dose of RA on E8-22hr. Since 
metanephros begins to develop at E l l , deficiency of RA from ElO to El l may 
contribute to disruption in kidney development. This chapter aimed to determine 
whether supplementation with RA could rescue embryos fi-om developing renal 
malformations. First, I have determined when within the period of ElO.O to El 1.0 
was RA supplementation necessary for restoring nephrogenesis. To achieve this, 
following injection with a teratogenic dose of 125 mg/kg RA on E8-22hr, pregnant 
mice were orally supplemented with 1.25 mg/kg RA by different dosing regimens 
with supplementation started at different time points. In one regimen, RA was first 
supplemented at ElO.O. Supplementation was then repeated at 12 hr interval for a 
total of 3 doses, with the last dose being given at El 1.0. The second dosing regimen 
was to start the supplementation at El0.5 and then repeated 12 hr later at El 1.0. The 
third dosing regimen was to supplement a single dose of RA at El 1.0. In each 
regimen, mice fed with equivalent volume of suspension vehicle served as the 
control. Results were summarized in Table 5.1 and presented in Graph 5.1. 
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I'irst, it was Ibuiul tlial vchicic supplementation, no matter given at what 
time and tor how many doses, did not cause any significant (lillcrcncc in the 
frequency and severity of renal malformations when compared with the group 
without any supplementation (p = 0.590). Moreover, there was not much diflcrencc 
in the frequency of resorption between RA-supplemented and control groups for all 
dosing regimens, suggesting that the dose of 1.25 mg/kg RA did not cause further 
teratogenic effect on the embryo. 
Among the three vehicle-supplemented controls, the frequency and 
severity of renal malformations were similar. In these groups, 100% of fetuses were 
found with renal malformations, among which 70-80% was bilateral renal agenesis, 
i.e. the most severe type of renal malformations. 
When a single dose of RA was supplemented at El 1.0, renal 
malformations were significantly (p < 0.001) ameliorated. The frequency of bilateral 
renal agenesis decreased dramatically to 48%, with a shift of renal malformations to 
the less severe non-agenesis type such as hypoplastic, dysplastic and polycystic 
kidneys. Six percent of fetuses were even found with a pair of normal kidneys, 
which were not observed in the control. When one more dose of RA was 
supplemented 12 hr earlier, i.e. at El0.5, 17% of fetuses had normal kidney 
development. The frequency of bilateral renal agenesis was further reduced to 34%. 
When RA supplementation was initiated another 12 hr earlier at ElO.O, and was 
given a total of 3 doses at 12 hr interval, 28% of fetuses were totally rescued from 
developing any renal malformations, and the frequency of bilateral renal agenesis 
dramatically reduced to 21 %. These results clearly demonstrated that 
supplementation with low doses o f R A could ameliorate the eftect of the teratogenic 
dose o f R A in causing renal malformations. 
It could be seen that when RA supplementation was initialed at earlier 
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time points, the pcrccntagc of tcliiscs with normal kidneys increased whereas the 
pcrccntagc of fetuses with bilateral renal agenesis dccrcascd. Analysis of the data by 
Spearman's rank correlation confinned that there was a significant negative 
correlation ( / . � = -0.377; p < 0.001) between the dosing regimen started at earlier 
time points and the severity of renal malformations, implying that when RA 
supplementation was initiated at earlier time points, renal malformations were less 
severe. 
To investigate whether continued supplementation with RA beyond 
El 1.0 could provide any further rescue effect, another dosing regimen was tested in 
which RA was supplemented for a total of 4 doses given at 12 hr interval, with the 
first dose of RA given at El 0.0 and the last dose at E l l .5. Results were summarized 
in Table 5.2 and presented in Graph 5.2. 
For fetuses that had received 4 doses of RA supplementation starting at 
El0.0, 28% of fetuses could be completely rescued from developing any renal 
malformations. The percentage of fetuses with bilateral renal agenesis was reduced 
to 21 %. These results were highly similar to the dosing regime of 3 doses with the 
last dose given at Ell.O, implying that the extra dose of RA given at El 1.5 did not 
provide any further rescue effect. 
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lahle 5.2 I Jfect of oral supplementation with 3 doses or 4 doses of 1.25 
ni^/kj» RA or vehicic as control stiirtinj^ at ElO.O following 
teratogenic RA insult on kidney development of fetuses. 
Teratogenic insult with maternal injection of 
125 mg/kg RA on E8-22hr 
3 doses of oral 4 doses of oral 
^ supplementation at supplementation at 
Treatment groups 
12 hr interval starting 12 hr interval starting 
at ElO.O at ElO.O 
1.25 mg/kg 1.25 mg/kg 
Control Control 
RA RA 
No. of litters 12 14 6 8 
No. of implantations 135 180 63 89 
No of live fetuses 107 150 49 53 
No. (%) of implantations underwent 28 30 14 36 
resorption (20.74) (16.67) (22.22) (40.45) 
No. (%) of live fetuses with two normal 0 42 0 15 
kidneys (0) (28.00) (0) (28.30) 
No. (%) of live fetuses with renal 107 108 49 38 
malformations (100) (72.00) (100) (71.70) 
83 31 39 11 
- B i l a t e r a l renal agenesis 
(77.57) (20.67) (79.59) (20.75) 
- U n i l a t e r a l renal agenesis (remaining 
10 23 5 10 
kidney with non-agenesis renal 
(9.35) (15.33) (10.20) (18.87) 
malformations) 
- U n i l a t e r a l renal agenesis (remaining 0 3 0 0 
kidney being normal) (0) (2.00) (0) (0) 
- Bilateral non-agenesis renal 13 40 5 10 
malformations (12.15) (26.67) (10.20) (18.87) 
- Unilateral non-agenesis renal 
1 11 0 7 
malformations (contralateral kidney 
(0.93) (7.33) (0) (13.21) 
being normal) 
/7-value in comparing 
<0.001* <0.001* 
Control vs. 1.25 mg/kg RA 
p- value in comparing 
0.886 
3 doses vs. 4 doses of 1.25 mg/kg RA * Stati tically ignificant (Jonckhccrc-Tcrpstra test) 
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5.4.2 Dose response to RA supplementation in rcsciiinj^ kidney 
development 
From the above result, it could be concludcd that from El0.0 to El 1.0 
was the optimal period for RA supplementation to rcscue kidney development. Then 
a dose response to RA supplementation was performed to determine whether a 
higher dose of RA supplementation could give a better rescue effect, and whether a 
lower dose of RA supplementation would produce less or same rescue effect. 
Different dosages of RA (0.625, 1.25 and 2.5 mg/kg) was orally fed to the pregnant 
mice starting from El0.0 at 12 hr interval for a total of 3 doses. Results were shown 
in Table 5.3 and presented in Graph 5.3. 
When 0.625 mg/kg of RA was supplemented in 3 doses, it could 
significantly (p < 0.001) reduce renal malformations when compared to the control. 
However, the extent of rescue was significantly {p = 0.002) lower than that of using 
1.25 mg/kg of RA. The frequency of fetuses with a pair of normal kidneys when 
given 0.625 mg/kg RA supplementation was 14%, which was half of that when 
supplemented with 1.25 mg/kg of RA. On the other hand, the frequency of bilateral 
renal agenesis in fetuses given the dose of 0.625 mg/kg RA was 42%, which was a 
double of the amount found in fetuses supplemented with the dose of 1.25 mg/kg 
RA. Analysis of the result by Spearman's rank correlation showed that there was a 
significant negative correlation (r^ = -0.520; p < 0.001) between the dosage of 
supplemented RA and the severity of renal malformations, implying that the higher 
dose (1.25 mg/kg) of RA supplementation could provide a better rescue on kidney 
development against the teratogenic effect of RA. However, when the supplemented 
dose was further increased to 2.5 mg/kg of RA, the rescuc effect on kidney 
development was significantly (p : 0.027) reduccd. The (icqucncy fetuses with 
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normal kidney development dropped to 13%, whereas the Ircqucncy (“�bilateral 
renal agenesis was raised to 44%. Moreover, the ircqucncy of resorption was greatly 
increased to 43%, which was about 2 times higher than the control as well as other 
RA-supplcnicntcd groups. The decrease in rescue effect and increase in resoprtion 
indicated that the dose of 2.5 mg/kg of RA was probably too high and thus caused 
further teratogenic effects on the embryo. Thus, this dosage of RA was not suitable 
for supplementation. It could be concluded that the dosing regimen of 1.25 mg/kg of 
RA being supplemented for a total of 3 doses at 12 hr interval starting at El0 .0 
provided the optimum time and dose for RA supplementation to rescue kidney 
development following the teratogenic insult by RA on E8-22hr. This dosing 
regimen was adopted for subsequent experiments. 
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lahle 5.3 KtTect of oral supplementation with 3 doses of various dosages of 
RA or vehicle as control startiiij» at ElO.O followiiij^ teratoj^enic RA 
insult on kidney development of fetuses. 
Teratogenic insult with maternal injection of 
125 mg/kg RA on E8-22hr 
3 doses of oral supplementation at 
Treatment groups 
12 hr interval starting at ElO.O 
0.625mg/kg 1.25 mg/kg 2.5 mg/kg 
Control 
RA RA RA 
No. of litters 12 7 14 11 
No. of implantations 135 85 180 127 
No of live fetuses 107 64 150 72 
No. (%) of implantations underwent 28 21 30 55 
resorption (20.74) (24.71) (16.67) (43.31) 
No. (%) of live fetuses with two normal 0 9 42 9 
kidneys (0) (14.06) (28.00) (12.50) 
No. (%) of live fetuses with renal 107 55 108 63 
malformations (100) (85.94) (72.00) (87.50) 
D-1 t 1 1 . 83 27 31 32 
- B i l a t e r a l renal agenesis (77.57) (42.19) (20.67) (44.44) 
- U n i l a t e r a l renal agenesis 川 ^ ^^ g 
= = ? ! ) = 二 ？ h — a g e n e s i s (935) (12.5O) (15.33) (12.50) 
- U n i l a t e r a l renal agenesis 0 2 3 0 
(remaining kidney being normal) (0) (3.13) (2.00) (0) 
- B i l a t e r a l non-agenesis renal 13 14 40 18 
malformations (12.15) (21.88) (26.67) (25.00) 
- U n i l a t e r a l non-agenesis renal 1 4 11 ^ 
- m a l f o r m a t i o n s (contralateral kidney (6.25) (7.33) (5.56) 
being normal) 
/7-value vs. Control - < 0.001 * < 0.001 * < 0.001 * 
尸-value in comparing 0.625 and 1.25 • 002* 
mg/kg RA . 
/7-value in comparing 1.25 and 2.5 ^ (P7* 
mg/kg RA . “ 
Spearman's rank correlation coefficient 
(r,.) in comparing Control, 0.625 and -0.520 -
1.25 mg/kg RA 
尸-value of Spearman's rank correlation < 0.001� -
* Statistically signigicant (Jonckheere-Terpstra test) 
“Statistically significant (Spearman's rank correlation) 
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Sincc the nidancphric kidney does not develop until amund 1:11，so what 
would be the ciTcct of the two doses of RA being supplemented at ElO.O and 1:10.5? 
It might be possible that RA supplemented at these two time points was accumulated 
to El 1.0 to support metanephric development. To test for this possibility, a single 
dose of 2.5 mg/kg RA was supplemented at El 1.0. If the rescue effect of the two 
doses of RA supplemented at ElO.O and El0.5 was mediated merely via 
accumulation to support metanephric development at El 1.0, a higher dose of RA 
(2.5 mg/kg) supplemented at El 1.0 only should provide a better rescue effect than a 
single dose of 1.25 mg/kg RA supplemented at this time. Results were summarized 
in Table 5.4, and presented in Graph 5.4. 
Results showed that when a single dose of 2.5 mg/kg RA was 
supplemented at El 1.0, it could significantly reduce the severity of renal 
malformations when compared with the control (p = 0.045). However, this rescue 
effect did not show any significant difference from the group supplemented with the 
lower dose of 1.25 mg/kg of RA, indicating that a higher dose of RA given at El 1.0 
could not provide a better rescue effect on kidney development. This finding 
therefore supported that the rescue effect offered by the two doses of RA 
supplemented at ElO.O and El0.5 was not mediated via accumulation to El 1.0 to 
support the development of the metanephric kidney, but should be via other 
mechanisms. 
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lahle 5.4 Ktfect of oral supplementation with a sinjjjlc dose of 1.25 or 2.5 
RA or vchicIc as control at KII.O foIIowinj4 tcrat零nic RA 
iiisult.on kidney development of fetuses. 
Teratogenic insult with maternal injection of 
125 mg/kg RA on E8-22hr 
Treatment groups 1 dose of oral supplementation at Ell.O 
1.25 mg/kg 2.5 mg/kg 
Control 
RA RA 
No. of litters 4 8 7 
No. of implantations 49 102 99 
No of live fetuses 40 86 83 
No. (%) of implantations underwent 9 16 16 
resorption (18.37) (15.69) (16.16) 
No. (%) of live fetuses with two normal 0 5 2 
kidneys (0) (5.81) (2.41) 
No. (%) of live fetuses with renal 40 81 81 
malformations (100) (94.19) (97.59) 
31 41 49 
- Bilateral renal agenesis 
(77.5) (47.67) (59.04) 
- U n i l a t e r a l renal agenesis (remaining 
4 14 15 
kidney with non-agenesis renal 
(10) (16.28) (18.07) 
malformations) 
- U n i l a t e r a l renal agenesis (remaining 0 0 1 
kidney being normal) (0) (0) (1.20) 
- Bilateral non-agenesis renal 5 21 14 
malformations (12.5) (24.42) (16.87) 
- U n i l a t e r a l non-agenesis renal 
0 5 2 
malformations (contralateral kidney 
(0) (5.81) (2.41) 
normal) 
/?-value vs. Control - 0.001* 0.045* 
value in comparing 
- 0.059 
1.25 and 2.5 mg.kg RA * Statistically signigicant (Jonckheere-Terpstra test) 
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5.4.3 RA supplementation restored various j»rowth parameters 
As mentioned in Chapter 3, a teratogenic dose of RA (125 mg/kg) 
injected on E8-22hr alfectcd various growth parameters of the fetuses, it 
significantly rcduccd the weight, crown-rump length (CRL), head length (HL) and 
tail length (TL). Thus, I have investigated whether these growth parameters could be 
restored after RA supplementation. Weight, crown-rump length, head length and tail 
length were measured for each RA supplementation regimens, and results were 
summarized in Table 5.5. The result of supplementation of 1.25 mg/kg RA for 3 
doses at 12 hr interval starting at ElO.O was presented in Graph 5.5. 
After teratogenic RA insult on E8-22hr, all fetuses were tailless. However, 
none of the RA dosing regimens could restore the growth of the tail. The tail length 
of all fetuses remained as zero. 
Conversely, for all RA dosing regimens, there was a significant increase 
in the weight and the head length of the fetuses when compared with the 
vehicle-supplemented control, although they were still significantly reduced when 
comparing with the fetuses not exposed to the teratogenic RA insult on E8-22hr. 
For the crown-rump length, 3 doses and 4 doses of RA supplementation, 
irrespective of the dosages, starting at ElO.O could significantly increase the 
crown-rump length of the fetuses. However, starting supplementation with 1.25 
mg/kg RA at ElO.5 for 2 doses or a single dose at Ell.O could not significantly 
increase the crown-rump length of the fetuses.. 
Together, these results clearly demonstrated that RA supplementation not 
only rescued renal malformations, but could also restore the weight, crown-rump 
length and head length of the fetuses that had been maternally insulted with a 
teratogenic dose o f�RA ()n E8-22hr. 
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5.4.4 RA supplementation rescued non-rcnal malformations 
In Chapter 3, it was shown that the teratogenic dose of RA incluccd a 
spcctruni of malformations together with kidney defccts. It is possible that some of 
these RA-induced malformations might also be attributed to our proposed “too much 
causes too little'' mechanism. Thus, I have investigated whether RA supplementation 
would ameliorate these malformations. The types of malformations examined were 
illustrated in Figure 5.1 to 5.3. 
Examples of malformations in the head region were illustrated in Figure 
5.1. Figure 5.1A showed a fetus with normal eye and ear. In the El8 fetus, the whole 
eye was covered by the eyelid and the external ear was folded. Figure 5.IB showed 
a fetus with bulging eye. The eyelid was absent and the eye was out of the orbit 
anteriorly. Moreover, the external ear of the fetus was totally absent. Figure 5.ID 
showed the less severe eye and ear abnormalities. Open eye was found in this fetus, 
in which the eyelid was absent, but the eye ball remained in its orbit. The external 
ear was present as small unfused patches and in some cases, such as the fetus 
illustrated in this figure, the ear structures were located in ectopic position in 
comparison with the fetus with normal external ear (Figure 5.1C). Figure 5.IE 
showed a fetus with normal jaw development, with separation between the maxilla 
and the mandible clearly seen. In contrast, the fetus shown in Figure 5.IF had 
abnormal jaws. The maxilla and mandible were hypoplastic and the jaws could not 
close completely. Figure 5.1G showed a fetus with the mouth being opened. It could 
be clearly seen that the secondary palatal shelves had fused in the midline. Figure 
5.1 H showed an example of cleft palate in which the secondary palatal shelves were 
not fused in the midline, resulting in the presence of a cleft. 
I^xamplcs of external mal format ions in other parts of the body were 
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illustrated in Figure 5.2. iMgurc 5.2A showed Ihc normal Ibrclinib oC a lulus 
consisting of 5 separated digits. Forclinib cctrodactyly is a mal format ion with one or 
more ccntral digits of the hand being absent. An example was illustrated in Figure 
5.2B. Figure 5.2C showed a fetus with a normal tail and a pair of normal hindlimbs. 
However, the tail of the fetus shown in Figure 5.2D was completely absent and the 
pair of hindlimbs grew out from the midline rather than the two sides of the body. 
This condition of fused hindlimbs is called sirenomelia, or commonly known 
as Mermaid Syndrome, because the fused limbs give the appearance of a mermaid's 
tail. As shown in Figure 5.2E, a small opening was found near the base of the tail, 
which was the anus of the fetus. Figure 5.2F showed a fetus with no anal opening, 
and is called imperforate anus. 
Examples of malformations of internal organs were illustrated in Figure 
5.3. As shown in Figure 5.3A, in the normal fetus, the thorax and the abdomen was 
separated by a diaphragm. Diaphragmatic hernia is a defect in which the diaphragm 
is incomplete (Figure 5.3 B). In Figure 5.3C, a pair of thymus was found at a position 
just above the heart, while bilateral thymic agenesis, i.e. absence of the thymus, was 
shown in Figure 5.3D. In normal condition, a pair of testes is located near the 
urinary bladder in the pelvic region (Figure 5.3E), Figure 5.3F showed an example 
of undescended testis, in which the pair of testes were found in much higher position 
in the abdominal region. 
All of the above mentioned malformations were found in fetuses that had 
been maternally exposed to a teratogenic dose of RA on E8-22hr. After RA 
supplementation, some of these malformations were rescued, while the incidence of 
other malforinations remained unchanged, or even increased. The fi-equency of 
various types of non-rcnal malformations in fetuses maternally supplemented with 
cliiVcrcnt closing regimens of RA was summarized in Tabic 5.6. The result of� 
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supplementation of 1.25 mg/kg RA li>r 3 doses at 12 hr interval starting at 丨,I ().()’ 
which was the optimum dosing rcgimcii for rescuing renal malformations, was 
presented in Graph 5.6. 
RA-insulted fetus that had received low doses of RA supplementation 
was obviously found with a larger size and with a more “normal’’ morphology 
(Figure 5.4C) when compared with the fetus without RA supplementation (Figure 
5.4B). However, morphological differences were still found between the rescued 
fetus and the fetus that had not been exposed to a teratogenic dose of RA (Figure 
5.4A). For example, the size of the rescued fetus was still comparatively smaller and 
it was tailless. 
RA-insulted fetuses had multiple abnormalities of facial structures 
including the jaws, the eye and the ear (Figure 5.4B), which were prominently 
ameliorated after receiving RA supplementation (Figure 5.4C). As shown in Table 
5.6 and Graph 5.6, hypoplasia of the mandible and maxilla occurred at high 
frequency in RA-insulted fetuses. Supplementation with RA starting at El0.0 could 
significantly rescue these defects and reduced the frequency by more than 50% for 
some dosing regimens. Similarly, other facial abnormalities, such as absence of 
eyelid and unfused small patches of ear structures, could be significantly reduced 
after RA supplementation, although some dosing regimens were more effective than 
others. Another common and readily observable malformation in RA-insulted 
fetuses was sirenomelia. RA supplementation could significantly reduce the 
frequency of this malformation by more than 70% in some dosing regimens. In 
comparing the effectiveness of the dosing regimens, it appeared that the rescue 
cffcct for some organs showed a positive correlation with the number of doses of RA 
supplementation. Three and 4 doses of 1.25 mg/kg RA supplementation could 
significantly rcscuc these dcfccts while 1 and 2 doses of supplementation could not. 
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Actually, rcscuc ctVcct by RA supplcmcnlation was not solely dependent on tlic 
number and dosages of supplementation, but might also be related lo the time ol' 
supplying the RA. As mentioned earlier, endogenous RA level was temporally 
regulated. Development of different organs requires RA in different stages. Thus, 
RA supplementation at different time points might rescue malformations of specific 
organs. In this study, supplementation with RA starting at ElO.O was most effective 
in offering the rescue effect. Initiation of RA supplementation at later time points 
though in general could still reduce the frequency, but might not reach a statistically 
significant level. 
RA supplementation could rescue some, but not all types of 
malformations induced by the teratogenic dose of RA injected on E8-22hr. For 
example, cleft palate and imperforate anus were found in 100% of the fetuses after 
injection of a teratogenic dose of RA. RA supplementation at whatever dosage and 
time points did not provide any rescue effect on these 2 defects. Similarly, RA 
supplementation did not provide any rescue effect on thymus development. As for 
the other two malformations of internal organs, i.e. diaphragmatic hernia and 
undescended testis, both of them occurred at low frequency in RA-insulted fetuses. 
Although there was a general trend that RA supplementation could reduce the 
frequency, the reduction was not enough to show any statistically significant 
difference from the vehicle-treated control. 
Forelimb ectrodactyly only occasionally occurred in fetuses receiving 
teratogenic RA insult. However, it is interesting that the frequency of this defect 
after RA supplementation was consistently higher than the control, although a 
statistically significant difference was only found in the experimental groups with 
RA supplementation starting at ElO.O, whereas other dosing regimens starting at 
later time points had not yet rcachcd a statistically significant dittcrcncc bccausc of 
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the comparatively low incidciiccs. 
Taken together, results showed that other than renal mallbrmations, RA 
supplementation could rescue many other types of malformations. Thus, supporting 
that these malformations induced by the teratogenic dose of RA may share the same 
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5.4.5 Wtl expression in the metanephros after RA supplementation 
Previous results of our laboratory showed that Wtl in the metanephros 
was significantly dovvn-rcgulatcd after teratogenic RA treatment (Tse ct al., 2005). 
Moreover, the finding that Wtl heterozygous embryos showed increased 
susceptibility to RA-induced renal malformations in comparison to their wild-type 
littemiates provided evidence tor a direct role of disrupted Wtl expression in the 
pathogenesis of RA-induced renal malformations. Results in section 5.4.1 showed 
that oral supplementation with 3 doses of 1.25 mg/kg RA given at 12 hr interval 
starting from El0.0 could rescue about 30% of fetuses from developing any renal 
malformations. Thus, I have investigated whether the amelioration of renal 
malformations by RA supplementation was accompanied by a restoration of Wtl 
expression in the early metanephros. The expression level of Wtl in the metanephros 
of El2.0 embryos with or without RA supplementation was measured by 
quantitative RT-PCR. Results were summarized in Table 5.7 and presented in Graph 
5.7. 
Results showed that teratogenic RA insult caused a significant (p < 0.001) 
down-regulation of the expression level of Wtl by 34%. However, RA 
supplementation could significantly {p = 0.004) increase the Wtl level, although the 
restored expression level was still significantly (p 二 0.031) lower than that without 
RA insult. 
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lahlc 5.7 Kffect of oral siipplenicntation with 3 doses of 1.25【叩/kj^ KA or 
vehiclc as control foIlo\viiij» teratoj^cnic RA insult on Wtl 
expression in the E12 metanephros. 
Teratogenic insult with maternal 
injection of 125 mg/kg RA on E8-22hr 
No teratogenic = — — — — — = _ _ _ = _ = = 
Treatment groups ^ ^ 3 doses of oral supplementation at 
12 hr interval starting at EIQ.O 
Control 1.25 mg/kg RA 
Sample size 6 7 6 
I I _ ___ -=- r-： - • , „ • •• ! * J： IT' I. ‘ 丄.••. - ！ -- - •.. 
Express ion levels of 0 .0866 0 .0573 0.0741 
Wtlifi-actin 土 SEM 士 0 .0032 士 0 .003 1 士 0 .0038 
/7-value vs. no tera tocenic 
… . 1 ‘ < 0 . 0 0 1 * 0 .031* 
R A insult -
/rvalue in comparing 
广 。 - 0 . 0 0 4 * 
Control vs. 1.25 mg/kg R A 
* Statistically significant (Independent Samples t-test) 
5.4.6 Apoptotic cell death in the metanephros after RA supplementation 
Previous results of our laboratory showed that other than causing a 
down-regulation of Wtl expression in the metanephros, there was also an increase in 
apoptosis in the metanephros of embryos following maternal exposure to a 
teratogenic dose of RA (Tse et al., 2005). Thus, I have investigated whether RA 
supplementation following teratogenic RA insult could reduce apoptosis in the 
metanephros of E l2 embryos. Results were shown in Table 5.8, and presented in 
Graph 5.7 and Figure 5.4. 
As shown in Figure 5.4A, apoptotic nuclei were only occasionally found 
in the metanephros of E l2 embryos. However, results showed that the teratogenic 
dose of RA could led to a significant (p < 0.001) increase in the number of apoptotic 
bodies by almost 5 fold. Apoptotic bodies were found mainly in the nictaiicphric 
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mcscnchymc of the 1{12 metanephros (Figure 5.4B). However, siipplcnicntation willi 
low doses of RA could significantly (/? < ().()() 1) rcducc the number of' apoptotic 
bodies by 50% (Figure 5.4C), although it was still significantly (p < 0.001) higher 
than that without exposure to the teratogenic dose of RA. 
Table 5.8 Effect of oral supplementation with 3 doses of 1.25 mg/kg RA or 
vchicic as control following teratogenic RA insult on apoptosis in 
the E12 metanephros. 
Teratogenic insult with maternal 
injection of 125 mg/kg RA on 
No teratogenic E8-22hr 
Treatment groups _ = _ _ _ _ _ _ _ _ _ 
RA insult 3 doses of oral supplementation at 
12 hr interval starting at ElO.O 
Control 1.25 mg/kg RA 
No. of metanephroi examined 5 8 9 
No. of apoptotic bodies per 35.00 169.89 85.76 
mnr 士 SEM 士 4.27 士 6.79 士 6.78 
p-value vs. no teratogenic RA 
<0.001* <0.001* 
insult -
p-value in comparing 
<0.001* 
Control vs. 1.25 mg/kg RA — * Statistically significant (Independent Samples t-test) 
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('luiplcr 5: RA Sii丨山'mriilu丨 — _ _ 
5.5 DISCUSSION 
In this study, we found that supplementation of 1.25 mg/kg of RA from 
El 0.0 to El 1.0 could effectively rcscue kidneys from developing renal 
malformations after teratogenic RA insult on E8-22hr. A lower dose of RA resulted 
in less rescue effect, whereas a higher dose of RA caused further teratogenic effect 
to the embryo and increased the resorption rate. 
Metanephros, which is the permanent kidney, develops at E l l in the 
mouse. The function of RA supplementation on ElO.O and E10.5 were not clear. 
Results (Table 5.4) showed that the rescue effect of RA supplementation on ElO.O 
and ElO.5 was not due to accumulation of RA until initiation of metanephric 
development at El 1.0. It was because a single dose of 1.25 mg/kg or 2.5 mg/kg of 
RA supplemented on El 1.0 resulted in similar extent of rescue. Results in Chapter 4 
showed that endogenous RA level in the whole embryo was reduced starting from 
ElO.O after teratogenic RA insult on E8-22hr. Thus, RA supplementation on ElO.O 
and ElO.5 may be used for supporting the development of the intermediate 
mesoderm and the mesonephros, which eventually develop into the metanephros. 
Wtl is already expressed in the urogenital ridge of the mouse embryo at about E9.5 
(Armstrong et a l , 1993). From the previous result of our laboratory, Wtl expression 
was reduced starting at ElO in the whole embryo after RA injection. Although this 
reduction did not reach a statistically significant level, this might be because the 
expression level at this stage was too low and the effect of reduction could be diluted 
by other tissues that did not express Wtl. Moreover, some other kidney related genes 
arc also regulated by RA, such as c-ret that is also expressed at the intermediate 
mesoderm before mctanephric development (Stahl et al.，2006). So, another possible 
role of' RA supplementation before El 1.0 may be to restore the expression level (W� 
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or other kidney related genes before the metanephros develops. 
Indeed, RA-trcatcd metanephros was shown to be rcscucd from 
degeneration and began to differentiate when cultured with fetal bovine scrum (FBS) 
(Tsc ct al., 2005). The rescue effcct was also found to be associated with Wtl. Its 
expression level was significantly restored after supplementation with FBS. 
However, rescue treatment by serum was only effective at E l l .25 and El2.25, after 
that, the rescue effect was not found. Unfortunately, the factors responsible for the 
rescue effect have not yet been defined. 
The present study showed that RA supplementation could also rescue 
some of the RA-induced non-renal malformations, such as maxilla and mandible 
hypoplasia, eye and ear defects and also sirenomelia. This finding suggests that 
these malformations induced by RA may share the same RA teratogenic mechanism 
as RA-induced renal malformations, i.e. when a teratogenic dose of RA is injected, it 
causes prolonged down-regulation of RA synthesis and results in reduction of 
endogenous RA. Indeed, precursors of these organs were found to have 
down-regulated Raldh2 expression as shown by the in situ hybridization result in 
Chapter 4. Such down-regulation was observed at the optic cup, which was the 
precursor of eye; at the otic vesicle, which was the precursor of ear, and also at the 
branchial arch, which was the precursor of maxilla and mandible. Together, results 
in Chapter 4 and Chapter 5 supported that RA-induced jaw, eye, ear and limb 
malformations were caused by RA deficiency. 
From external observation, after fetuses were treated with teratogenic 
dose of RA, their hearts also showed abnormality. The two ventricles turned into 
much darker color. This might be due to mixing of blood between chambers in the 
heart as a result of RA-induced septal defects. Interestingly, the incidence of 'dark 
heart' in fetuses was found to be reduced alter RA supplementation. However，the 
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cxact inaltorniatioiis in tlic heart have to be analyzed by histological examination. 
Our laboratory has shown that RA-induccd renal malformations were 
attributed to the down-regulation of IV(I expression in the metanephros from 1:1 1 to 
El2. In situ hybridization study shows that Wtl is normally expressed in the 
metanephric niescnchymc, which eventually forms the renal vesicles, S-shaped 
bodies and also glomerular epithelium (Armstrong et al., 1993). Failure of WtJ 
expression leads to urogenital dcfects. In WtJ homozygous null mutant embryos, the 
ureteric bud failed to penetrate into the metanephric mesenchyme and the 
metanephric mesenchyme failed to differentiate into nephrons (Kreidberg et al., 
1993). This finding reveals that IV11 is a crucial transcription factor for regulating 
early neplirogenesis. 
After RA supplementation, Wtl expression in the kidney was 
significantly increased when compared with the control. However, it was still 
significantly lower than in embryos without RA insult. This result showed that RA 
level was correlated with the expression level of Wtl. Indeed, WtJ expression in F9 
carcinoma cells was reported to be regulated by RA. Wtl expression in F9 
carcinoma cells was increased significantly after 12 to 24 hr of incubation with RA 
(Kudoh et al., 1996). Moreover, in PI9 embryonic carcinoma cells, Wtl mRNA and 
proteins were normally not detected. However, under the stimulation of RA, Wtl 
expression was strongly activated. Similar activation of WtJ by RA was also found 
in embryonic stem cells. Furthermore, as mentioned earlier, RARE is found in the 
upstream region of Wtl in zebrafish. Together, all these findings suggest that IV11 
level during kidney development may be controlled by the level of RA. Interestingly, 
Guadix et al. (2011) has suggested a different mechanism between RA and WfJ 
expression. In IV11 null embryos, heart and liver defects were also observed. 
Interestingly, the cpicarclial ccl Is of the heart and the co domic ccll lining (he liver 
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showed dccrcascd or abscncc of Raldh2 expression (Ijpcnbcrg ct al., 2007). 'I his 
suggests that Wtl regulates cpicardial and coelomic RA signaling via direct 
activation of the Raldhl gene. This shows that the relationship between WlI 
expression and RA may not be solely in one direction, but they may also interact 
with cach other, depending on the site and stage of their expressions. 
Besides restoring the expression of Wtl in the metanephros, RA 
supplementation was also found to reduce apoptosis in the developing kidney. This 
reduction of apoptosis may indeed be attributed to the up-regulation of Wt\. 
Anti-apoptotic effect of Wtl is well studied. In the Wtl knock out mice, apoptosis in 
several organs was found to be increased, including kidneys, gonad, retina and 
spleen (Kreidberg et al., 1993). Also, disruption of Wtl by small interfering RNA 
(siRNA) during early kidney development increased apoptosis which mimics the 
phenotypes in the mutant (Davies et al , 2004). However, as mentioned earlier, 
kidney development requires apoptosis. Repression of apoptosis may cause 
abnormal development of the metanephros and prevent it from differentiating into 
nephrons. 
The anti-apoptotic role of Wtl was also shown in breast cancer cells. 
Breast cancer cells trans feet ed with the HER2/neu oncogene increased Wtl 
expression by nearly 3 fold than the parental breast cancer cells (Tuna et al , 2005). 
When HER2/neu was inhibited by antibodies, Wtl expression was significantly 
reduced. Reduction of Wtl caused cell cycle arrest at the G1 phase and increased 
apoptosis in the breast cancer cells. These findings reveal that Wtl plays a crucial 
role in regulating apoptosis in this type of cancer cells. 
Several mechanisms of the anti-apoptotic role of Wtl have been reported, 
yet, the most wcll-documented one is the inhibition of p53-mediated apoptosis and 
the up-rcgulation of anti-apoptotic BCL-2 protein by the expression of Wt I. is a 
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tumor suppressor gene which coclcs Ibr the gene product 'I P53 (Mutlashcwski ct al., 
When it is activated, it can initiate programmed ccll death. It is activated in 
response to UV (Kapoor and Lozano, 1998), infra red (Fci and El-Dciry, 2003), 
oxidative stress (Han ct al., 2008) and some chcmical reagents including hydrogen 
peroxide (Datta et al., 2002). In an osteosarcoma cell line, when Wtl and p53 were 
CO trans feet ed into it, p53 expression increased alongside with the increased 
expression of Wtl (Maheswaran et al., 1995). In the same study, it also showed that 
Wtl expression inhibited p53-mediated apoptosis triggered by UV irradiation. 
BCL-2 is a family member of the apoptosis regulatory proteins with 
anti-apoptotic activity (Tsujimoto et al., 1984). In rhabdoid cell lines, 
over-expression of Wtl activated the expression of endogenous bcl-2 gene (Mayo et 
al., 1999). Wtl directly activates bcl-2 expression by positively stimulating the 
promoter of he I-2. In addition, cells with up-regulated bcl-2 were found with a 
higher resistance to apoptosis when induced by staurosporine, vincristine and 
doxorubicine (Mayo et al., 1999). 
To conclude, there is a tight and complicated interaction between RA, 
Wtl and apoptosis in the developing kidney. Dysregulation in any of these factors 
may disturb normal development of the kidney and result in renal defects. Thus, 
further investigation in this interaction is required. 
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Exccss and dcficicncy of RA during pregnancy can result in the same 
types of congenital malformations in some organ systems, including the kidney. 
Moreover, it has been pointed out that “in many cases, the critical period of RA 
injection for inducing specific malformation is well before the presence of that 
specific anlage” (Shenefelt, 1972). The aim of this thesis is to test these 
phenomenons using our hypothesis: “Too much causes too little" in the RA-induced 
renal malformations mouse model previously established by our laboratory (Tse et 
al., 2005). 
In Chapter 3, a detailed time and dose response study on the 
susceptibility of embryos to RA-induced kidney malformations was performed. It 
was found that 125 mg/kg body weight o f R A injected intraperitoneally to pregnant 
mice at E8-22hr could result in renal malformations in 100% of the fetuses, among 
which 75% was bilateral agenesis, which is the most severe type of renal 
malformations. Besides renal malformations, other types of defects were also found 
after RA treatment, such as cleft palate, abnormal eyes and ears, micrognathia and 
sirenomelia. These RA-induced malformations may also be attributed to our 
proposed teratogenic mechanism of RA. Moreover, weight, crown-rump length and 
head length of the RA-treated embryo were found to be significantly reduced in 
comparison with the control. 
Results of Chapter 3 demonstrate that the teratogenic effect of RA in 
inducing specific malformation is very much time-dependent. For example, when 
125 mg/kg of RA was injected at E9, which was 2 hr later than the optimum time 
point, the Ircqucncy of bilateral renal agenesis was sharply reduced from 75% to 
25%. This narrow window of RA teratogenicity is found not only in RA-induccd 
- 1 5 1 -
(lidptcr 6: C \>nclusi()n (V /''iiliirc /'rrs/wc/ncs 
renal ma I format ions, but also in other RA-iiuluccd dclbcts. l^urlhcr investigation on 
the changes of embryonic events within this narrow window, which cause such a 
ditTcrcncc in susceptibility to RA, is necessary in order to have a better 
understanding on the mechanism of RA-induced embryopathy as well as normal 
embryo development. 
To prove our hypothesis, first, the mRNA expression level of various RA 
synthesizing and catabolizing enzymes, and the endogenous RA level in the embryo 
at various time points after RA treatment were determined in Chapter 4. Results of 
RT-PCR and in situ hybridization studies showed that the expression of all 3 
isoforms of RA synthesizing enzymes, Raldh 1, Raldh2 and Raldh3, was 
significantly down-regulated in RA-treated embryos when compared to the control. 
This reduction in the expression level of the RA synthesizing enzymes was also 
found in the developing kidney. Moreover, the expression level and pattern of the 
RA catabolizing enzymes, Cyp261, Cyp26hl and Cyp26cJ, also showed significant 
changes after RA treatment. Concomitant with alteration in the expression level of 
RA synthesizing and catabolizing enzymes, the endogenous RA level in the whole 
embryo and in the developing kidney was found to be significantly reduced when 
compared with the control. Thus, the findings in Chapter 4 clearly showed that 
elevated RA level in the embryo caused a prolonged reduction of RA synthesis and 
subsequently led to subnormal level of RA in the embryo. 
Since RA is diffusible within the embryo (Niederreither et al., 2002), it is 
not sufficient to study the site of RA synthesis within the RA-treated embryo by in 
situ hybridization. Further study can be conducted by using the lacZ transgenic 
mouse that contains the lacZ reporter transgene with expression driven by a RARE 
(Rossant ct al., 1991). By using this mutant, tissues with RA activity can be 
localized, and thus allow a better understanding of the relationship between RA and 
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spcciHc congenital dctccts. Although I have shown that cxccss RA can causc 
down-regulation o t^  Raldhs, the underlying median ism lor this down-regulation is 
unclear. To my knowledge, there are no reports which show the presence of RARE 
in any of the iso forms of Raldh. Further study should be conducted to investigate 
whether the promoter or the enhancer region of different iso forms of Raldh contain 
any canonical RARE sequences. Besides, other than altering endogenous RA levels 
via affecting the expression level of RA synthesizing and catabolizing enzymes, 
excess RA was shown to alter other factors involved in the retinoid pathway such as 
CRABPII (Astrom et al., 1991), RAR(3 (Wan et al., 1998) and endogenous retinol 
level (Satre and Kochhar, 1989). Further study should be carried out to investigate if 
these changes may also contribute to RA deficiency in the embryo in order to have a 
better picture of this negative feedback mechanism. 
To further decipher the linkage between RA deficiency and renal 
malformations, in Chapter 5, multiple low doses of RA were orally fed to the 
pregnant mouse after the teratogenic RA insult on E8-22hr in order to alleviate RA 
deficiency in the embryo. It was found that both the frequency and the severity of 
renal malformations were significantly reduced in a dose-dependent manner by RA 
supplementation. Thirty percent of the embryos were totally rescued from 
developing any renal malformations. Moreover, the rescue effect was not limited to 
kidney development, other abnormalities of the eye, ear, jaw and limbs were also 
ameliorated by low doses of RA supplementation. Furthermore, embryos with RA 
supplementation have significantly re-gained weight and had longer head length and 
crown-rump length when compared with control embryos that had been subjected to 
teratogenic RA insult but without RA supplementation. Results also showed that RA 
supplementation could restore Wtl expression and reduced apoptosis in the 
developing kidney of embryos exposed to teratogenic dose ot RA. 
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Although allcr RA supplcmenlation, embryos were rcscucd from renal 
malformations. 111rther work should be conducted to confirm whether the 
endogenous RA levels in the whole embryo and in the kidney arc indeed increased. 
is one of the master genes during early kidney development. Wtl can in turn 
control other genes important for kidney development such as amphiregulin, 
Syndecan-1 and Pcl\-2 (Cook et al., 1996: Lee et al., 1999). Disturbed expression of 
any one of these transcription factors may also lead to abnormal kidney development. 
Thus, there should be further investigation to determine if the expression of these 
genes was affected by teratogenic RA treatment and also RA supplementation. This 
can decipher the pathway between RA deficiency and renal malformations and help 
in understanding the molecular changes after RA treatment. Furthermore, the finding 
that some other malformations could also be rescued by RA supplementation 
support that our proposed RA teratogenic mechanism may also be applicable to 
other organ systems. Future work can involve studying the effector genes in specific 
organs that are responsible for RA teratogenicity. It has been reported that some 
other RA-responsive genes are important for organ development, for example, 
Hoxa5 (Chen et al., 2007) and Pitx2 (Kumar and Duester, 2010), which are 
important for lung and eye development respectively. 
In conclusion, results of this thesis have shed light on an undescribed 
mechanism of RA-induced embryopathy, which can explain why too much and too 
little RA can lead to the same type of malformations in some organ systems. 
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Figures 
Figure 3.1 Examples of various types of renal malformations. 
Ventral view o f E l 8 fetuses with abdomen opened. 
A Two normal kidneys. A pair o f adrenal glands (yellow arrowhead) was 
lying on top o f the kidneys (K). Normal kidney has a bean-shape. 
B Bilateral renal agenesis. Kidneys on both sides were missing while a pair o f 
adrenal glands was still present. 
C Unilateral renal agenesis with remaining kidney being normal. The right 
kidney (left side o f the figure) was missing while the adrenal gland was 
still present. 
D Unilateral renal agenesis with hypoplastic kidney. The right kidney was 
missing while the left kidney was much smaller in size. 
E Dysplastic kidney with contralateral kidney being normal. The right kidney 
was distorted in shape while the left kidney was normal. 
F A pair o f polycystic kidneys. There were fluid-fi l led cysts (blue arrowhead) 
within the kidney. 
Labels: K Kidney 
Symbols: Blue arrowhead Cyst 
Yellow arrowhead Adrenal gland 
Scale bar: A to F 2 mm 
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Figure 3.2 Illustration on how to measure various growth parameters of El 8 
fetuses. 
A Crown-rump length (CRL). Measurement from the top o f the head (crown) 
to the bottom o f the buttock (rump). 
B Head length (HL). Measurement from the tip o f the nose to the hindbrain. 
C Tail length (TL). Measurement from the base to the tip o f the tail. 





Figure 4.1 Expression of Raldh 1 in embryos of control (CON) and RA-
treated (RA) mice at E9.5 detected by whole mount in situ 
hybridization. 
A In the control embryo, Raldh 1 was prominently expressed in the optic 
vesicle (Op) and the third pharyngeal pouch (arrow). It was also weakly 
expressed in the otic vesicle (Ot). 
B In the RA-treated embryo, there was obvious reduction o f Raldh 1 
expression in the optic vesicle. 
C Higher magnification o f the forebrain region o f the control embryo showed 
that expression o f Raldh 1 was restricted to the dorsal part o f the optic 
vesicle. 
D Higher magnification o f the forebrain region o f the RA-treated embryo 
showed that there was prominent reduction o f Raldh 1 expression in the 
dorsal part o f the optic vesicle. 
E Higher magnification o f the hindbrain region o f the control embryo showed 
that Raldh 1 was weakly but homogenously expressed in the otic vesicle. 
F Higher magnification o f the hindbrain region o f the RA-treated embryo 
showed that there was hardly any Raldh 1 expression in the otic vesicle. 
G Higher magnification o f the heart region o f the control embryo showed that 
Rcildhl was specifically expressed in the third pharyngeal pouch. 
H Higher magnification o f the heart region o f the RA-treated embryo showed 
that Raldh 1 expression in the third pharyngeal pouch was prominently 
reduced. 
Labels: Op Optic vesicle 
Ot Otic vesicle 
Symbols: Arrow Third pharyngeal pouch 
Scale bar: A, B 1 mm 
C to F 0.5 mm 
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Figure 4.2 Expression of Raldhl in embryos of control (CON) and RA-
treated (RA) mice at ElO.O, Ell.O and E12.0 detected by whole 
mount in situ hybridization. 
A Expression domains o f Raldhl in the control embryo at ElO.O were similar 
to that at E9.5. It was prominently expressed in the dorsal optic vesicle (Op) 
and the third pharyngeal pouch (arrow), and also weakly expressed in the 
otic vesicle (Ot). 
B In the RA-treated embryo at ElO.O, other than the optic vesicle and the 
third pharyngeal pouch, weak expression o f Raldhl was also observed in 
the otic vesicle. 
C In the E l l .O control embryo, distinctive Raldhl expression was only 
detectable in the developing eye. 
D Similar to the control embryo, Raldhl expression was only detectable in 
the developing eye o f the RA-treated embryo at E l l .0. 
E Higher magnification o f the head region o f the E l l .O control embryo 
showed that within the developing eye, there was strong expression o f 
Raldhl in the dorsal retina (Re) and weaker expression in the lens (Le). 
F Higher magnification o f the head region o f the E l l .O RA-treated embryo 
showed that there was obvious reduction in Raldhl expression in the dorsal 
retina as well as the lens. 
G Similar to El l .O, Raldhl expression was mainly found in the developing 
eye o f the control embryo at E l 2.0. 
H RA-treated embryo at El2.0 showed no observable difference from the 
control embryo in Raldhl expression. 
Labels: Le Lens 
Op Optic vesicle 
Ot Otic vesicle 
Re Retina 
Symbol: Arrow Third pharyngeal pouch 
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Figure 4.3 Expression of Cyp26al in embryos of control (CON) and RA-
treated (RA) mice at ElO.O and El0.5 detected by whole mount in 
situ hybridization. 
A In the control embryo, Raldh2 was strongly expressed at multiple sites. 
B In the RA-treated embryo, there was a general reduction in the expression 
ofRaIdh2. 
C Higher magnification o f the head region o f the control embryo showed that 
R 遍 2 was expressed in the region (red arrowhead) between the optic 
vesicle (Op) and the first branchial arch (FBA). 
D Higher magnification o f the head region o f the RA-treated embryo showed 
that there was obvious reduction o f Raldh2 expression in the region 
between the optic vesicle and the first branchial arch. 
E Higher magnification o f the lower part o f the body o f the control embryo 
showed that Raldh2 was extensively expressed. In the trunk, Raldhl was 
highly expressed in the developing lung bud (orange arrowhead), paraxial 
mesoderm (blue arrowhead), midgut diverticulum (white arrowhead) and 
also along the dorsolateral edges o f the intra-embryonic coelomic cavity 
(green arrowhead) including tissues that formed the urogenital ridge. 
Towards the caudal end, Raldh2 was strongly expressed in the cloacal 
region (yellow arrowhead) containing the nephrogenic cord tissue and in 
the presomitic mesoderm (pink arrowhead). 
F Higher magnification o f the lower part o f the body o f the RA-treated 
embryo showed that there was a general reduction oiRaldh2 expression in 
all expression domains. 
Labels: FBA First branchial arch 
Op Optic vesicle 
Symbols: Blue arrowhead Paraxial mesoderm 
Green arrowhead Dorsolateral edges o f the intra-embryonic 
coelomic cavity 
Orange arrowhead Developing lung bud 
Pink arrowhead Presomitic mesoderm 
Red arrowhead Region between the optic vesicle and the first 
branchial arch 
White arrowhead Midgut diverticulum 
Yellow arrowhead Cloacal region 
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Figure 4.4 Expression of Cyp26al in embryos of control (CON) and RA-
treated (RA) mice at ElO.O and El0.5 detected by whole mount in 
situ hybridization. 
A Raldhl expression patterns in the control embryo at ElO.O was similar to 
that at E9.5. 
B The body o f the RA-treated embryo was truncated just behind the cloacal 
region (yellow arrowhead). 
C Higher magnification o f the control embryo showed that Raldhl expression 
in the otic vesicle (Ot) was restricted to the lateral portion. 
D In the RA-treated embryo, there was hardly any expression of Raldh2 in 
the otic vesicle. 
E In the control embryo, strong Raldh2 expression was observed along the 
dorsolateral edges o f the coelom (green arrowhead) and in the cloacal 
region which included tissues for forming the mesonephric system. 
Moreover, Raldh2 was expressed in the newly-developed somites (circled) 
that were clearly delineated. 
F In the RA-treated embryo, expression o f Raldh2 in the same region o f the 
control embryo with newly-developed somites was homogenous rather 
than demarcated into block-like somitic structures. 
Labels: Ot Otic vesicle 
Symbols: Circle Region with newly-developed somites 
Green arrowhead Dorsolateral edges o f the intra-embryonic 
coelomic cavity 
Yellow arrowhead Cloacal region 
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Figure 4.4 Expression of Cyp26al in embryos of control (CON) and RA-
treated (RA) mice at ElO.O and El0.5 detected by whole mount in 
situ hybridization. 
A In the control embryo, Raldh2 expression was down-regulated in the 
differentiated somites (blue arrowhead) while expression in other domains 
persisted. 
B In the RA-treated embryo, expression o f Raldh2 in the head region was 
reduced. 
C Higher magnification o f the head region o f the control embryo showed that 
other than expressing specifically in the lateral portion o f the otic vesicle 
(Ot), expression was also initiated in the maxillo-mandibular cleft (circled). 
D Higher magnification o f the head region o f the RA-treated embryo showed 
that there was hardly any expression in the otic vesicle and in the 
maxillo-mandibular cleft. 
Labels: Ot Otic vesicle 
Symbols: Blue arrowhead Differentiated somites 
Circle Maxillo-mandibular cleft 
Scale bar: A, B 1 mm 
C, D 0.5 mm 
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Figure 4.6 Expression of Cyp26al in embryos of control (CON) and RA-
treated (RA) mice at ElO.O and El0.5 detected by whole mount in 
situ hybridization. 
A Expression pattern of Raldhl in the control embryo at El 1.0 was similar to 
that at El0.5. Raldh2 was almost switched of f in the differentiated somites 
(blue arrowhead). Strong expression was observed in the spinal cord in the 
cervical region (green arrow) and expression in the heart (Ht) became 
prominent. In the head, specific expression in the lateral portion of the otic 
vesicle (Ot) persisted. 
B In the RA-treated embryo, there was a general reduction oiRaldh2 expression. 
Raldh2 remained unexpressed in the otic vesicle 
C Higher magnification of the facial region of the control embryo showed that 
other than the cleft between the maxilla (Mx) and the mandible (Mn), Raldh2 
was also expressed strongly in the tissue between the developing eye and the 
maxillary component of the first branchial arch (pink arrow). 
D In the RA-treated embryo, much lower and disorganized expression of Ralcih2 
was observed in the maxillary and mandibular components of the first 
branchial arch and in the tissue between the developing eye and the maxilla. 
E-F It was difficult to distinguish differences in Raldh2 expression between control 
(Figure E) and RA-treated embryos (Figure F) in the caudal region. Embryos 
were sectioned at the level (broken line) of the cloacal region (yellow 
arrowhead) to examine expression in the early metanephros (Figures G and H) 
G In the metanephros of the control embryo, the ureteric bud (UB) had just 
penetrated into the metanephric mesenchyme (MM). There was high level of 
Raldh2 expression in the metanephric mesenchyme, but no expression in the 
ureteric bud. 
H In the metanephros of the RA-treated embryo, expression of Raldh2 in the 
metanephric mesenchyme was prominently reduced. 
Labels: Ht Heart Mx Maxilla 
M M Metanephric mesenchyme Ot Otic vesicle 
Mn Mandible UB Ureteric bud 
Symbols: Blue arrowhead Differentiated somites 
Broken line Level of section 
Green arrow Cervical spinal cord 
Pink arrow Tissue between the developing eye and the 
maxillary component of the first branchial arch 
Yellow arrowhead Cloacal region 
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Figure 4.4 Expression of Cyp26al in embryos of control (CON) and RA-
treated (RA) mice at ElO.O and El0.5 detected by whole mount in 
situ hybridization. 
A In the control embryo at E l l . 5 , Raldh2 was still strongly expressed in the 
same domains as E l 1.0. 
B The expression o f Raldh2 in the facial region o f the RA-treated embryo 
showed the most noticeable difference from that o f the control. 
C Raldh2 expression in the facial region o f the control embryo was restricted 
to specific domain ventral to the eye. Raldh2 was expressed in specific 
patterns in the interdigital region o f the forelimb (FL) and hindlimb bud 
(HL). To examine in more details the expression o f Raldh2 in the 
developing metanephros, embryo was sectioned at the level (broken line) 
o f the hindlimb bud. 
D There were prominent differences in the expression pattern o f Raldh2 in 
the facial region, and in the forelimb and hindlimb buds o f the RA-treated 
embryo in comparison with the control embryo shown in Figure C. 
E In the metanephros o f the control embryo, Raldh2 was expressed at high 
levels in the metanephric mesenchyme (MM), but not in the ureteric bud 
F In the metanephros o f the RA-treated embryo, Raldh2 expression in the 
metanephric mesenchyme was severely reduced. 
Labels: FL Forelimb bud 
HL Hindlimb bud 
m m Metanephric mesenchyme 
UB Ureteric bud 
Symbol: Broken line Level o f section 
Scale bar: A, B 1.6 mm 
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Figure 4.210 Expression of Cyp26al in embryos of control (CON) and RA-
treated (RA) mice at ElO.O and El0.5 detected by whole mount in 
situ hybridization. 
A In the control embryo at E9.5, RaldhS was strongly expressed in the cranial 
region. Distinctive expression was also observed in a pair o f nephrogenic 
cord (red arrow) at the caudal region. There was weak signal in the otic 
vesicle (Ot). 
B In the E9.5 RA-treated embryo, RaldhS was expressed in the same domains 
as the control embryo. 
C Higher magnification o f the head region o f E9.5 control embryo. Intense 
expression oiRaldhS was found in the surface ectoderm overlying the optic 
vesicle (Op) and the olfactory region (Of). 
D Higher magnification o f the head region o f E9.5 RA-treated embryo 
showed that there was less intense expression o f RaldhS in the surface 
ectoderm overlying the optic vesicle and the olfactory region. 
E In the ElO.O control embryo, the expression pattern was similar to E9.5, 
except the expression domain was more limited to the optic vesicle rather 
than in the peripheral surface ectoderm. 
F In ElO.O RA-treated embryo, the expression of RaldhS in the optic vesicle 
was reduced. 
G Intense expression o f RaldhS was found in the nephrogenic cord at the 
caudal region o f ElO.O control embryo. 
H In the ElO.O RA-treated embryo, there was prominent reduction of RaldhS 
expression at the caudal region. 
Labels: O f Olfactory region 
Op Optic vesicle 
Ot Otic vesicle 
Symbol: Red arrow Nephrogenic cord 
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Figure 4.212 Expression of Cyp26al in embryos of control (CON) and RA-
treated (RA) mice at ElO.O and El0.5 detected by whole mount in 
situ hybridization. 
A In E l 1.0 control embryo, RaldhS expressed in the caudal region had 
diminished. In the developing eye, RaldhS was expressed in the ventral half 
o f the retina (Re). Expression o f RaldhS at the otic vesicle (Ot) became 
localized in the margin. Strong expression persisted in the olfactory region 
(Of). b 
B In E l 1.0 RA-treated embryo, there was slight reduction o f RaldhS in the 
olfactory region. 
C In the control embryo at El2.0, expression o f RaldhS in the olfactory 
region had disappeared. Expression was limited to the ventral retina. 
D The RA-treated embryos at El2.0 showed no observable difference in 
RaldhS expression when compared with the control. 
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Figure 4.10 Expression of Cyp26al in embryos of control (CON) and RA-
treated (RA) mice at ElO.O and El0.5 detected by whole mount in 
situ hybridization. 
A In the control embryo, Cyp26al was prominently expressed in the cranial 
region, but not in the optic (Op) and otic (Ot) vesicles. Posteriorly, it was 
expressed in the tail bud (TB) at the caudal extremity. 
B In the RA-treated embryo, there was prominent up-regulation of Cyp26a 1 
in all expression domains. 
C Higher magnification o f the cranial region o f the control embryo showed 
that there was intensive Cyp26al expression in the cranial mesenchyme 
(CM), in the maxillary (Mx) but not the mandibular (Mn) component o f the 
first branchial arch, and specifically in the maxillo-mandibular cleft 
(MMC). 
D Higher magnification o f the cranial region o f the RA-treated embryo 
showed that the expression domains o f Cyp26al had expanded and ectopic 
expression RaldhS was found in the developing heart (Ht). 
E In the posterior region o f the control embryo, Cyp26al was exclusively 
expressed in the tail bud (TB) at the caudal extremity. 
F In the posterior region o f the RA-treated embryo, Cyp26al expression had 
expanded to the presomitic mesoderm (PSM) and also in the ventral body 
wall (BW) o f the trunk. 
Labels: BW Body wall 
CM Cranial mesenchyme 
Ht Heart 
M M C Maxillo-mandibular cleft 
Mn Mandible 
Mx Maxil la 
Op Optic vesicle 
Ot Otic vesicle 
PSM Presomitic mesoderm 
TB Tail bud 
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Figure 4.11 Expression of Cyp26al in embryos of control (CON) and RA-
treated (RA) mice at ElO.O and El0.5 detected by whole mount in 
situ hybridization. 
A In the control embryo at ElO.O, Cyp26a 1 continued to express in similar 
domains as E9.5, including anteriorly, in the cranial mesenchyme (CM), 
around the maxillo-mandibular cleft (MMC), but not in the optic (Op) and 
otic (Ot) vesicles. Posteriorly, it was expressed in the tail bud (TB) at the 
caudal extremity. 
B In the RA-treated embryo at ElO.O, the ectopic expression o f Cyp26a 1 
found in E9.5 had switched o f f Expression had returned to similar levels 
and similar domains as the control embryo except at the caudal end. 
C Higher magnification o f the caudalmost region o f the ElO.O control embryo 
showed intense expression o f Cyp26a 1 in the tail bud. 
D Higher magnification o f the caudalmost region o f the ElO.O RA-treated 
embryo showed that Cyp26a 1 expression at the caudal extremity was very 
much reduced. 
E In the control embryo at El0.5, Cyp26a 1 continued to express in similar 
domains as ElO.O. Cyp26al expressed specifically in the first branchial 
arch region (circled). 
F In the RA-treated embryo at El0.5, Cyp26a 1 expression in the first 
branchial arch region was distorted. 
Labels: C M Cranial mesenchyme 
Op Optic vesicle 
Ot Otic vesicle 
TB Tail bud 
M M C Maxillo-mandibular cleft 
Symbol: Circle First branchial arch 
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Figure 4.12 Expression of Cyp26al in embryos of control (CON) and RA-
treated (RA) mice at Ell.O, E11.5 and E12.0 detected by whole 
mount in situ hybridization. 
A In the control embryo at El l .O, Cyp26al at the caudal extremity had 
almost diminished as the tail bud started to regress. Cranially, the main site 
o f expression was in the midline o f the retina (Re) and in the hindbrain 
region (circled). 
B In the RA-treated embryo at El l .O, Cyp26al expression in the hindbrain 
region was reduced. 
C Expression of Cyp 2 6a J in the control embryo at E l l . 5 was similar to that 
a tE l l .O. 
D Reduction o f Cyp26al in the hindbrain domain was still observable in 
E l 1.5 RA-treated embryo. 
E Expression o f Cyp26a] in the retina and hindbrain region persisted in 
E l2 .0 control embryo. 
F The difference in Cyp26a 1 expression persisted in the hindbrain region o f 
E l2 .0 RA-treated embryo. 
Labels: Re Retina 
Symbol: Circle Expression domain in the hindbrain region 
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Figure 4.13 Expression of Cyp26al in embryos of control (CON) and RA-
treated (RA) mice at ElO.O and El0.5 detected by whole mount in 
situ hybridization. 
A In the E9.5 control embryo, Cyp26bl was mainly expressed intensively in 
the cranial region. 
B In the RA-treated embryo at E9.5, there was up-regulated expression o f 
Cyp26hl in the entire embryo. 
C Higher magnification o f the cranial region o f the E9.5 control embryo 
showed that Cyp26bl was mainly expressed in the rhombomere (r) 2-5. 
Expressions in r2, r3 and r4 were restricted to the basal region, whereas 
expressions spanned the entire rhombomere in r5 and r6. 
D Higher magnification o f the cranial region o f the E9.5 RA-treated embryo 
showed that the expression domains o f Cyp26hl had expanded beyond the 
rhombomere. 
E In the control embryo at ElO.O, other than the cranial domains, Cyp26bl 
expression was also observed in the forelimb (FL) and hindlimb bud (HL). 
F In the RA-treated embryo at ElO.O, there was prominent difference in 
Cyp26bl expression in the cranial region when compared with the control. 
G Higher magnification o f the cranial region o f the ElO.O control embryo 
showed that besides rhombomeres 2-6, Cyp26bl expression was also 
observed in the metencephalon (Me). 
H Higher magnification o f the cranial region o f the ElO.O RA-treated embryo 
showed that Cyp26bl expression in the rhombo meres was severely reduced. 
In contrast, its expression in the metencephalon was expanded to a broader 
domain. 
Labels: FL Forelimb bud 
HL Hindlimb bud 
Me Metencephalon 
r rhombomere 
Scale bar: A, B 1 mm 
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Figure 4.14 Expression of Cyp26hl in embryos of control (CON) and RA-
treated (RA) mice at El0.5 , Ell.O, E11.5 and E12.0 detected by 
whole mount in situ hybridization. 
A In the El0.5 control embryo, Cyp26hl continued to express in rhombomere 
(r) 2-6 and the metencephalon (Me). 
B In the RA-treated embryo at El0.5’ up-regulated expression o f Cyp26hl 
was observed in the metencephalon. Expression in the rhombomeres had 
also distinguished. 
C In the E l l .O control embryo, Cyp26hl expression was found at the 
metencephalon and myelencephalon (My). 
D In the E l l .O RA-treated embryo, expression o f Cyp26hl continued to be 
prominently up-regulated in the metencephalon, but severely 
down-regulated in the myelencephalon. 
E The expression o f Cyp26hl in the control embryo at E l l . 5 was similar to 
that at El l .O. 
F In the RA-treated embryo at E l 1.5, prominent down-regulation ofCyp26bl 
was still observed in the myelencephalon, while expression in the 
metencephalon was more comparable with the control 
G In the E12 control embryo, other than the cranial domain, Cyp26bl was 
also expressed in specific pattern in the interdigital regions o f the forelimb 
(FL) and hindlimb buds (HL). 
H The RA-treated embryo at El2.0 did not show much difference from the 
control embryo in Cyp26hl expression. 
Labels: FL Forelimb bud 
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Fijilue 5.1 Examples of RA-induced malformations in El8 mouse fetuses (1). 
A Normal fetus with closed eyelid (yellow arrowhead) and folded external 
ear (circled). 
B Malformed fetus without the eyelid. The eye was bulging out anteriorly out 
o f the orbit. The external ear o f the fetus was totally absent. 
C Higher magnification o f Figure A to show the relative position o f the eye 
and external ear. 
D Malformed fetus without the eyelid but the eye still remained in its orbit. 
The external ear was composed o f unflised small patches and located in an 
abnormal position relative to the eye. 
E Fetus with normal jaw development. Separation between the maxilla (Mx) 
and the mandible (Mn) was clearly seen. 
F Malformed fetus with hypoplasia o f both the maxilla and the mandible. The 
upper and lower jaws could not close completely. 
G Normal palate (red arrowhead) o f a fetus. The secondary palatal shelves 
were completely fused in the midline. 
H Malformed fetus with cleft palate, in which the secondary palatal shelves 
were not completely fused, resulting in a cleft in the midline. 
Labels: Mn Mandible 
Mx Maxil la 
Symbols: Circle External ear 
Red arrowhead Palate 
Yellow arrowhead Eyelid 
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Ear ^ W J IH^l J 
T � . J P ^ ^ 
/ V ！ 、 
Ear Z 1 : 着< • » f 
I I * / •:��. \ t \ Z 
I I 、一 ' 1 
气.如—�. ..‘:•::.、、 M . jr'-
她 • 國 
p a 丨 a t e t • 
Fijilue 5.1 Examples of RA-induced malformations in El8 mouse fetuses (226). 
A Normal forelimb (FL) o f a fetus containing 5 separated digits. 
B Malformed fetus with forelimb ectrodactyly in which one or more central 
digits o f the hand was absent. 
C Normal fetus with a long tail (blue arrowhead) and a pair ofhindl imbs (HL) 
separately projecting out from the two sides o f the body. 
D Malformed fetus without a tail (caudal regression) and both hindlimbs 
joining in the midline, a defect known as sirenomelia. 
E Normal fetus with a small anal opening (orange arrowhead) near the base 
o f the tail. 
F Malformed fetus without any anal opening (imperforate anus). 
Labels: FL Forelimb 
HL Hindlimb 
Symbols: Blue arrowhead Tail 
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Fijilue 5.1 Examples of RA-induced malformations in El8 mouse fetuses (5). 
A Normal fetus with a diaphragm (green arrowhead) separating the abdomen 
and the thorax. 
B Malformed fetus with a large hole on the left side o f the body, a defect 
known as diaphragmatic hernia. 
C Normal fetus with a pair o f thymus (circled) located above the heart (Ht). 
D Malformed fetus with bilateral thymic agenesis, in which the thymus on 
both sides failed to develop. 
E Normal male fetus with a pair o f testes (Te) located close to the urinary 
bladder (Ur). 
F Malformed male fetus with undescended testes, in which the testes did not 
descended into the pelvis from the abdominal region. 
Labels: Ht Heart 
Te Testis 
Ur Urinary bladder 
Symbols: Circle Thymus 
Green arrowhead Diaphragm 
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Figire 5.4 External morphology of E18 mouse fetuses with or without RA 
treatment. 
A Normal E18 fetus without exposure to any exogenously applied RA. 
B E l8 fetus maternally insulted with a teratogenic dose (125 mg/kg) o f RA 
on E8-22 hr followed by oral feeding with 3 doses o f suspension vehicle as 
control. The fetus was prominently reduced in size, with multiple external 
defects affecting the eye, ear, jaws and the lower limb. The fetus did not 
have a tail. 
C E l 8 fetus maternally insulted with a teratogenic dose (125 mg/kg) o f RA 
on E8-22hr followed by oral supplementation with 3 low doses (1.25 
mg/kg) o f R A a t 12 hr interval starting at El0.0. The fetus was prominently 
larger in size than the RA-insulted control fetus shown in Figure B. Most o f 
the external malformations were ameliorated except the fetus was tailless. 
Scale bar: A to C 1 cm 
No teratogenic RA insult 
_ 
• 1 1 
Teratogenic RA insult Teratogenic RA insult 
without followed by 
RA supplementation RA supplementation 
Fioure 5.5 TDNEL staining of apoptosis in the metanephros of El2.0 
embryos with or without RA treatment. 
A TUNEL-stained section o f an El2.0 embryo without exposure to any 
exogenously applied RA. The metanephros was outlined by the broken 
circle. Apoptotic nuclei (yellow arrowhead) were occasionally found in the 
metanephric mesenchyme ( M M ) and the ureteric bud (UB). 
B TUNEL-stained section o f an El2.0 embryo that had been maternally 
insulted with a teratogenic dose (125 mg/kg) o f RA on E8-22 hr followed 
by oral feeding with 3 doses o f suspension vehicle as control. Extensive 
apoptosis was found in the metanephric mesenchyme. 
C TUNEL-stained section o f an El2.0 embryo that had been maternally 
insulted with a teratogenic dose (125 mg/kg) o f RA on E8-22hr followed 
by oral supplementation with 3 low doses (1.25 mg/kg) o f RA at 12 hr 
interval starting at ElO.O. Apoptosis was greatly ameliorated when 
compared with the metanephros o f the RA-insulted control embryo. 
Labels: M M Metanephric mesenchyme 
UB Ureteric bud 
Symbols: Circle Outline o f the metanephros 
Yellow arrowhead Apoptotic nuclei 
Scale bar: A to C 100 \im 
No teratogenic RA insult 
m 
Teratogenic RA insult Teratogenic RA insult 
without followed by 
RA supplementation RA supplementation 
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Graph 4.3 Relative expression levels of Cyp26al in embryos of RA-
trcatcci (RA) and control (CON) micc at different time 
points after treatment. 
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Graph 4.4 Relative expression levels of Cyp26al in embryos of RA-
trcatcci (RA) and control (CON) micc at different time 
points after treatment. 
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Graph 4.5 Relative expression levels of Cyp26al in embryos of RA-
trcatcci (RA) and control (CON) micc at different time 
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^ p< 0.01 vs. CON at the same developmental stage 
Graph 4.6 Relative expression levels of Cyp26a l in embryos of RA-
trcatcci (RA) and control (CON) micc at different time 
points after treatment. 
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^ p < 0.005 vs. CON at the same developmental stage 
Graph 4.7 Relative expression levels of Cyp26al in the metanephros 
of embryos of RA-trcatcd (RA) and control (CON) mice 
at different time points after treatment. 
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Graph 4.8 Relative expression levels of Cyp26al in the metanephros 
of embryos of RA-trcatcd (RA) and control (CON) mice 
at different time points after treatment. 
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Graph 4.9 Relative expression levels of Cyp26al in the metanephros 
of embryos of RA-trcatcd (RA) and control (CON) mice 
at different time points after treatment. 
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Developmental stage 
Sample size in parentheses. 
Data were analyzed by Independent Samples t-test. 
* /? < 0.05 vs. CON at the same developmental stage 
料 p < 0.01 vs. CON at the same developmental stage 
Graph 4.10 Relative expression levels of Cyp26al in the metanephros 
of embryos of RA-trcatcd (RA) and control (CON) mice 
at different time points after treatment. 
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Data were analyzed by Independent Samples t-test. 
* < 0.05 vs. CON at the same developmental stage 
Graph 4.11 Relative expression levels of Cyp26al in the metanephros 
of embryos of RA-trcatcd (RA) and control (CON) mice 
at different time points after treatment. 
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Sample size in parentheses. 
Data were analyzed by Independent Samples t-test. 
* /? < 0.05 vs. CON at the same developmental stage 
Graph 4.12 Relative expression levels of Cyp26al in the metanephros 
of embryos of RA-trcatcd (RA) and control (CON) mice 
at different time points after treatment. 
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Sample size in parentheses. 
Data were analyzed by Independent Samples t-test. 
No significant difference found between CON and RA-treated groups at the 
same developmental stage. 
Graph 4.13 Amount of RA in embryos of RA-treatcd (RA) and 
control (CON) mice at different time points after 
treatment. 
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Sample size in parentheses. 
Data were analyzed by Independent Samples t-test. 
* /7 < 0.05 vs. CON at the same developmental stage 
Graph 4.14 Amount of RA in the metanephros of embryos of RA-
trcatcd (RA) and control (CON) mice at different time 
points after treatment. 
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Data were analyzed by Independent Samples t-test. 
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C i r a p h 5.1 E f f c c t of o r a l s u p p l e m e n t a t i o n w i t h v a r i o u s doses ol 1.25 
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p o i n t s a f t e r t e r a t o g e n i c R A insu l t on r e n a l 
m a l f o r m a t i o n s . 
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m Two normal kidneys 
• Unilateral non-agenesis renal malformations (contralateral kidney being normal) 
Bilateral non-agenesis renal malformations 
Unilateral renal agenesis (remaining kidney being normal) 
Unilateral renal agenesis (remaining kidney with non-agenesis renal malformations) 
Bilateral renal agenesis 
No Suppl.: Wi thout any supplementation. 
CON: Oral supplementation w i th suspension vehicle. 
Sample size in parentheses. 
Data were analyzed by Jonckhccrc-Tcrpstra test. 
* p ‘ ().()() 1 vs. CON ol ' thc same closing regimen 
Cilrapli 5 .2 Effect of oral s u p p l e m e n t a t i o n with 3 or 4 doses of 1.25 
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tcrato^cnic RA insult on renal m a l f o r m a t i o n s . 
⑴ 100 p — I m ^ m i m — 
卜=• = • 
2 60 
^ 4 0 ~~: CO — • � 
a 
0 20 
5 0 - J L _ J _ _ _ _ L _ 
(107) (150) (49) (53) 
CON 1.25 RA CON 1.25 RA 
3 doses 4 doses 
starting at E10.0 starting at E10.0 
H Two normal kidneys 
• Unilateral non-agenesis renal malformations (contralateral kidney being normal) 
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CON: Oral supplementation w i th suspension vehicle. 
Sample size in parentheses. 
Data were analyzed by Jonckheere-Terpstra test 
* /? < 0.001 vs. CON o f the same dosing regimen 
C r a p h 5 .3 Kffcct of oral s u p p l e m e n t a t i o n with varyinj* dosaj^es of 
R A for 3 doses j»ivcn at 12 hr interval startinjj; at ElO.O 
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Unilateral renal agenesis (remaining kidney with non-agenesis renal malformations) 
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" p - 0.05 vs. 1.25 RA 
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Bilateral renal agenesis 
CON: Oral supplementat ion w i t h suspension vehicle. 
Sample size in parentheses. 
Data were analyzed by Jonckhecre-Terpstra test. 
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“ p < 0.05 vs. C O N 
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CON: Oral supplementation with suspension vehicle. 
Sample size in parentheses. 
Data were analyzed by Independent Samples t-tcst. 









































































































































































































































































Graph 5.7 Effcct of oral supplementation with 1.25 mj^kj^ RA for 3 
doses given at 12 hr interval starting at FJO.O after 
teratogenic RA insult on Wtl expression in El 2 
metanephros. 
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CON: Oral supplementation wi th suspension vehicle. 
Sample size in parentheses. 
Data were analyzed by Independent Samples t-test. 
a厂 < 0.001; < 0.05 vs. No teratogenic RA insult; 
* / 7 < 0.005 vs. CON 
Craph 5.8 Effect of oral supplementation with 1.25 RA for 3 
doses given at 12 hr interval starting at El0.0 after 
teratogenic RA insult on the number of apoptotic nuclei 
in El2 metanephros. 
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CON: Oral supplementation wi th suspension vehicle. 
Sample size in parentheses. 
Data were analyzed by Independent Samples t-test. 
林 p < 0.001 vs. No teratogenic RA insult 
* / ? < 0.001 vs. CON 
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